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Abstract 
 
 
The brain is dependent on a constant supply of glucose as its primary fuel. Consequently, 
the brain has developed ways to tightly control intake of glucose, via glucose sensing 
neurones containing the enzyme glucokinase (GK). This thesis identifies a role for a subset of 
glucose sensing neurones in the arcuate nucleus (ARC) of the hypothalamus to promote 
glucose intake. These neurones form part of a pathway separate to the control of peripheral 
glucose homeostasis.  
Direct injection of a GK activator into the ARC increases glucose intake. Stereotactic 
injection of recombinant adeno-associated virus containing GK antisense (rAAV-GKAS) into 
the ARC of rats chronically decreases GK activity compared to controls. Knockdown of ARC 
GK reduces glucose intake in an acute and long-term setting. Direct injection of an 
ATP-sensitive potassium (KATP) channel inhibitor into the ARC increases glucose intake in a 
similar manner to that of a GK activator. In addition, pre-treatment with a KATP channel 
activator attenuates the orexigenic effect of a GK activator. ARC glucose sensing neurones 
are likely mediated by neuropeptide Y (NPY) as both activation of GK and inhibition of KATP 
channels stimulate NPY release in hypothalamic explants. Also, pharmacological inhibition of 
Y1 and Y5 receptors, and P/Q type voltage gated calcium channels, attenuate the orexigenic 
effect of GK activators. 
ARC glucose sensing neurones represent a novel pathway that may be part of a mechanism 
to ensure adequate glucose is constantly available to the brain.  This work suggests that ARC 
GK has a physiological role in the homeostatic regulation of glucose intake. ARC GK responds 
to periods of fasting and may contribute to an increased preference for glucose. Thus, ARC 
glucose sensing may drive dietary sugar intake, which may be a contributing factor in 
obesity.   
3 
 
Declaration of Contributors 
 
 
The majority of the work in this thesis was performed by the author. All collaboration and 
assistance is described below. 
Recombinant AAV was prepared by Dr James Gardiner. GK-pTR-CGW plasmid was prepared 
by Dr James Gardiner, Dr Errol Richardson and Dr Sufyan Hussain. In vitro testing of rAAV-
GKAS was conducted by Dr Errol Richardson. 
Assistance with the molecular cloning, preparation of probes and the glucokinase activity 
assay was provided by Dr David Ma. 
Feeding studies and stereotactic injections were performed in collaboration with Dr Sufyan 
Hussain, Dr David Ma and Mr Ivan De Backer.  
Hypothalamic explants were performed with assistance from Prof. Waljit Dhillo and Dr 
James Kinsey-Jones. 
Radioimmunoassays were performed under supervision of Prof. Mohammed Ghatei. Alpha 
MSH antibody and label was prepared by Prof. Mohammed Ghatei. 
  
4 
 
Declaration of Copyright 
 
 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use 
it for commercial purposes and that they do not alter, transform or build upon it. For any 
reuse or redistribution, researchers must make clear to others the licence terms of this 
work. 
  
5 
 
Acknowledgements 
 
 
I would like to thank my supervisor James Gardiner for his guidance and coaching 
throughout my research. 
I am very grateful to be part of the “dream team” with David Ma, Sufyan Hussain and Ivan 
De Backer. Thank you for your mentorship and assistance during many experiments. 
Thank you to everyone within the Bloom group for providing continual support: in particular 
from Lucy Brooks and Kat Banks in the form of new ways to make me laugh. 
I would also like to thank the Biotechnology and Biological Sciences Research Council 
(BBSRC) for my funding. 
Finally, many thanks go to my family and friends, especially Amy, Mum and Dad. Your 
support during my many years of student life is much appreciated.  
6 
 
Abbreviations 
2DG   2-Deoxyglucose 
3OMG   3-O-methyl-N-acetylglucosamine 
5TG   5-thio-d-glucose-6-phosphate 
AAV   Adeno-associated virus 
ACC   Acetyl-coenzyme A carboxylase 
aCSF   Artificial cerebrospinal fluid 
ADP   Adenosine diphosphate 
AgRP   Agouti related peptide 
Amp   Ampicillin resistance gene 
AMPK   Adenosine monophosphate activated protein kinase 
α-MSH  Alpha melanocyte stimulating hormone 
ANOVA  Analysis of variance 
ARC   Arcuate nucleus 
AP   Area postrema 
AS   Antisense 
ATP   Adenosine triphosphate 
BBB   Blood brain barrier 
BLAST  Basic local alignment search tool 
Bp   Base pairs 
CART   Cocaine-and amphetamine-related transcript 
cDNA   Copy DNA 
CFTR   Cystic fibrosis transmembrane regulator 
CNS   Central nervous system 
CRR   Counterregulatory response 
7 
 
CSF   Cerebrospinal fluid 
DMN   Dorso medial nucleus 
DMNX   Dorsal motor nucleus of the vagus 
DNA   Deoxyribonucleic acid 
dNTP   Deoxynucleotide triphosphate 
DREADD Designer receptors exclusively activated by designer drugs 
DTT   Dithiothreitol 
DVC   Dorsal vagal complex 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme-linked immune-sorbent assay 
GABA   Gamma-aminobutyric acid 
GDW   Glass distilled water 
GE   Glucose-excited 
GEE   General estimating equation 
GFP   Enhanced green fluorescent protein 
GI   Glucose-inhibited 
GK   Glucokinase 
GKAS   GK antisense 
GKRP  GK regulatory protein 
GKS   GK sense 
GLP-1   Glucagon-like peptide-1 
GLUT   Transmembrane glucose transporters 
G-6-P   Glucose-6-phosphate 
GTE  Glucose-Tris-EDTA 
HEK   Human embryonic kidney 
HFD   High fat diet 
8 
 
ICV   Intracerebroventricular 
IP   Intraperitoneal 
ITR  Inverted terminal repeats 
ITT  Insulin tolerance test 
JAK   Janus kinase 
KATP   ATP-sensitive potassium channel 
kcal   Kilo calorie 
kDa   Kilo dalton 
Kir   Inward-rectifier potassium ion channel 
kJ   Kilo joule 
Km   Michaelis constant 
KO   Knock out 
LH   Lateral hypothalamus 
MCH   Melanin-concentrating hormone 
ME  Median eminence 
mM   Milli Molar 
mRNA   Messenger ribonucleic acid 
MSH   Melanocyte stimulating hormone 
mw   Molecular weight 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBD   Nucleotide binding site 
NO   Nitric oxide 
NPY   Neuropeptide Y 
NTS   Nucleus of the solitary tract 
p  Probability 
PBS   Phosphate buffered saline 
9 
 
PCR  Polymerase chain reaction 
POMC   Pro-opiomelanocortin 
PVN   Paraventricular nucleus 
rAAV   Recombinant adeno associated virus 
rAAV-GFP  rAAV enhanced green fluorescent protein 
rAAV-GKAS  rAAV glucokinase antisense 
rAAV-GKS  rAAV glucokinase sense 
rpm  Revolutions per minute 
RNA   Ribonucleic acid 
RT-PCR Real-time PCR 
SAP   Shrimp alkaline phosphatase 
SDS   Sodium dodecyl sulfate 
SEM   Standard error of the mean 
SGLT-1  Sodium-dependant glucose transporter 1 
SSC   Saline sodium citrate 
SUR1   Sulfonylurea receptor 1 
TAE   Tris-acetate EDTA 
TE   Tris EDTA 
tRNA   Transfer ribonucleic acid 
VMH   Ventromedial hypothalamus 
VMN   Ventromedial hypothalamic nucleus 
WPRE   Woodchuck hepatitis virus post-transcriptional regulatory element  
10 
 
Table of Contents 
CHAPTER ONE: GENERAL INTRODUCTION ................................................................................................... 14 
1.1 THE OBESITY PANDEMIC .................................................................................................................................... 15 
1.2 THE CENTRAL CONTROL OF ENERGY HOMEOSTASIS .................................................................................................. 16 
1.2.1 Ventromedial hypothalamus ............................................................................................................... 16 
1.2.2  Lateral hypothalamus ........................................................................................................................ 17 
1.2.3 Paraventricular and dorsomedial nuclei ............................................................................................. 18 
1.2.4 Dorsal vagal complex of the brainstem .............................................................................................. 18 
1.3 THE IMPORTANCE OF GLUCOSE HOMEOSTASIS ....................................................................................................... 19 
1.3.1 Pancreatic glucose sensing ................................................................................................................. 20 
1.3.2 Brain glucose sensing .......................................................................................................................... 20 
1.3.3 The reward value of glucose ............................................................................................................... 21 
1.3.4 Glucose-sensing neurones ................................................................................................................... 22 
1.3.4.1 GE neurone glucose sensing ............................................................................................................. 22 
1.3.4.2 GI neurone glucose sensing .............................................................................................................. 24 
1.3.5 Glucose sensing neurones in the CNS .................................................................................................. 26 
1.3.5.1 VMN glucose sensing ....................................................................................................................... 26 
1.3.5.2 ARC glucose sensing ......................................................................................................................... 27 
1.3.5.3 Brainstem glucose sensing ............................................................................................................... 28 
1.4 MECHANISM OF GLUCOSE SENSING ..................................................................................................................... 29 
1.4.1 Glucokinase ......................................................................................................................................... 29 
1.4.2 Transmembrane glucose transporters ................................................................................................ 30 
1.4.3 ATP-sensitive potassium channels ...................................................................................................... 31 
1.4.4 The multiple roles of glucose sensing cells .......................................................................................... 34 
1.5 APPROACHES FOR INVESTIGATING THE NEURONAL CIRCUITS CONTROLLING ENERGY HOMEOSTASIS IN RODENTS .................. 35 
1.5.1 Direct cannulation ............................................................................................................................... 35 
1.5.2 Genetic modification by global mutation ............................................................................................ 36 
1.5.3 Selective genetic modification ............................................................................................................ 37 
1.5.4 Vectors used for gene transfer ............................................................................................................ 37 
1.5.4.1 Retroviral vectors ............................................................................................................................. 38 
1.5.4.2 Adenoviral vectors ........................................................................................................................... 39 
1.5.4.3 Adeno-associated viral vectors ........................................................................................................ 39 
1.6 SUMMARY ..................................................................................................................................................... 40 
CHAPTER TWO: MATERIALS AND METHODS ............................................................................................... 41 
2.1. METHODS USED TO PRODUCE PLASMIDS CONTAINING GK AND TO PRODUCE RAAV ..................................................... 42 
2.1.1 Production of rAAV.............................................................................................................................. 42 
2.1.2 Digestion of PCR products ................................................................................................................... 42 
2.1.3 Electroelution of DNA fragments ........................................................................................................ 43 
2.1.4 Ligation of PCR product into pTR-CGW ............................................................................................... 44 
2.1.5 Transformation of competent bacteria by heat shock ........................................................................ 45 
2.1.6 DNA sequencing .................................................................................................................................. 46 
2.1.7 Large scale preparation of plasmid ..................................................................................................... 46 
2.1.8 Caesium chloride gradient purification ............................................................................................... 47 
2.1.9 Plasmid digestion for dot blot and in situ hybridisation ..................................................................... 49 
11 
 
2.1.10 Quantification of total virus titre by dot-blot analysis ...................................................................... 50 
2.1.11 In vitro transfection of GKAS pTR-CGW into cultured cells ............................................................... 52 
2.2 METHODS USED FOR PHYSIOLOGICAL AND PHARMACOLOGICAL MEASUREMENT OF GLUCOSE SENSING IN VIVO ................... 54 
2.2.1 Animal maintenance ........................................................................................................................... 54 
2.2.2 Optimisation of successful stereotactic injection ................................................................................ 54 
2.2.3 Stereotactic injection of rAAV-GK antisense into the arcuate nucleus of rats .................................... 55 
2.2.4 Stereotactic cannulation of the left arcuate nucleus in rats ............................................................... 56 
2.2.5 Feeding studies with genetically altered animals ............................................................................... 57 
2.2.6 Twenty four hour feeding studies with intra-ARC injections ............................................................... 57 
2.2.7 Collection of tissue samples ................................................................................................................ 58 
2.3 METHODS USED FOR EX VIVO MEASUREMENT OF GLUCOSE SENSING .......................................................................... 59 
2.3.1 Glucokinase activity assay .................................................................................................................. 59 
2.3.2 Production of radiolabelled RNA probes for in situ hybridisation ....................................................... 61 
2.3.3 In situ hybridisation for glucokinase and WPRE mRNA ....................................................................... 62 
2.3.5 Hypothalamic explant static incubation system ................................................................................. 64 
2.3.6 Measurement of NPY and α-MSH in aCSF samples ............................................................................. 65 
2.3.6.1 α-MSH radioimmunoassay ............................................................................................................... 66 
2.3.6.2 NPY radioimmunoassay ................................................................................................................... 67 
2.3.7 Cresyl violet staining of ink injected rat brains ................................................................................... 67 
2.4 STATISTICAL ANALYSIS ....................................................................................................................................... 68 
CHAPTER 3: THE EFFECT OF ALTERED ARC GLUCOKINASE ACTIVITY ON GLUCOSE INTAKE ............................ 69 
3.1 INTRODUCTION ............................................................................................................................................... 70 
3.1.1 The glucostatic control of food intake ................................................................................................ 70 
3.1.2 Glucokinase and food intake ............................................................................................................... 70 
3.1.3 Techniques used to alter glucokinase in vivo ...................................................................................... 71 
3.2 HYPOTHESIS AND AIMS ..................................................................................................................................... 73 
3.2.1 Hypothesis ........................................................................................................................................... 73 
3.2.2 Aims .................................................................................................................................................... 73 
3.3 RESULTS ........................................................................................................................................................ 74 
3.3.1 Localisation of GK expression in the hypothalamus ............................................................................ 74 
3.3.2 Effect of pharmacologically increasing ARC GK activity on chow and glucose intake ........................ 75 
3.3.3 Visualisation of accurate ARC injection ............................................................................................... 79 
3.3.4 Measurement of total viral titre by dot blot analysis ......................................................................... 80 
3.3.5 Quantification of GK knockdown in vitro ............................................................................................ 80 
3.3.6 Quantification of knockdown of ARC GK in vivo .................................................................................. 81 
3.3.7 Effect of ARC GK knockdown on body weight ..................................................................................... 82 
3.3.8 Effect of ARC GK knockdown on food intake ....................................................................................... 83 
3.3.9 Effect of ARC GK knockdown on acute glucose intake ........................................................................ 84 
3.3.10 Effect of ARC GK knockdown on cumulative glucose intake ............................................................. 85 
3.4 DISCUSSION .................................................................................................................................................... 89 
3.4.1 Endogenous expression of GK in the rat hypothalamus ...................................................................... 89 
3.4.2 Increasing arcuate glucokinase activity increases glucose intake ...................................................... 89 
3.4.3 Accurate injection of substances into the ARC .................................................................................... 90 
3.4.4 Methods and measurements of altered glucokinase activity ............................................................. 90 
3.4.5 Decreasing arcuate glucokinase activity decreases glucose intake .................................................... 91 
3.4.6 ARC glucokinase and the control of overall calorie intake .................................................................. 92 
3.4.7 Two separate physiological roles for hypothalamic glucokinase ........................................................ 92 
3.4.8 The physiological relevance of ARC GK in the regulation of food intake............................................. 95 
12 
 
3.4.9 Conclusion ........................................................................................................................................... 95 
CHAPTER 4: PHARMACOLOGICAL MANIPULATION OF ARCUATE NUCLEUS GLUCOSE SENSING .................... 96 
4.1 INTRODUCTION ............................................................................................................................................... 97 
4.1.1 The role of ATP-sensitive potassium channels .................................................................................... 97 
4.1.2 The role of voltage-gated calcium channels in ARC GK-regulated glucose intake .............................. 98 
4.1.3 The neurotransmitters involved in ARC GK-regulated increase in glucose intake ............................. 100 
4.2 HYPOTHESIS AND AIMS ................................................................................................................................... 102 
4.2.1 Hypothesis ......................................................................................................................................... 102 
4.2.2 Aims .................................................................................................................................................. 102 
4.3 RESULTS ...................................................................................................................................................... 104 
4.3.1 Effect of pharmacologically inhibiting ARC KATP channels on chow and glucose intake ................... 104 
4.3.2 Effect of pharmacologically activating ARC KATP channels on chow and glucose intake ................... 108 
4.3.3 Effect of pharmacologically activating ARC GK and KATP channels on NPY and α-MSH release from 
hypothalamic neurones ............................................................................................................................. 112 
4.3.4 Effect of pharmacologically activating KATP channels on the ARC GK-regulated increase in glucose 
intake ......................................................................................................................................................... 114 
4.3.5 Effect of simultaneously activating ARC GK and KATP channels on hypothalamic NPY release ......... 116 
4.3.6 Role of voltage-gated calcium channels in the ARC GK-regulated increase in glucose intake .......... 118 
4.3.7 Effect of NPY receptor inhibition on the ARC GK-regulated increase in glucose intake .................... 120 
4.4 DISCUSSION .................................................................................................................................................. 122 
4.4.1 The link between GK and KATP channels in ARC glucose sensing neurones ....................................... 122 
4.4.2 ARC GK neurones release NPY ........................................................................................................... 122 
4.4.3 ARC GK-induced increase of glucose intake is mediated via P/Q-type VGCC .................................... 123 
4.4.4 ARC GK-regulated increase in glucose intake is mediated by Y1 and Y5 receptors ........................... 124 
4.4.5 Other mechanisms of glucose sensing .............................................................................................. 126 
4.5 CONCLUSIONS ............................................................................................................................................... 127 
CHAPTER 5: GENERAL DISCUSSION ............................................................................................................128 
5.1 INTRODUCTION ............................................................................................................................................. 129 
5.2 PREVIOUS INVESTIGATION OF GLUCOSE SENSING .................................................................................................. 129 
5.3 INVESTIGATING THE ROLE OF ARC GK IN APPETITE ............................................................................................... 130 
5.4 INVESTIGATING THE MECHANISMS OF ARC GLUCOSE SENSING ................................................................................ 131 
5.5 THE SIGNIFICANCE OF THIS WORK FOR OBESITY AND DIABETES RESEARCH .................................................................. 134 
5.6 LIMITATIONS AND UNRESOLVED QUESTIONS ........................................................................................................ 135 
5.7 FUTURE DIRECTIONS ....................................................................................................................................... 137 
5.8 CONCLUSION ................................................................................................................................................ 138 
6. REFERENCES ..........................................................................................................................................139 
7. APPENDIX .............................................................................................................................................153 
7.1 APPENDIX I – SOLUTIONS ................................................................................................................................ 153 
7.2 CORONAL SECTION OF THE RAT BRAIN ................................................................................................................ 159 
7.3 APPENDIX II – NUTRITIONAL INFORMATION FOR RM1 STANDARD CHOW DIET .......................................................... 160 
7.4 APPENDIX III – DNA SEQUENCING OF PLASMID FOR IN SITU HYBRISIDATION .............................................................. 161 
7.5 APPENDIX IV – LIST OF SUPPLIERS ..................................................................................................................... 162 
 
 
13 
 
List of Figures and Tables 
 
Figure 1.1 Glucose excited neurone .................................................................................................... 23 
Figure 1.2 Glucose inhibited neurone .................................................................................................. 25 
Figure 1.3 Protein structures and modulators of SUR1 and Kir6.2 subunits of KATP channels ........... 33 
Figure 2.1 Schematic of the two step reaction in the GK activity assay ............................................. 59 
Figure 3.1 Endogenous GK mRNA expression in the rat hypothalamus ............................................ 74 
Figure 3.2 Effect of increasing ARC GK activity on food intake .......................................................... 76 
Figure 3.3 Effect of increasing ARC GK activity on 2% glucose intake ................................................ 77 
Figure 3.4 Effect of increasing ARC GK activity on chow and 2% glucose intake ............................... 78 
Figure 3.5 Confirmation of cannula placement in rats cannulated into the ARC .............................. 79 
Figure 3.6 Effect of in vitro GKAS-pTR-CGW plasmid transfection on GK activity ............................. 80 
Figure 3.7 Confirmation of GK knockdown by activity assay.............................................................. 81 
Figure 3.8 Effect of decreasing ARC GK on body weight ..................................................................... 82 
Figure 3.9 Effect of decreasing ARC GK on food intake ...................................................................... 83 
Figure 3.10 Effect of decreasing ARC GK on acute glucose and chow intake ..................................... 84 
Figure 3.11 Effect of decreasing ARC GK on glucose intake ................................................................ 85 
Figure 3.12 Effect of decreasing ARC GK on food intake .................................................................... 86 
Figure 3.13 Effect of decreasing ARC GK on energy intake ................................................................. 87 
Figure 3.14 Effect of decreasing ARC GK on body weight ................................................................... 88 
Figure 4.1 Effect of inhibiting KATP channels on food intake ............................................................. 105 
Figure 4.2 Effect of inhibiting KATP channels on glucose intake ........................................................ 106 
Figure 4.3 Effect of inhibiting KATP channels on chow and glucose intake ....................................... 107 
Figure 4.4 Effect of KATP channel activation on food intake .............................................................. 109 
Figure 4.5 Effect of KATP channel activation on glucose intake ......................................................... 110 
Figure 4.6 Effect of KATP channel activation on chow and glucose intake ........................................ 111 
Figure 4.7 Effect of pharmacological agents on neuropeptide release from hypothalamic neurones
 ........................................................................................................................................................ 113 
Figure 4.8 Effect of KATP channel activation on the ARC GK-regulated increase in glucose intake .. 115 
Figure 4.9 Effect of increased ARC GK and KATP channel activities on hypothalamic NPY release .. 117 
Figure 4.10 Effect of VGCC inhibition on the ARC GK-regulated increase in glucose intake ........... 119 
Figure 4.11 Effects of NPY receptor inhibition on the ARC GK-mediated increase in glucose 
consumption ................................................................................................................................... 121 
Figure 5.1 Proposed mechanism of ARC glucose sensing ................................................................. 133 
Figure 7.1 Schematic of a coronal section of the rat brain ............................................................... 159 
Figure 7.2 Nutritional information for RM1 standard chow diet ..................................................... 160 
Figure 7.3 Sequence of GK-pTR-CGW-plasmid .................................................................................. 161 
 
  
14 
 
Chapter one: General introduction 
  
15 
 
1.1 The obesity pandemic 
Obesity is a leading cause of preventable death worldwide. The prevalence of obesity is 
increasing; more than 24% of UK adults are currently obese compared with less than 15% in 
1993, according to data collected by the Health & Social Care Information Centre (2014). A 
rise in the prevalence of obesity is detrimental for the long-term health of the population as 
it increases the risk of diabetes, cardiovascular diseases, cancers and many other diseases 
(Stevens, Singh et al. 2012). Regular exercise and a reduction in energy-dense foods are the 
most efficient and cost effective ways to treat obesity, but weight loss is rarely maintained 
over the long term. Unfortunately, pharmacological treatments have fared little better in 
promoting weight loss, and there is not yet an effective non-surgical treatment for obesity 
(Viktoria, Matthias et al. 2013).  
Obesity arises from an imbalance in energy homeostasis with more energy consumed than 
energy used. Excess energy is stored as adipose tissue, as a reserve for times when food is 
scarce. However, there does not seem to be a mechanism to prevent excess storage when 
food is in abundance. Historically, an excess of dietary fat intake was thought to be the main 
contributor to obesity. This premise initiated the production of many low-fat foods in an 
attempt to create healthier diets. Unfortunately, sugars were added as a substitute to fat. 
Foods with high sugar content are now considered a major contributor of obesity and it is 
likely that the high quantity of both fat and sugar as energy sources in Western-type diets is 
a major cause of the obesity pandemic.  
Key questions to be answered are why the homeostatic mechanisms within the body still 
allow continuous intake of high energy food; and why, in many people, there does not seem 
to be an adiposity threshold to limit food intake. Understanding the mechanisms behind 
energy homeostasis is crucial for treating the obesity pandemic. 
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1.2 The central control of energy homeostasis 
Maintenance of a stable supply of nutrients to all cells in the body is governed by 
homeostatic processes. Energy homeostasis regulates the balance between food intake, 
energy expenditure and body adiposity.  
The brain plays a pivotal role in integrating signals governing energy homeostasis from 
several parts of the body including the liver, pancreas and gastrointestinal tract. Signals pass 
to the hypothalamus in many different ways, including in the blood and via sensory 
neurones in the vagus nerve. Much of the information is integrated by the hypothalamus; a 
relatively small region of the brain, recognised as a key junction for much of the information 
regarding energy homeostasis (Thorens 2011). The hypothalamus consists of several nuclei, 
which have discrete populations of neurones and are thought to control specific aspects of 
energy homeostasis. Neuronal connectivity studies show that there are more neuronal 
outputs from the hypothalamus than inputs; supporting the view that the hypothalamus 
coordinates responses from many circuits (Oh, Harris et al. 2014).  
 
1.2.1 Ventromedial hypothalamus 
Specific ablation of the ventromedial hypothalamus (VMH) in rats provided the first 
evidence that the pathways of hunger and satiety can be separated (Hetherington and 
Ranson 1940). Lesions of the VMH produce profound hyperphagia, leading to the hypothesis 
that specific areas of the hypothalamus control food intake. The VMH is subdivided into the 
ventromedial nucleus (VMN) and the arcuate nucleus (ARC) to separate the different 
functions and populations of neurones in these nuclei. 
The VMN is historically considered the satiety centre. In early lesion studies, hyperphagia 
was most pronounced in animals with lesions ablating the entire VMN (Hetherington and 
Ranson 1940, King 2006). Interestingly, most VMN ablated animals continue over eating 
until a certain level of adiposity is achieved, individual to each animal; after which eating 
levels return to relatively normal levels (Brooks and Lambert 1946). This phenomenon 
suggests that the VMN sets a threshold, around which energy homeostasis is regulated (King 
2006). The mechanism for VMN-mediated control of food intake is likely via the vagus 
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nerve, as vagotomy considerably blunts the VMN ablation phenotype (Cox and Powley 
1981).  
The ARC is located in the basal part of the VMH closest to the median eminence and basal 
part of the third ventricle. This is a specialised location in the hypothalamus for monitoring 
hormones and nutrients from both the blood and cerebral spinal fluid (CSF). The median 
eminence is highly fenestrated to allow more blood-borne constituents to pass through it, 
compared to other areas of the brain where the blood brain barrier (BBB) is intact  (Langlet, 
Levin et al. 2013). The median eminence facilitates diffusion of circulating hormones and 
nutrients to the ARC in concentrations that are closer to blood concentrations, compared 
with other parts of the central nervous system. The ARC also receives tanycyte projections 
from the lining of the third ventricle to facilitate the transport of CSF constituents (Langlet, 
Mullier et al. 2013).  
There are two well characterised populations of neurones in the ARC that regulate energy 
homeostasis. Anorexigenic neurons express pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART). These neurones are activated by leptin and 
insulin to reduce feeding (Cone, Cowley et al. 2001). An important result of leptin activation 
is the increased expression of POMC; the precursor for many peptides. One peptide in 
particular is alpha-melanocyte stimulating hormone (α-MSH), which acts as an anorexigenic 
neurotransmitter at melanocortin receptors within the hypothalamus. Another well 
characterised population of ARC neurones co-express neuropeptide Y (NPY) and agouti-
related peptide (AgRP) (Gropp, Shanabrough et al. 2005, Tong, Ye et al. 2008). NPY/AgRP 
neurones are powerful drivers of food intake. Optogenetic stimulation of just 800 AgRP 
neurones are sufficient to produce intense feeding (Aponte, Atasoy et al. 2011). NPY/AgRP 
neurones are activated by the hunger-stimulating peptide ghrelin, and are inhibited by 
leptin (Cone, Cowley et al. 2001).  
 
1.2.2 Lateral hypothalamus 
Early studies suggested that the lateral hypothalamus (LH) was the ‘hunger centre’ (Anand 
and Brobeck 1951). The LH contains populations of neurones involved in the regulation of 
reward, motivation and arousal. Reward behaviours are in part regulated by orexin-
18 
 
containing neurones in the LH that project to the cortex, limbic system and other 
hypothalamic nuclei (Horvath, Diano et al. 1999, Harris, Wimmer et al. 2005). The LH also 
contains populations of neurones that express the powerful orexigenic peptide melanin 
concentrating hormone (MCH). Ablating MCH neurones in mice decreases their preference 
for sucrose over non-caloric sweeteners and reduces striatal dopamine release (Domingos, 
Sordillo et al. 2013). Both orexin and MCH neurones in the LH are inhibited by anorexigenic 
NPY projections from the ARC to reduce food intake (Mercer, Chee et al. 2011).  
 
1.2.3 Paraventricular and dorsomedial nuclei 
Neurones in the anterior part of the paraventricular nucleus (PVN) release hormones into 
the blood at the median eminence and posterior pituitary (Tasker and Dudek 1991). These 
include thyrotropin-releasing hormone, which regulates release of thyroid hormones in the 
thyroid-hypothalamic-pituitary axis. Neurones in the posterior PVN project to autonomic 
neurones in the brainstem, which control peripheral tissues via the vagus nerve, and also 
receive information from several neuroendocrine pathways involved in energy homeostasis. 
For example, GLP-1 infusion decreases neuronal activation within the PVN as shown by 
manganese-enhanced magnetic resonance imaging (Parkinson, Chaudhri et al. 2009). In 
addition, NPY and orexin-A injection into the PVN stimulates food intake, indicating that the 
PVN plays an important role in integrating the information regarding food intake (Stanley, 
Chin et al. 1985, Edwards, Abusnana et al. 1999).  
Neurones within the dorsomedial nucleus (DMN) communicate with the nearby ARC in 
relation to energy balance.  CART and NPY colocalise in DMN neurones of diet-induced 
obese mice (Lee, Verma et al. 2013). DMN NPY expression significantly increases in rodent 
models of obesity (Guan, Yu et al. 1998, Bi, Ladenheim et al. 2001) and it is hypothesised 
that DMN neurones modulate ARC feeding signals (Dhillo, Small et al. 2002). 
 
1.2.4 Dorsal vagal complex of the brainstem 
The dorsal vagal complex (DVC) comprises nuclei that regulate the autonomic response to 
energy homeostasis: the nucleus of the solitary tract (NTS), area postrema (AP) and dorsal 
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motor nucleus of the vagus (DMNX). DMNX and NTS neurones receive input from several 
peripheral tissues regarding energy balance including the gastrointestinal tract, pancreas 
and liver (Grill 2006). The information from these sensory afferents merges with central 
pathways regulating energy homeostasis. Feedback is also provided by parasympathetic 
projections from the CNS to peripheral organs (Shapiro and Miselis 1985, Rinaman 2010). 
The DMNX plays an important role in determining meal size (Grill 2006). 
The AP is a circumventricular organ with highly fenestrated capillaries, similar to the median 
eminence. The AP resides beneath the fourth ventricle to allow access to blood and CSF 
nutrients at similar concentrations to that in the median eminence. Ablation of the AP 
results in an increase in food intake in rodents (Adachi, Kobashi et al. 1995). A similar effect 
is observed with leptin receptor knockdown in the AP and medial NTS (Hayes, Skibicka et al. 
2010).  
In conclusion, several regions of the CNS are involved in regulating energy homeostasis. 
Many of these are interconnected to form neuronal networks that control specific 
physiological processes.  
 
 
1.3 The importance of glucose homeostasis  
Glucose is used as the primary fuel in humans and other mammals. Blood glucose levels are 
tightly regulated by the coordinated actions of several tissues. In non-diabetic humans pre-
prandial glucose levels are typically 4.0-5.9mM and 2 hour post-prandial levels rise up to 
8.0mM (Diabetes Diabetes 2014). Similar levels are observed in rodents (Wynne, Stanley et 
al. 2005). Hypoglycaemia triggers a counterregulatory response that activates 
neuroendocrine pathways to increase glucagon and adrenaline release (Evans, McCrimmon 
et al. 2004). Liver and kidney glucose production increases, while muscle and adipose tissue 
glucose uptake decreases. Hyperglycaemia triggers an increase in insulin release and 
glucose uptake. Blood glucose levels also influence food intake. Intravenous injection of 
glucose decreases feeding in several mammal species (Woods, Stein et al. 1984, Burggraf, 
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Willing et al. 1997). Conversely, injection of insulin to induce hypoglycaemia rapidly 
increases food intake (Biggers, Myers et al. 1989, Dunn-Meynell, Sanders et al. 2009).  
 
1.3.1 Pancreatic glucose sensing 
Blood and extracellular glucose concentrations are monitored by specific glucose sensors. In 
pancreatic β-cells the intracellular glucose concentration is correlated with the release of 
insulin. The enzyme glucokinase (GK) catalyses the first step in glycolysis and is the critical 
component of glucose sensing (Matschinsky and Ellerman 1968, Liang, Najafi et al. 1990, 
Schuit, Huypens et al. 2001, Levin, Routh et al. 2004).  
Glucose sensing in β-cells occurs when glucose enters the cell via GLUT2 transporters and is 
phosphorylated into glucose-6-phosphate (G6P) by GK. G6P undergoes further metabolism 
in glycolysis and the tri-carboxylic acid cycle leading to the production of adenosine 
triphosphate (ATP). An increase in the ratio of ATP to adenosine diphosphate (ADP) blocks 
ATP-sensitive potassium (KATP) channels, resulting in an increase in intracellular cations. If 
sufficient KATP channels are blocked, the β-cell membrane potential exceeds a threshold and 
the membrane depolarises to stimulate opening of voltage-gated calcium channels and 
insulin release (Ashcroft, Proks et al. 1994).  
 
1.3.2 Brain glucose sensing 
While glucose sensing in β-cells is important for glucose homeostasis, the brain is central to 
coordination of the complete response to altered glucose concentrations. More than 60 
years ago Jean Mayer hypothesised that a central glucostatic mechanism controls food 
intake, in an alternative pathway to energy homeostasis (Mayer 1953). It was previously 
established that small variations in food intake regulate long term adiposity and energy 
expenditure. Mayer argued that glucose is the primary signal to provide this regulation 
(Mayer 1955). He recognised that peripheral signals such as insulin must be integrated by a 
specific regulatory network, but the main signalling molecule should be a metabolite that 
can affect hunger and satiety. Therefore Mayer hypothesised that a fall in blood glucose 
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would trigger hunger for foods high in glucose. Similarly, George Bray describes glucose as 
having a dynamic role in homeostasis by initiating food intake (Bray 1996).  
 
1.3.3 The reward value of glucose 
Mayer’s theory is in accord with current investigation into the physiological role of 
hypothalamic glucose sensing in conveying the reward value of sugar (Mayer 1953). Glucose 
is the preferred energy source over other types of food (Sclafani 2004, Johnson and Kenny 
2010). During food restriction in mice, the reward value of sucrose (glucose and fructose 
combined) was found to be more powerful than optogenetic stimulation of limbic 
dopaminergic neurones (Domingos, Vaynshteyn et al. 2011). Magnetic resonance imaging in 
humans suggest that ingestion of glucose, but not fructose; increases connectivity between 
the hypothalamus and striatum (Page, Chan et al. 2013). It is likely that there is an innate 
mechanism to ensure that available glucose is consumed, possibly via reward processes. As 
the brain is reliant on glucose as a fuel, it is possible that the mechanism is in place to 
ensure that there is a constant supply of glucose. 
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1.3.4 Glucose-sensing neurones 
CNS glucose sensing occurs in specific glucose-sensing neurones, which are classed into two 
groups depending on their electrophysiological properties. Those that respond to increasing 
concentrations of glucose by increasing frequency of their action potentials are named 
glucose-excited (GE); those that decrease the frequency of their action potentials are 
glucose-inhibited (GI), (Spanswick, Smith et al. 1997, Song, Levin et al. 2001).  
 
1.3.4.1 GE neurone glucose sensing 
Analogous to β-cells, glucokinase is expressed in most GE and GI neurones in the CNS (Dunn-
Meynell, Routh et al. 2002, Kang, Routh et al. 2004) and has been identified as a major 
regulator in neuronal glucose sensing (Levin, Routh et al. 2004). GE neurones and pancreatic 
β-cells share the same mechanism for detecting an increase in glucose levels (Levin, Routh 
et al. 2004). GK activity is dependent upon the prevailing glucose concentration. Metabolism 
of glucose results in an increase in ATP that is thought to close KATP channels and increase 
the intracellular cation concentration. Closure of enough KATP cannels results in 
depolarisation and neuronal firing (figure 1.1).  
Some GE neurones have been shown to express sodium-dependent glucose transporters 
(SGLT) (O’Malley, Reimann et al. 2006). The SGLT1 activator α-methylglucopyranosid 
activates GE neurones in primary cultures of rat hypothalamic neurones independent of KATP 
channel sensitivity. Intracerebroventricular (ICV) injection of the SGLT1 antagonist phloridzin 
stimulates feeding in rats (Tsujii and Bray 1990), thus may describe an alternative 
mechanism for GE neurone glucose sensing. However the roles of SGLT1-expressing 
neurones in glucose sensing are unclear. A similar transporter has been identified in 
Drosophila, which detects sugar intake (Dus, Ai et al. 2013). 
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Figure 1.1 Glucose excited neurone: Mechanism for glucose sensing in GE neurones. 
Glucokinase phosphorylates glucose at a rate proportional to glucose influx. Local ATP levels 
affect K+ permeability via KATP channels therefore affecting neuronal firing and 
neurotransmitter release. ΔVm, change in membrane potential, membrane depolarisation. 
Adapted from Diggs-Andrews, Silverstein et al. (2009).  
 
  
Glucose-excited neurone 
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1.3.4.2 GI neurone glucose sensing 
GI neurones may utilise several different molecular mechanisms for glucose sensing 
(Thorens 2012). GK is expressed in most GI neurones (Kang, Dunn-Meynell et al. 2006), but 
an increase in glucose concentration results in membrane hyperpolarisation, therefore it is 
likely that a different intracellular mechanism to KATP channels is involved. Calcium imaging 
studies reveal that over 70% of GI neurones in the VMN are affected by GK inhibitors (Dunn-
Meynell, Routh et al. 2002), indicating that GK is an important regulator in most GI 
neurones. AMP-activated kinase (AMPK), nitric oxide (NO) synthase and cystic fibrosis 
transmembrane regulator (CFTR) channels are also implicated in the mechanism of GI 
glucose sensing (figure 1.2).  
Insulin and low glucose concentrations increase the ratio of AMP to ATP, which alters AMPK 
activity and NO signalling in GI neurones (Fioramonti, Lorsignol et al. 2004, Canabal, Potian 
et al. 2007). Reduced ATP concentrations may close CFTR channels and depolarise the cell 
membrane during low glucose levels (Gadsby, Vergani et al. 2006). CFTR channels regulate 
chloride ion flow and likely control membrane potential in GI neurones (Sheppard and 
Robinson 1997). However, much of the mechanism of GI neurones has only been shown in 
vitro. Some evidence for a role of AMPK in GI neurones has been demonstrated in vivo. 
Leptin activates AMPK and NO synthase in VMH GI neurones (Murphy, Fakira et al. 2009). 
Also, knockout of the α2 subunit for AMPK specifically in POMC or AgRP neurones impairs 
glucose sensing. Therefore AMPK may be an important regulator of glucose sensing in some 
neurones (Claret, Smith et al. 2007).  
  
25 
 
 
 
Figure 1.2 Glucose inhibited neurone: Mechanism for glucose sensing in GI neurones. 
Glucokinase phosphorylates glucose at a rate proportional to glucose influx. Neuronal firing 
is dependent upon Cl- permeability, possibly controlled by AMPK and NO synthase. A 
decrease in glucose phosphorylation results in an increase in neuronal firing (Claret, Smith 
et al. 2007). ΔVm, change in membrane potential, membrane depolarisation. Adapted from 
Diggs-Andrews, Silverstein et al. (2009). 
  
Glucose-inhibited neurone 
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1.3.5 Glucose sensing neurones in the CNS 
Intravenous glucose and insulin injections have been shown to alter neuronal activity during 
electrophysiological studies performed as many as 50 years ago (Anand, Chhina et al. 1964). 
The physiological importance of this response has since been investigated. ICV injection of 
glucose reduces food intake in rats (Tsujii and Bray 1990). Conversely, injection of 2-
deoxyglucose (2-DG), an analogue of glucose that cannot undergo glycolysis and inhibits ATP 
production, results in an increase in food intake (Tsujii and Bray 1990). Injection of 2-DG into 
the VMH also increases blood glucose concentrations (Borg, Sherwin et al. 1995). Further 
investigation is required to understand the physiological roles of specific hypothalamic 
nuclei in glucose homeostasis. 
 
1.3.5.1 VMN glucose sensing 
Electrophysiological recordings in rats reveal that 14-19% of VMN neurones are glucose-
excited and 3-14% are glucose-inhibited (Song, Levin et al. 2001, Dunn-Meynell, Routh et al. 
2002). Of these, 64% of GE and 43% of GI neurones express GK (Kang, Routh et al. 2004). 
The main role of VMN GK neurones is mediating the counterregulatory response (CRR) to 
hypoglycaemia (Borg, Sherwin et al. 1995). VMN glucose sensing neurones detect acute 
drops in blood glucose and respond by sending signals to the pancreas and adrenal glands 
for stimulating hormone secretion and raising blood glucose concentrations (Levin, Becker 
et al. 2008). Increasing GK activity in vivo decreases the release of several peripheral 
hormones including adrenaline, noradrenaline and glucagon. In contrast, reducing the 
expression or activity of VMN GK elicits the opposite response by stimulating adrenalin 
release and increasing glucose availability (Levin, Becker et al. 2008). Glucagon and 
adrenalin levels are also elevated when VMN neurones are hyperpolarised by KATP channel 
openers (McCrimmon, Evans et al. 2005, Chan, Lawson et al. 2007). Hyperpolarisation 
mimics the effects of decreased GK activity in GE neurones, therefore reduced GE (and 
increased GI) firing likely drives the CRR to hypoglycaemia. Consistent with this, activation of 
NO signalling in GI neurones also induces adrenaline release (Fioramonti, Marsollier et al. 
2010).  
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Lactate, a source of energy provided by astrocytes during periods of hypoglycaemia, further 
demonstrates the physiological role of GI neurones in the CRR to hypoglycaemia. Lactate 
increases firing in VMN GE neurones, similar to glucose (Song and Routh 2005). However, 
lactate does not affect the CRR to hypoglycaemia via GI neurones during hypoglycaemia, 
indicating that glucose concentrations are the primary regulators of this pathway. The 
neurotransmitters involved in VMN glucose signalling have not been fully elucidated, but 
may include a short feedback loop via inhibitory GABA in the VMN (Chan, Lawson et al. 
2007). 
 
1.3.5.2 ARC glucose sensing 
Electrophysiological recordings from ARC neurones reveal that there are two distinct regions 
of glucose sensing neurones. In the medial portion of the ARC, 14% of neurones are GI and 
3% are GE; in the lateral portion of the ARC, 13% of neurones are GE and 1% are GI (Wang, 
Liu et al. 2004). However, high levels of GK mRNA are observed in both parts of the ARC: as 
high as that expressed in the VMN (Lynch, Tompkins et al. 2000). GK is expressed in POMC 
and NPY neurones. Whole cell patch clamp recordings from mouse brain slices show that 
most POMC neurones have GE properties (Ibrahim, Bosch et al. 2003). Selective knockout of 
KATP channels in POMC neurones impairs glucose-induced depolarisation (Parton, Ye et al. 
2007). In contrast, almost all GI responses found in one study were from NPY neurones 
(Muroya, Yada et al. 1999). In addition, many AgRP expressing neurones have a reduced 
expression of AMPK in response to glucose (Lee, Li et al. 2005, Mountjoy, Bailey et al. 2007). 
This reveals that POMC and NPY neurones resemble to some extent GE and GI neurones 
respectively. However, the independent roles of the ARC and VMN in glucose homeostasis 
have not been investigated (Levin, Routh et al. 2004, McCrimmon, Evans et al. 2005, Levin, 
Becker et al. 2008). As expression of POMC, CART, NPY and AgRP are different in ARC and 
VMN neurones, differences in GE and GI neurone signalling may be altered.  
The extracellular glucose concentration throughout most of the brain remains relatively 
stable, even when blood glucose levels fluctuate (Wang, Liu et al. 2004). In non-glucose 
sensing neurones, transporters carry glucose across the BBB and into cells to make use of all 
available glucose (Vannucci, Maher et al. 1997). However, extracellular glucose 
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concentrations are more similar to the blood in brain regions near the 3rd and 4th ventricles 
than other regions of the CNS (Silver and Erecinska 1994, de Vries, Arseneau et al. 2003, 
Langlet, Levin et al. 2013). Extracellular VMH glucose concentrations vary between 0.5 and 
2.5mM, whereas concentrations remain around 0.5mM in other regions of the CNS (de 
Vries, Arseneau et al. 2003, Wang, Liu et al. 2004). In parallel, the neuroendocrine form of 
GK is most sensitive to glucose within 0.5 and 2.5mM, identifying the VMH as ideal for 
glucose sensing (Kang, Dunn-Meynell et al. 2006). 
To further enhance neuronal glucose sensitivity, areas where the lining of the BBB is 
discontinuous can expose regions of the CNS to glucose concentrations more closely 
mirroring blood levels. Tanycyctes project extensively from the median eminence to the ARC 
as shown by GLUT1 immunoreactivity: allowing ARC neurones to be exposed to higher levels 
of glucose than the VMN (Peruzzo, Pastor et al. 2000). Recently, the structural organisation 
of the BBB in the ME has been shown to change during hypoglycaemia (Langlet, Levin et al. 
2013). Both fasting and administration of 2-DG increases the permeability of ARC cells to 
improve their access to nutrients. In addition, some ARC GE neurones are responsive to high 
extracellular glucose concentrations (above 5mM) via an AMPK pathway (Fioramonti, 
Lorsignol et al. 2004). There is no evidence that GLUT1 tanycytes project to the VMN. 
Therefore, it is likely that glucose sensing within the VMN and ARC differ, however the 
physiological role of this difference has not been identified. 
 
1.3.5.3 Brainstem glucose sensing 
Brainstem neurones integrate hypothalamic pathways with vagal efferent signalling to the 
pancreas and other peripheral tissues to control glucose homeostasis. Insulin secretion is 
partly controlled by orexinergic projections from the LH to the brainstem (Buijs, Chun et al. 
2001). Detection of hypoglycaemia by the CNS activates vagal projections to the pancreas 
via the DMNX and NTS (Wu, Gao et al. 2004).  
The brainstem also contains neurones for glucose and amino acid sensing, similar to the 
hypothalamus (Adachi, Kobashi et al. 1995, Blouet and Schwartz 2012). Some neurones 
express GK and KATP channels, indicating that the brainstem may have an important role in 
glucose sensing (Balfour, Hansen et al. 2006). Similar to the ARC, GK has been detected in 
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cells surrounding the 4th ventricle that have direct access to CSF. Immunoreactivity for both 
GLUT2 and KATP channels are observed in NTS and AP neurones nearest the 4
th ventricle 
(Maekawa, Toyoda et al. 2000). The functions of these glucose sensors, and to what extent 
they modulate the hypothalamic signals, are not yet known. However, recent evidence 
indicates that tanycytes in the AP closely resemble those in the median eminence (Langlet, 
Mullier et al. 2013). Therefore ambient glucose concentrations surrounding the AP might 
more closely resemble that of glucose in the blood, compared with other regions of the CNS. 
 
1.4 Mechanism of glucose sensing 
The intracellular machinery involved in glucose sensing, which was originally modelled in β-
cells, utilises GK as an intracellular regulator. A similar mechanism appears to occur in most 
GE neurones as GK remains the most specific marker of glucose sensing neurones.  
 
1.4.1 Glucokinase 
GK is part of the hexokinase family of enzymes that convert intracellular glucose to G6P in 
all mammalian cells. Of the four types of hexokinase identified within eukaryotic cells, GK 
(also called hexokinase IV) plays a distinct role. Unlike other hexokinases, GK phosphorylates 
glucose at a rate proportional to the intracellular glucose concentration (Printz, Magnuson 
et al. 1993). GK has a higher Michaelis constant (Km) for glucose than the other hexokinases 
therefore it is less easily saturated by increasing intracellular glucose concentrations. This is 
considered to play a role in glucose sensing.  
It is important to note that in cells expressing GK, other hexokinases are also present to 
maintain a constant supply of G6P regardless of fluctuations in extracellular glucose 
concentrations. It is possible that glucose sensing involving GK is a compartmentalised 
reaction within cells as not to interfere with normal ATP production. In support of 
compartmentalisation, glucose transporters and KATP channels are located proximal to each 
other on the cell membrane (Arkhammar, Nilsson et al. 1987). 
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In humans and rodents, GK is expressed in the liver, β-cells and CNS (Grossbard and Schimke 
1966, Matschinsky and Ellerman 1968, De Vos, Heimberg et al. 1995). In the CNS, GK is 
expressed in the VMN, ARC, PVN, DMN, LH, medial amygdala nucleus, NTS, AP and parts of 
the thalamus (Lynch, Tompkins et al. 2000, Hawrylycz, Ng et al. 2014). The role of GK in the 
hypothalamus and brainstem has been investigated previously to some extent; the role of 
GK in the thalamus and medial amygdala is mostly unknown. In the medial amygdala 
nucleus, a subset of GK neurones have been shown to project to the VMN and influence the 
CRR to hypoglycaemia (Zhou, Podolsky et al. 2010).  
Hepatic GK and neuroendocrine GK are the two major functional isoforms of GK. 
Neuroendocrine GK, a 465 amino acid peptide, is expressed in β-cells and the CNS (Roncero, 
Alvarez et al. 2000). The neuroendocrine isoform of GK is 15 amino acids longer than the 
hepatic isoform (Magnuson and Shelton 1989). Both catalyse the same reaction but hepatic 
GK is regulated by insulin and has a role in glucose clearance after feeding (Massa, 
Gagliardino et al. 2011), whereas neuroendocrine GK functions as a direct glucose sensor. 
Post-transcriptional processing of neuroendocrine GK produces a minor form of GK in β-cells 
with a lower affinity for glucose (Magnuson and Shelton 1989). However, this alternate 
isoform is not thought to participate in glucose sensing. GK activity is controlled by GK 
regulatory protein (GKRP) in some regions of the CNS, but the physiological function of this 
regulation is unknown (Alvarez, Roncero et al. 2002). 
 
1.4.2 Transmembrane glucose transporters 
Glucose transporters (GLUT) control the entry and exit of glucose, allowing rapid cellular 
uptake of glucose. Fourteen isoforms of GLUT have currently been identified, many of which 
are expressed in the human brain. GLUT1 is expressed in astrocytes and endothelial cells 
and plays an integral role in transporting glucose across the BBB (Simpson, Vannucci et al. 
2001, Mueckler and Thorens 2013). GLUT6, 8 and 10 are also expressed in the brain but 
their specific roles in glucose homeostasis, if any, remain unclear. GLUT3 is the main 
transporter for facilitating glucose uptake in neurones (Leino, Gerhart et al. 1997). GLUT3 
has a high apparent affinity for glucose (around 3mM) therefore is suited for low 
extracellular concentrations in the brain (Uldry, Ibberson et al. 2002). GLUT2 is important in 
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pancreatic β-cells for controlling insulin secretion, so it is likely to be an integral part of 
glucose sensing in the CNS as well (Navarro, De Fonseca et al. 1996, Schuit, Huypens et al. 
2001, Uldry, Ibberson et al. 2002). Despite GLUT2 having a low apparent affinity for glucose 
(17-20mM), the uptake of glucose into β-cells is still significantly higher than the rate of 
glucose phosphorylation by GK (Mueckler and Thorens 2013). While GLUT3 is highly 
expressed in glucose sensing neurones, GLUT2 co-localises with GK (Navarro, De Fonseca et 
al. 1996, Kang, Routh et al. 2004). GLUT2 is also expressed in tanycytes lining the floor of the 
third ventricle (Garcia, Millan et al. 2003). The proximity of tanycytes to higher levels of 
glucose in CSF and blood may explain why a high affinity for glucose is not required for 
uptake in glucose sensing neurones. GLUT2 knockout mice have an impaired regulation of 
NPY expression in response to fasting and re-feeding that is not due to impaired β-cell 
function (Bady, Marty et al. 2006). Furthermore, ICV injection of 2-DG does not promote 
feeding in GLUT2 knockout mice. Selective knockdown of GLUT2 in the ARC inhibits glucose 
sensing and insulin secretion  (Leloup, Orosco et al. 1998).  
While GLUT2 and 3 are important for glucose sensing, the regulation of glucose entry is not 
considered the regulatory step in most of types of glucose sensitive neurones during 
physiological conditions. This is partly because GLUT isoforms are also involved in the 
maintenance of a stable intracellular glucose concentration as a fuel for all intracellular 
processes. Therefore even during periods of hypoglycaemia there are mechanisms in place 
to take up any available glucose from the blood and extracellular space to maintain these 
processes.  
 
1.4.3 ATP-sensitive potassium channels 
Glucose sensing in β-cells is regulated by GK but an intracellular mediator triggers insulin 
release. KATP channels are thought to couple GK with cell membrane depolarisation. KATP 
channels control movement of K+ ions across the cell membrane and are abundantly 
expressed in many different cell types that can depolarise such as cardiac, skeletal and 
vascular smooth muscle (Seino and Miki 2003). KATP is an octameric protein consisting of two 
subunits (figure 1.3). Different cell types express specific KATP subunits that have slight 
variations in electrophysiological properties for different functions (Seino and Miki 2003). In 
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β-cells, Kir6.2 make up the pore and SUR1 the regulatory subunit in the form of two 
homomeric tetramers (Inagaki, Gonoi et al. 1997). The ratio of ATP to ADP ultimately 
determines closing of the channel pore. ATP is a negative allosteric regulator of KATP 
channels and binds primarily to Kir6.2 (Tucker, Gribble et al. 1998), which closes the pore 
and prevents K+ ions exiting the cell.  Other adenosine nucleotides, namely ADP, stimulate 
KATP channels by binding to SUR1 in the presence of Mg
2+ (Gribble, Tucker et al. 1997). This 
interaction is disrupted by sulfonylureas such as glibenclamide, thus enabling ATP to have a 
more potent effect at Kir6.2 and reducing K
+ conductance further (Hambrock, Löffler-Walz et 
al. 2002). In diabetic patients sulfonylureas are used as a treatment to stimulate insulin 
secretion (U. K. Prospective Diabetes Study U. K. Prospective Diabetes Study Group 1998).  
Kir6.2 and SUR1 are expressed throughout the CNS, including in the hypothalamus and 
brainstem (Karschin, Ecke et al. 1997). KATP channels are expressed in both POMC and NPY 
neurones in the ARC as 70% of neurones within the ARC respond to the potassium channel 
blocker tolbutamide (van den Top, Lyons et al. 2007). Global Kir6.2 knockout markedly 
impairs the response to glucose in hypothalamic neurones (Park, Choi et al. 2011). When 
Kir6.2 knockout is restricted to POMC neurones there are global impairments in glucose 
tolerance and glucose-stimulated α-MSH release (Parton, Ye et al. 2007). On the other hand, 
injection of diazoxide in the VMN to stimulate KATP channel opening and hyperpolarise 
affected neurones amplifies the CRR to hypoglycaemia (McCrimmon, Evans et al. 2005). 
Therefore KATP channels likely play an important role in hypothalamic glucose sensing. 
Interestingly, ATP binds to both CFTR and KATP channels to trigger depolarisation as they 
share similar homology (figure 1.3), but they control depolarisation in GI and GE neurones 
respectively. 
 
 
 
 
 
33 
 
 
 
 
 
Figure 1.3 Protein structures and modulators of SUR1 and Kir6.2 subunits of KATP channels:  
(A) Schematic of SUR1 and Kir6.2 subunits. SUR1 has two cytoplasmic nucleotide binding 
domains (NBD1 and NBD2) and Kir6.2 has two transmembrane helices that form the pore 
(M1 and M2). The cytoplasmic linker L0 binds the protein-specific N-terminal domain to the 
subunit’s core structure, which is present in similar receptors such as CFTR. (B) Schematic of 
the quaternary structure of KATP channels. (C) Ligands of KATP channels. Sulfonylureas such as 
glibenclamide bind to SUR1 at site A and B, whereas Mg-nucleotides bind to the NBDs. ATP 
binds to Kir6.2. Adapted from Martin, Chen et al. (2013). 
 
  
A
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1.4.4 The multiple roles of glucose sensing cells 
The multiple mechanisms that have been described within glucose sensing cells illustrate 
that not all glucose sensors are part of the same neuronal circuits. While some hypothalamic 
glucose sensing neurones have been shown to control the CRR to hypoglycaemia, some 
glucose sensing neurones might have different roles. Therefore it is likely that glucose 
sensing neurones that express different glucose transporters, enzymes and ion channels 
exert many different physiological effects. Many glucose sensing neurones are responsive to 
other metabolic signals and may be communicating a more general representation of 
energy homeostasis rather than glucose specifically. Intracellular mediators such as AMPK 
and KATP channels are involved in glucose, leptin and insulin signalling (Spanswick, Smith et 
al. 2000, Claret, Smith et al. 2007). As GK is not expressed in all glucose sensing neurones, it 
is likely that some neurones respond to a variety of metabolic signals involving other 
mechanisms. For example, glucose sensing via phosphorylation of AMPK has been described 
in both GE and GI neurones, but it is unclear whether AMPK regulates glucose sensing or 
cellular energy homeostasis in these neurones (Claret, Smith et al. 2007, Murphy, Fakira et 
al. 2009). 
Insulin and leptin are amongst other metabolic signals that induce changes in energy 
homeostasis via similar machinery to that used in glucose sensing neurones. Leptin and 
insulin can both open KATP channels resulting in a decrease in membrane potential and the 
inhibition of action potentials (Spanswick, Smith et al. 1997, Spanswick, Smith et al. 2000). 
However, leptin and insulin also act via alternate signalling pathways, namely PIP3-mediated 
signals, in POMC neurones (Plum, Ma et al. 2006). Similarly, in fatty acid sensing pathways, 
oleic acid depolarises POMC neurones by blocking KATP channels (Jo, Su et al. 2009). 
Esterification of long chain fatty acids to fatty acyl-CoAs enables ATP production via β-
oxidation and thus inhibition of KATP channels (Lam, Schwartz et al. 2005). As fatty acid 
sensing neurones have been identified in the hypothalamus, it is possible that integration of 
fatty acid and glucose sensing signals occurs within some neurones (Migrenne, Cruciani-
Guglielmacci et al. 2006).  
A lactate-facilitated mechanism of glucose sensing has been investigated (Song and Routh 
2005). Lactate is integral to neuronal metabolism as it is provided as a substitute fuel by 
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astrocytes, and converted to acetyl-CoA in neurones (Pellerin and Magistretti 1994, Pellerin, 
Bouzier-Sore et al. 2007). Blocking the monocarboxylate transporter desensitises orexin 
neurones in the LH to changes in glucose (Parsons and Hirasawa 2010).  Whether release of 
lactate by astrocytes is proportional to glucose concentrations during euglycaemia remains 
to be investigated, but this pathway further demonstrates other mechanisms of glucose 
sensing. The contribution of the multiple pathways and metabolic signals therefore requires 
further investigation. 
 
1.5 Approaches for investigating the neuronal circuits controlling energy 
homeostasis in rodents 
1.5.1 Direct cannulation 
Investigating the mechanisms involved in glucose sensing is important for understanding the 
pathophysiology of obesity and diabetes. To achieve this, several techniques are utilised to 
elucidate the specific roles of molecules in vivo. Acute changes in specific enzyme or 
receptor activity within the CNS can be investigated by direct administration of compounds. 
ICV injections have proven useful for studying the effects of peptides regulating food intake 
such as NPY, AgRP and α-MSH in the brain (Zarjevski, Cusin et al. 1993, Rossi, Kim et al. 
1998). Injection of compounds into specific nuclei by cannulation enables the investigation 
of the physiological role of specific nuclei involved in energy homeostasis. This has been 
performed in rodents to identify endogenous peptides involved in feeding (Edwards, 
Abusnana et al. 1999, Batterham, Cowley et al. 2002). However, direct cannulation is not 
suitable for looking at the chronic effects of compounds. The pharmacological activity of 
most compounds only last for a short time, but direct injections can only be repeated a 
limited number of times before local inflammation and tissue damage occurs around the 
injection site.  
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1.5.2 Genetic modification by global mutation 
Chronic investigation of the mechanisms regulating energy homeostasis can be achieved by 
generating genetic modifications of specific genes in vivo. Null mutations and gain of 
function mutations can be introduced into the mouse gene to create a permanent global 
alteration in that gene. Measuring the alterations due to a genetic knockout can identify 
important genes involved in food intake such as those that encode leptin (Halaas, Gajiwala 
et al. 1995) but there are a few drawbacks to this approach. Compensatory mechanisms can 
result in up-regulation of similar genes during development to correct for the effects of the 
deleted gene (Picciotto 1998). Additionally, global knockout of a gene may produce 
unwanted side effects due to expression in other areas of the body. An example of 
compensation can be observed in NPY knockout mice. Despite NPY knockout not resulting in 
any changes in food intake or energy homeostasis, postnatal knockdown ablation of NPY 
produces irreversible starvation (Erickson, Clegg et al. 1996, Luquet, Perez et al. 2005, 
Mercer, Chee et al. 2011).  
Global homozygous knockout of the glucokinase gene results in neonatal lethality (Remedi, 
Koster et al. 2005). This highlights the physiological importance of the enzyme to 
development, and shows that other hexokinases are not able to compensate in order to 
adequately control glucose metabolism. By disrupting a neuroendocrine-specific exon, 
targeted knockout of neuroendocrine GK aims to retain normal liver functionality and only 
reduce GK in the CNS and pancreas (Terauchi, Sakura et al. 1995). These mice are still 
significantly insulin resistant and develop severe diabetes and die within a week. In contrast, 
heterozygous GK knockout produces a milder phenotype yet still results in partially reduced 
global GK expression. These animals can be made hyperglycaemic on high fat diet (Baker, 
Atkinson et al. 2014). However the precise role of CNS GK in the contribution of the 
hyperglycaemic phenotype cannot be quantified with the heterozygous knockout. Therefore 
a knockout of GK in specific tissue subtypes would produce a more selective model but this 
is technically challenging as no differences between hypothalamic and pancreatic GK genes 
have been identified.  
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1.5.3 Selective genetic modification 
Site specific recombinase technology allows selective expression of a transgene in specific 
tissues or brain regions. Cre-Lox recombination relies upon the inversion or removal of DNA 
by Cre-recombinase (Cre) at a specific binding site flanked by short target sequences named 
Lox-P. Insertion of both Cre and Lox-P genes can be linked to a tissue-specific endogenous 
promoter to restrict the extent of Cre activation and transgene expression. Cre-Lox 
recombination has been used to investigate the effects of specific alterations in 
hypothalamic feeding circuits; for example, the development of mice with leptin receptor 
knockout exclusively in POMC expressing neurones (Balthasar, Coppari et al. 2004). Mice 
expressing Cre under the POMC promoter were crossed with mice with LoxP sites flanking 
the Janus kinase (JAK) docking site of the leptin receptor allele. As the only functional leptin 
receptors in POMC expressing cells are in ARC neurones this creates a model for studying 
the effects of leptin knockdown in ARC POMC neurones. A limitation of this technique is 
that developmental compensation can still occur. For example, knockout of AgRP/NPY 
expressing neurones in neonates does not affect feeding, but selective ablation of the same 
neurones using diphtheria toxin in adult mice, does (Luquet, Perez et al. 2005).  
A disadvantage of Cre-Lox recombination is that investigation is restricted to transgenic 
mice only. Transgenic modifications in wild-type rats can be achieved by direct injection of 
foreign DNA encoding for a particular protein. A transgenic alteration in the brain requires 
stereotactic injection under general anaesthesia to ensure accurate and specific expression 
of the gene. An advantage of direct injection is that it eliminates developmental changes 
caused by expression during development. Also, location-specific injection provides the 
benefit of genetic alteration in a specific area to avoid side effects of global alterations.  
 
1.5.4 Vectors used for gene transfer 
As injection of naked DNA is not able to efficiently infect host cells in vivo, the gene of 
interest is packaged into a vector. The most efficient vectors are based on wild-type viruses 
that can efficiently infect mammalian cells. Other non-viral vectors have been used but they 
have not made much success in clinical and preclinical experiments (Lam and Dean 2010). 
Use of virus-mediated transfection is a powerful and efficient way to provide selective 
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genetic modification in vivo. However, any immune response and replication of the virus 
needs to be eliminated. Depending on the severity of the host’s immune response, 
destruction of a foreign body by proteasome degradation, production of antibodies or fever 
can occur. The immune response can affect transduction of the gene of interest and the 
host’s physiological response to the treatment. To circumvent the immune response, wild-
type viruses are re-engineered by removal of as much endogenous viral DNA as possible. 
Removal of the genes required for self-replication also eliminates the ability for the virus to 
multiply. The virus is therefore safer to work with and cannot spread to other areas of the 
host once after the initial infection.   
A limitation of stereotactic injection of vectors is that the extent of expression is dependent 
upon the skill of the surgeon. In addition, sufficient time should be allowed for maximal 
gene expression, which can be up to four weeks.  
 
1.5.4.1 Retroviral vectors 
Retroviral vectors are able to integrate into the host’s chromosomes to increase their 
effectiveness, unlike many viral vectors that are present in the nucleus as an episome. 
However, depending on where the vector integrates in the chromosome, disruption of an 
endogenous gene can occur due to insertional mutagenesis. With the exception of the 
lentivirus, retroviral vectors only have the ability to transfect dividing cells. These are 
therefore useful as a treatment for cancer but are not ideal when introducing a gene into 
quiescent adult neurons. Also many retroviral-based vectors have a low transfection 
efficiency and a low titre (Gardlik, Palffy et al. 2005). Lentiviruses overcome many of these 
limitations and are ideal for in vivo transfection as they do not produce a significant immune 
response (Quinonez and Sutton 2002). They also allow large therapeutic genes to be 
inserted at over 18kb (Kumar, Keller et al. 2001). However, as they are based on human 
immunodeficiency virus, they pose a potential safety risk during production, as a replication-
competent virus can potentially be generated. Also, lentivirus vectors spread further than 
the intended injection site, which is a concern when injecting into specific brain areas 
(Blömer, Naldini et al. 1997). 
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1.5.4.2 Adenoviral vectors 
Recombinant adenoviruses can be produced at a high titre and can transfect a high ratio of 
cells making them useful for altering gene expression in large tissues like the liver (Brunetti-
Pierri, Stapleton et al. 2007). The double stranded DNA of an adenovirus is enclosed in a 
large capsid made up of several different proteins. Even deletion of many unnecessary 
genes in recombinant adenoviral vectors still results in an immediate innate immune 
response and antibody production. The significant host immune response has hindered the 
use of this vector in many applications (Kay 2011).  
 
1.5.4.3 Adeno-associated viral vectors 
Adeno-associated viral (AAV) vectors are minimally pathogenic, highly persistent and can be 
produced at a high titre (Ponnazhagan, Mukherjee et al. 1997). Twelve human serotypes 
and over 100 primate serotypes have been identified, each having tropism for particular cell 
types (Howard, Powers et al. 2008). AAV contains single stranded DNA that requires 
conversion into double stranded DNA once successfully transfected into the host; a process 
that can be slow and delays maximal expression by up to 3 weeks in vivo (Wang, Ma et al. 
2003).  The majority of viral DNA is removed in recombinant AAV (rAAV), including the 
genes encoding Rep and Cap proteins for capsid production and insertion into the host’s 
chromosomes. The remaining viral DNA consists of inverted terminal repeats at both ends 
that are essential for transfection. Removal of inessential genes creates a larger insertion 
cassette for therapeutic genes.  
AAV2 has a tropism for neurones, therefore is valuable when investigating overexpression 
or knockdown of genes in the CNS (Gardiner, Kong et al. 2005). When administered in vivo, 
rAAV2 spread is limited to around the site of injection as co-transfection of a helper plasmid 
containing the necessary genes for replication is required. The infection rate into the CNS is 
approximately 70% (Palomeque, Chemaly et al. 2007). While rAAV has the ability for a larger 
gene to be inserted than AAV, the size of the cassette is still smaller than other vectors 
(4.5kb vs. <18kb for lentivirus). To overcome this, trans-splicing vectors can be engineered 
(Yan, Zhang et al. 2000). The cassette size can be doubled with the independent infection of 
complimentary rAAV vectors that recombine in the cytoplasm. A benefit of rAAV is that 
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stable expression seems to persist for several months despite the DNA being present as an 
episome.  Transfection of rAAV containing glucokinase has previously been successful in vivo 
in our laboratory (Hussain, Richardson et al. 2014). 
1.6 Summary 
The brain has developed a complex set of neuronal circuits to control food intake and 
homeostasis. Many of these circuits involve neurones in the arcuate nucleus of the 
hypothalamus, where nutrients and hormones from the blood and CSF provide feedback to 
fine tune neuronal responses. Hypothalamic glucose sensing neurones have previously been 
described to control counterregulatory responses to hypoglycaemia and hyperglycaemia. 
However, a specific role for arcuate nucleus glucose sensing neurones in regulating food 
intake has not has not been investigated. The work in this thesis investigates arcuate 
nucleus glucose sensing and its role in food intake using rats. 
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Chapter two: Materials and methods 
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2.1. Methods used to produce plasmids containing GK and to produce 
rAAV 
2.1.1 Production of rAAV 
Recombinant AAV was produced by Dr J Gardiner (Division for Diabetes, Endocrinology and 
Metabolism), Dr SS Hussain (Division for Diabetes, Endocrinology and Metabolism) and Dr E 
Richardson (Division of Women's Health, King's College London). Full length glucokinase cDNA was 
isolated and amplified by PCR from the plasmid pCMV4.GKB1 encoding full length glucokinase cDNA 
(gift from Prof. Magnuson, Nashville).  
GK DNA were cloned into the plasmid pTR-CGW (gift from Dr. Verhaggen, Amsterdam) in the 
forward and reverse orientation to produce GK sense (GKS) and antisense (GKAS), respectively. 
Recombinant AAV particles were produced using the two-plasmid system with a helper plasmid pDG 
(Grimm, Kern et al. 1999), then recovered and purified using a Sepharose column. This was used to 
make rAAV-GKS and rAAV-GKAS.  
 
2.1.2 Digestion of PCR products 
The previous PCR products from isolated GK cDNA were cut to isolate the fragment of interest.  
Materials 
GK-pTR-CGW plasmid (AAV-CMV-eGFP-WPRE-Amp) 
Restriction endonucleases: BamHI, PSTI (New England Biolabs) 
10x Restriction buffer (appendix 1) 
10x Bovine serum albumin (BSA) (New England Biolabs) 
Shrimp alkali phosphatase (SAP) 4U/µl (GE Healthcare) 
Phenol/chloroform pH8 (VWR) 
2M Sodium acetate pH5.2 (appendix 1) 
100% ethanol (VWR) 
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Methods 
GK-pTR-CGW was diluted twice in GDW in separate microcentrifuge tubes. Restriction buffer and 
BSA were added to give a final concentration of 1x. Eight microlitres of BamHI and PstI (30U each) 
were added to give the volume of enzyme added as less than 10% of the final volume. The reaction 
was incubated at 37°C for at least 1 hour and 8U SAP added to one reaction 30 minutes before the 
end of the incubation. SAP removes 5‟ phosphate groups preventing self-ligation of the plasmid. The 
reactions were extracted with an equal volume of phenol/chloroform and the phases separated by 
centrifugation for 3 minutes at 13,000xg. The DNA was ethanol precipitated with 0.1 volumes 
sodium acetate pH5.2 and 2.5 volumes absolute ethanol and was incubated at -20°C for at least one 
hour. The DNA was recovered by centrifugation for 7 minutes at 13,000xg. 
 
2.1.3 Electroelution of DNA fragments 
Following the PCR reaction it is advantageous to purify the DNA fragment of interest and remove any 
contaminating fragments. This is especially true for plasmids as restriction digests are not 100% 
efficient and a small amount of closed plasmid DNA can produce a high background during 
transformations. The DNA was therefore size fractionated by electrophoresis on an agarose gel and 
the bands of interest electroeluted. 
Materials 
Agarose, type II-A medium EEO (VWR) 
50x TAE (Appendix I) 
Ethidium Bromide (10mg/ml) (VWR) 
Dialysis tubing (VWR) 
Gel loading buffer (Appendix I) 
1Kb plus DNA marker (Invitrogen) 
DNA fragments 
Methods 
A 1% (w/v) agarose gel was prepared by boiling 3g agarose and 6ml 50X TAE in 300ml GDW, allowing 
this to cool, then adding 13µl ethidium bromide before pouring into a cassette. The precipitated 
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DNA was dissolved in 20μl GDW and 6μl loading buffer added. One microlitre of DNA marker was 
added to 9μl GDW and 3μl loading buffer added. Samples were loaded onto the gel and 
electrophoresed at 10V/cm. 
The DNA was visualised by illumination with UV light (300nm), the band of interest was cut out from 
the gel using a scalpel and placed into dialysis tubing. Four hundred microlitres of 0.5x TAE was 
added to the gel slice, air excluded from the end of the tubing and the other end sealed with a clip. 
The DNA was eluted from the gel by electrophoresis at 20V/cm for 20 minutes. The TAE was 
removed from the tubing, phenol/chloroform extracted and the DNA was recovered by ethanol 
precipitation (as described in section 2.1.2).  
The DNA was then quantified spectrophotometrically: 10μl DNA was diluted 1:100 and placed into a 
quartz cuvette. Absorbance was read at 260 and 280nm UV 1101 spectrophotometer (WPA). The 
reading at 280nm gives an indication of the purity of the sample as proteins and phenol absorbs 
more strongly at 280nm than DNA. The concentration of the DNA was calculated using the following 
formula: 
Concentration (μg/ml) = (A260 x dilution factor) x 50 
 
 
2.1.4 Ligation of PCR product into pTR-CGW 
Materials 
T4 DNA ligase, 6U/μl (New England Biolabs) 
10x Ligase buffer (New England Biolabs) 
Digested plasmid: insert (27ng/µl) and cut plasmid (46ng/µl) 
Methods 
DNA ligation was used to insert the digested GK into pTR-CGW plasmid. Twenty nanograms of cut 
plasmid DNA were dissolved in GDW and a fourfold molar excess of PCR product added. Ligase 
buffer was added to a final concentration of 1x and 6U T4 DNA ligase added to give a final volume of 
10μl. The reaction was incubated at 16°C overnight. 
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2.1.5 Transformation of competent bacteria by heat shock 
A sudden increase in temperature opens transient pores in the bacteria plasma membrane allowing 
the plasmid to move into the cell. pTR-GCW contains an ampillicin resistance gene. Calcium chloride 
is added to the environment to reduce electrostatic repulsion between the plasmid and bacterial cell 
membrane. Subsequent incubation allows the expression of the resistance genes before exposure to 
antibiotic. 
Materials 
LB culture medium (Appendix I) 
LB(amp) plates (Appendix I) 
E. coli BL21 bacteria (Invitrogen) in frozen aliquots of 0.1M CaCl2 and 15% glycerol  
Methods 
On ice, 5ng of ligation products were added to an aliquot of thawed bacteria, mixed gently and 
incubated on ice for 10 minutes. The mixture was heated to 42°C for 45 seconds, then immediately 
incubated on ice again. 450µl LB was added and was shaken rigorously at 250 rpm for 1 hour at 37°C. 
Agar plates (supplemented with 100μg/ml ampicillin) were warmed and 150μl of the transformed 
bacteria added to the plate. The bacteria were spread over the surface of the agar, the plate 
inverted and incubated at 37°C overnight. Efficiently transformed colonies were collected and 
sequenced. 
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2.1.6 DNA sequencing 
Sequencing of GKS-pTR-CGW plasmid was performed by the Imperial College Genomics Core 
Laboratory.  
Materials 
GKS-pTR-CGW 
20µM GK forward primer 5’-ACGTACCGGTATTCACATCTGGTACCTGGG -3’ (Oswel DNA Service)  
20µM GK reverse primer 5’-AGCTCGTACGTATTAGGACAAGGCTGGTGG-3’ (Oswel DNA Service) 
 
Methods 
Prior to sequencing 200ng of plasmid DNA was diluted and mixed with 3.2pmole of either the 
forward or reverse primer that was used during the initial production of the plasmid. Samples were 
cycle sequenced using BigDye v3.1 (Applied Biosystems Ltd, Warrington, UK). Sequencing results 
were analysed for homology to known rat GK gene sequences using the Basic Local Alignment Search 
Tool (BLAST) on the National Centre for Biotechnology Information (NCBI) internet site. 
 
 
2.1.7 Large scale preparation of plasmid 
A large scale preparation of a plasmid or maxi preparation is used to obtain a large supply of high 
quality plasmid.   
Materials 
LB(amp) (Appendix I) 
GTE (Appendix I) 
Lysozyme (Sigma) 
0.2M sodium hydroxide/1% (w/v) SDS (Appendix I) 
5M potassium acetate (KAc) (VWR) 
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Propan-2-ol (VWR) 
100x TE (Appendix I) 
DNase free RNase A 10mg/ml in GDW (GE Healthcare) 
Phenol/Chloroform (VWR) 
Methods 
A small quantity of bacteria containing pTR-CGW was inoculated into 500ml LB(amp) and incubated 
at 37°C overnight with shaking at 250 rpm. The bacteria were split into two and each recovered by 
centrifugation for 8 minutes at 3000xg at 4°C. The pellets were resuspended in 12.5ml GTE 
supplemented with 2mg/ml lysozyme and incubated at room temperature for 5 minutes. Twenty 
five millilitres of NaOH/SDS were added, the samples mixed by inversion and incubated on ice for 5 
minutes until they cleared. Then 18.75ml 5M KAc were added, the samples mixed by inversion and 
incubated on ice for 5 minutes. Bacterial debris was removed by centrifugation for 10 minutes at 
9000xg at 4°C. The supernatants were transferred to a clean tube and 0.6 volumes isopropanol 
added. The samples were incubated on ice for 15 minutes and the DNA recovered by centrifugation 
for 15 minutes at 9000xg at 4°C. The pellets were dissolved in 5ml GDW and combined together, to 
which 100μl 100x TE was added. RNase A was added at a concentration of 0.1mg/ml and the 
reaction incubated at 37°C for 60 minutes. The reaction was extracted with an equal volume of 
phenol/chloroform and the phases separated by centrifugation for 20 minutes at 10000xg and 4°C. 
The DNA was recovered by addition of 0.1 volumes 2M sodium acetate pH 5.2 and one volume 
isopropanol and incubation at -20°C for at least one hour. The DNA was then purified by caesium 
chloride gradient. 
 
2.1.8 Caesium chloride gradient purification 
Large scale plasmid purification was carried out using a caesium chloride gradient (Sambrook, Fritsch 
et al. 1989). This purification method depends on the decrease in density of nucleic acids when 
bound to ethidium bromide. Because ethidium bromide binds by intercalation into the DNA, it 
causes unwinding of the helix. Closed circular DNA of a plasmid increases supercoiling so binding of 
ethidium bromide is limited and the plasmid has a higher buoyant density than linear or nicked 
plasmids. The difference in buoyant density allows separation of the plasmid on a caesium chloride 
density gradient. 
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Materials 
TES: 50mM Tris-HCL (pH 8.0), 50mM NaCl, 5 mM EDTA in GDW (Appendix I) 
Caesium chloride (Boehringer) 
10mg/ml ethidium bromide (VWR) 
Caesium chloride-saturated propan-2-ol (Appendix I) 
Methods 
DNA obtained from large scale plasmid purification was recovered by centrifugation for 20 minutes 
at 24,000xg and 4°C. The DNA was then dissolved in 8.20ml TES. Eight point four grams of caesium 
chloride were dissolved in the DNA solution and 200μl of ethidium bromide added and the solution 
shaken to disperse. The sample was divided into two polyallomer tubes (Ultracrimp, Du Pont), 
balanced, and overlaid with paraffin oil. The tubes were sealed and centrifuged for 16 hours at 20°C 
and 216,518xg (60,000rpm in a T-8100 rotor in a Sorvall 100SE centrifuge, Fisher Scientific). 
After centrifugation, DNA bands were visualised by UV illumination and the band containing the 
closed pTR-CGW DNA removed using a 20-gauge needle and a 2ml syringe. Ethidium bromide was 
removed from the plasmid by repeated extraction with an equal volume of caesium chloride 
saturated isopropanol until both phases were colourless. The DNA was precipitated by addition of 
two volumes of GDW and six volumes of room temperature absolute ethanol. DNA was recovered by 
centrifugation at 24,000xg and 20°C for 20 minutes. The supernatant was poured off and the DNA 
pellet was dissolved in 0.4ml GDW, ethanol precipitated with 0.1 volume of sodium acetate and 2.5 
volumes of absolute ethanol at -20°C for 60 minutes and recovered by centrifugation for 7 minutes 
at 13,000xg. The DNA was then air dried for 10 minutes and dissolved in 1ml GDW. GK-pTR-CGW 
was quantified by spectrophotometric measurement at a wavelength of 260nm. Negligible protein 
contamination was confirmed by a low absorbance at 280nm. 
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2.1.9 Plasmid digestion for dot blot and in situ hybridisation 
GK-pTR-CGW plasmid was cut to produce a linear cDNA fragment that could be used for dot blot 
analysis and in situ hybridisation. Restriction endonucleases were used to digest the DNA fragments 
of interest as previously sequenced in 2.1.6.  
Materials 
GK-pTR-CGW (1.6mg/ml) and pTR-CGW (4.5mg/ml) 
Restriction endonucleases: BamHI, PSTI (New England Biolabs) 
10x Restriction buffer (appendix 1) 
10x Bovine serum albumin (BSA) (New England Biolabs) 
Phenol/chloroform pH8 (VWR) 
2M Sodium acetate pH5.2 (appendix 1) 
100% ethanol (VWR) 
Methods 
Samples were subjected to endonuclease digestion (as described in 2.1.2, without SAP). GK-pTR-
CGW was digested by BamHI and PstI in separate reactions to produce antisense and sense probes, 
respectively. pTR-CGW containing WPRE, which was previously prepared by Dr Errol Richardson, was 
digested with BamHI and EcoRI. Products were diluted in GDW to a final concentration of 200ng/µl. 
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2.1.10 Quantification of total virus titre by dot-blot analysis 
The concentration of rAAV depicts the level of transgene expression so the total particle number was 
determined by dot-blot analysis. Similar to northern and southern blotting techniques, dot-blot 
analysis measures RNA or DNA using a radio-labelled probe.  Rather than being separated by size 
and transferred to a membrane, the sample being analysed is placed directly onto a membrane. 
Analysis of DNA by dot-blot is more accurate than other techniques such as RT-PCR in that a probe 
with a higher specificity can be used because the original genome sequence is used. 
Materials  
rAAV-GFP and rAAV-GKAS viral preparations  
Solution A: 10mM Tris-HCl (pH 8.0), 1mM MgCl2 and 8U/ml DNase I in GDW (Appendix I) 
Solution B: 10mM Tris-HCl (pH 8.0), 100mM NaCl, 10mM EDTA, 0.5% SDS and 1mg/ml proteinase K 
in GDW (Appendix I) 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) 25:24:1 (VWR) 
5M Glycogen (5mg/ml) (Life Technologies) 
100% Ethanol (VWR) 
75% Ethanol 
2M Sodium acetate (pH 5.2) (Appendix I)  
Denaturing solution: 2M NaCl in 0.5M NaOH (Appendix I)  
Neutralising solution (pH 7.5): 2M NaCl, 0.5M Tris-HCl (Appendix I)  
pTR-CGW plasmid (4.5mg/ml)  
Hybridisation buffer (Appendix I) 5mg/ml dried milk powder, 2.5mM EDTA, 0.25M Na phosphate 
buffer, 5% SDS and 25µM ATA in GDW (Appendix I) 
Woodchuck post-transcriptional regulatory element (WPRE) cDNA fragment  
5x ABC Buffer containing deoxynucleotides, random oligonucleotides and mercaptoethanol 
(Appendix I)  
BSA, fraction V (10mg/ml) (Sigma)  
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(α-32P)-dCTP: 10Ci/ml, 3Ci/mol (Perkin Elmer)  
DNA polymerase I, Klenow fragment (9U/μl) (GE Healthcare)  
Sephadex G50 (Appendix I)  
1x TE (pH 7.5) (Appendix I)  
Amasino wash buffer: 1mM Na phosphate buffer (pH 7.2), 1mM EDTA and 2% SDS in GDW 
(Appendix I) 
Universal wash buffer: 0.2% SDS and 0.02x SSPE in GDW (Appendix I) 
Nylon filter paper (Hybond N+, GE healthcare) 
Methods  
Forty five microlitres of solution A were added to 5μl rAAV virus stock and incubated for thirty 
minutes at 37°C. Two hundred microlitres of solution B were added and the sample was incubated at 
55°C for one hour. DNA was extracted by adding an equal volume of phenol/chloroform and the 
phases separated by centrifugation for three minutes at 13,000xg. The top phase containing the DNA 
was ethanol precipitated by adding 0.1 volumes sodium acetate, 40μg glycogen and 2.5 volumes ice 
cold 99.7-100% ethanol. After one hour at -20°C the solution was centrifuged for seven minutes at 
8,000xg and 4°C and the supernatant discarded. The pellet was washed in 450μl 75% ice cold 
ethanol with centrifugation as before, supernatant removed and air-dried. The pellet was re-
suspended in 10μl GDW and 1μl applied to a nylon membrane. A series of dilutions of the original 
plasmid pTR-CGW (50 to 0.1ng) were also applied to the membrane to act as a standard curve. The 
membrane was washed for five minutes in denaturing solution then washed twice for five minutes in 
neutralising solution. The membrane was then baked at 80°C for two hours. Pre-hybridisation was 
carried out by placing the membrane into a heat sealed polythene bag containing 10ml hybridisation 
buffer without probe. The membrane was incubated at 60°C for four hours. 
A cDNA fragment of WPRE was used as a probe for rAAV transgenes. To radio-label the probe, 20ng 
of DNA in a total volume of 13μl of GDW were boiled for five minutes. After boiling, the solution was 
made up to a total volume of 25μl containing 1x ABC buffer, 2mg/ml BSA, 10μCi dCTP and 1U 
Klenow. The reaction was incubated at 37°C for at least one hour. Incorporation of radio-labelled 
nucleotide into the DNA probe was measured using a mini Sephadex G50 column. The column was 
prepared by plugging a glass Pasteur pipette with glass wool, and adding Sephadex G50. The 
labelling reaction volume was made up to 200μl 1x TE and loaded onto the column. The column was 
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then eluted with 1x TE and 200μl fractions collected. The fractions were counted and the percentage 
incorporation calculated. The hottest two fractions were pooled and half was boiled and added to 
10ml hybridisation buffer. Hybridisation was carried out overnight at 60°C by emptying the pre-
hybridisation buffer from the polythene bag, adding fresh buffer containing probe and resealing.  
The following day the membrane was washed to remove any non-specifically bound probe. Three 
twenty minute washes at 60°C were carried out in amasino wash buffer followed by a further three 
twenty minute washes at 60°C in universal wash buffer. The filter was then sealed in a clean plastic 
bag and exposed to a storage phosphorimager screen (GE Healthcare) for two days. Radio-labelled 
areas were visualised and quantified by image densitometry using ImageQuant software (GE 
Healthcare). Quantification was performed by comparing viral DNA to known amounts of pTR-CGW 
in the standard curve. 
 
2.1.11 In vitro transfection of GKAS pTR-CGW into cultured cells 
The ability of GKAS plasmid to transfect mammalian cells was tested using a human hepatocellular 
carcinoma (HEPG2) cell line, which express large quantities of GK, by Dr E Richardson (Division of 
Women's Health, King's College London).  
Materials 
Human hepatocellular carcinoma (HEPG2) (ATCC) 
Dulbeccos modified eagle medium (DMEM) (Invitrogen) 
Foetal Bovine Serum, heat inactivated (FBS) (Invitrogen) 
2.5% Trypsin in hanks balanced salt solution (Invitrogen) 
Versene (appendix I) 
2x HEPES-buffered saline (HBS) (appendix I) 
2M calcium chloride (appendix I) 
40μg/ml plasmid DNA in 0.1x TE 
DMEM (Invitrogen) 
 
53 
 
Methods 
HEPG2 cells were cultured in DMEM containing 4.5mg/ml glucose and 1mM sodium pyruvate 
supplemented with 10% (v/v) FBS at 37°C in 5% carbon dioxide. The medium was changed every 
three days and the cells sub-cultured when 70-80% confluent using 0.25% trypsin in versene. The 
medium was aspirated and cells incubated at 37°C for 5 minutes with fresh trypsin/versene until 
they detached from the flask. The trypsin was inactivated by the addition of 10ml of fresh medium 
and the cells recovered by centrifugation for 5 minutes at 100xg. The cells were resuspended in fresh 
medium and transferred to a new flask at a 1:10 dilution. 
Cells at approximately 60% confluence were sub-cultured and plated at a density of 1x104 cells/cm2 
in 90mm Petri dishes. The following day, the medium was replaced with fresh medium. A calcium 
phosphate co-precipitation was used to transfect large quantities of exogenous DNA. Briefly, a co-
precipitate was formed by mixing 300μl 10xHBS with 28μg plasmid DNA in 2.5ml GDW and slowly 
adding 180μl 2M calcium chloride, while gently mixing using air expelled from a pipette aid. The 
solution was incubated at room temperature for 5 minutes to allow formation of the precipitate. The 
precipitate was added to the cells and they were incubated at 37°C in 5% carbon dioxide for 18 
hours. The medium containing the precipitate was replaced with fresh media, cells were incubated 
for 48 hours after which time, cells were lysed in GK extraction buffer and a GK activity assay was 
performed as described below in 2.3.1. 
  
54 
 
2.2 Methods used for physiological and pharmacological measurement 
of glucose sensing in vivo  
2.2.1 Animal maintenance 
Male Wistar rats (specific pathogen free, Charles River UK Ltd) were maintained under a controlled 
environment (temperature  21-23°C, 12 hour light-dark cycle, lights on at 07:00) with ad libitum 
access to standard chow (RM1 diet, Special Diet Services UK Ltd), except where stated, and water. 
All animal procedures were approved under the British Home Office Animals (Scientific Procedures) 
Act 1986 (Project Licence no. 70/7229). Prior to all experiments animals were acclimatised to the 
Imperial College animal holding rooms for 7 days. Animals were pseudo-randomised to treatment 
and control groups of approximately equal mean and standard error of mean bodyweight.  
 
 
2.2.2 Optimisation of successful stereotactic injection 
Stereotactic micro-injection into the rat ARC is technically challenging as the structure is 
approximately 1mm3 each side of the third ventricle. Glucokinase mediates glucose homeostasis in 
other areas of the hypothalamus, namely the VMN adjacent to the ARC. Therefore, if rAAV-GKAS is 
delivered inaccurately, GK knockdown will occur in CNS areas other than, or as well as, the ARC. This 
will make the phenotype inconsistent and difficult to interpret. For this reason, stereotactic micro-
injection was optimised with injection of Indian ink. This allowed improvements in technique and 
accuracy of micro-injection into the ARC until there was a bilateral accuracy rate of 85% or greater. 
Furthermore, after the following experiments requiring stereotactic surgery, accuracy of each 
injection was confirmed histologically. Animals that were not injected into the correct area were not 
included in the analysis. 
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2.2.3 Stereotactic injection of rAAV-GK antisense into the arcuate nucleus of rats 
Recombinant AAV-GKAS (titre:  1.85x1013 genome particles/ml) (n=12 per group) or AAV-GFP (titre: 
8.57x1013 genome particles/ml) was bilaterally injected into the ARC of male Wistar rats. GFP has 
previously been used as a marker of successful gene transfer in mammalian cells (Zhang, Gurtu et al. 
1996). 
Materials  
Isoflurane (Abbott Laboratories Ltd) 
Betadine (10% w/v povidine-iodine solution) (Seton Scholl Healthcare Ltd.)  
rAAV-GFP (titre: 8.57x1013 genome particles/ml)  
Amoxicillin powder for injection (500mg) (CP Pharmaceuticals)  
Flucloxacillin powder for injection (500mg) (CP Pharmaceuticals)  
0.9% NaCl (Braun Medical Ltd., Sheffield, UK)  
Buprenorphine hydrochloride (Temgesic) (0.3mg/ml) (Schering-Plough Ltd.)  
Internal cannula custom cut to length (Plastics One) 
Guide cannula custom cut to length (Plastics One) 
Method  
Male Wistar rats of approximately 250g were anesthetised with 2L/minute oxygen and 4% isoflurane 
and held in a Kopf stereotactic frame. Under aseptic conditions, the surgical area was shaved then 
cleaned with betadine. A 1cm rostro-caudal incision was made in the skin over the vertex of the skull 
and the periosteum removed from the underlying bone to expose bregma. Using an electric drill, 
which was mounted onto the stereotactic frame, bilateral burr holes were drilled according to 
coordinates calculated previously and by using the ‘The rat brain in stereotactic coordinates’ 
(Franklin and Paxinos, 2007). The ARC coordinates were 3.4mm posterior to bregma, ±0.5mm lateral 
to bregma and 10.5mm below the skull surface. Each rat received an intra-ARC injection of 1μl both 
sides (n=12 per group). The injection was delivered over five minutes using a stainless steel injector 
and an infusion pump. The cannula and injector were left in position for five minutes to limit back-
diffusion and then slowly withdrawn. The scalp incision was sutured with a 4.0 polypropylene suture 
(Ethicon).  
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After surgery, rats were placed in a warming chamber. Prophylactic flucloxacillin and amoxicillin 
(50mg/kg each) were administered intraperitoneally and 2.5ml 0.9% NaCl were given by 
intraperitoneal injection for rehydration. Analgesia was administered by subcutaneous injection of 
0.12mg/kg buprenorphine hydrochloride at anaesthetic induction. 
 
2.2.4 Stereotactic cannulation of the left arcuate nucleus in rats 
Stereotactic cannulation of the ARC allows intra-nucleus injection of drugs directly into the arcuate 
in freely moving animals. This is particularly useful for acute feeding studies as food intake can be 
measured immediately after the injection. 
Materials 
Isoflurane (Abbott Laboratories Ltd) 
Betadine (10% w/v povidine-iodine solution) (Seton Scholl Healthcare Ltd.)  
Amoxicillin powder for injection (500mg) (CP Pharmaceuticals)  
Flucloxacillin powder for injection (500mg) (CP Pharmaceuticals)  
0.9% NaCl (Braun Medical Ltd.)  
Buprenorphine hydrochloride (Temgesic) (0.3mg/ml) (Schering-Plough Ltd.)  
Guide cannula custom cut to length (Plastics One) 
Acrylic dental cement and powder (Kemdent) 
Miniature 1.6 x 3 stainless steel screws (Montrose Fasteners) 
Dummy cannula custom cut to length (Plastics One) 
Methods 
Animals were prepared and mounted onto a stereotactic frame as described previously. Anaesthetic, 
analgesia and antibiotics were administered as previously described. A hand drill was used to score 
three marks into the skull where stainless steel screws were lightly tightened to act as anchors. A 
unilateral burr hole was drilled according to coordinates calculated previously; 3.4mm posterior to 
bregma and -0.5mm lateral to bregma. A stainless steel cannulae held by an arm mounted onto the 
stereotactic frame was inserted 9.5mm below the skull surface. Dental acrylic was used to form a 
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pedestal fixing the cannulae into a stationary position with support from the mounting screws. This 
was left to dry and the scalp incision was sutured over the pedestal if necessary with a 4.0 
polypropylene suture (Ethicon, Gargrave). A cap was screwed onto the cannula to prevent infection. 
 
 
2.2.5 Feeding studies with genetically altered animals 
Animals that were injected bilaterally into the ARC with rAAV-GKAS or rAAV-GFP were monitored for 
changes in chow intake and body weight three times per week for 33 days.  
In some cohorts, glucose feeding studies were then performed. Appropriate concentrations of 
glucose solution were calculated previously. For acute studies, animals were acclimatised to a 2% 
(w/v) glucose solution provided ad libitum in pouches alongside the water bottles. After a period of 
at least 24 hours without glucose, animals were provided with 2% glucose, chow and water ad 
libitum from 19:00h. Glucose and chow intake was measured at 0, 1, 2, 4, 8, 12, 16 and 24 hours. 
For chronic glucose feeding studies, animals were provided with 10% (w/v) glucose solution 
provided ad libitum in pouches alongside the water bottles. Body weight, glucose and chow intake 
was measured three times per week for 33 days. For both acute and chronic glucose feeding studies, 
total caloric intake was measured. Total energy intake was calculated using 14.75 kJ/g for RM1 diet 
(appendix II) and 16.0 kJ/g for glucose. 
 
 
2.2.6 Twenty four hour feeding studies with intra-ARC injections 
Unless stated otherwise, animals were fasted for two hours before injection and the animals were 
placed in a clean cage to ensure no food remained. Water was provided ad libitum in a bottle with a 
lick-type nozzle. For studies requiring measurement of 2% (w/v) glucose solution via a nozzle, water 
was provided via a smaller bottle situated in the food hopper. Animals were acclimatised to the 
glucose solution over approximately 72 hours, after which 24 hour feeding studies commenced 
twice per week for up to four weeks. 
For studies involving CpdA, glibenclamide and diazoxide a single injection of 1µl was administered 
using an internal injector cut 1.0mm longer than the cannula to ensure microinjection into the left 
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arcuate nucleus. The injection was delivered over thirty seconds using an infusion pump. The 
injector was left in position for thirty seconds to limit back-diffusion and then withdrawn. The animal 
was placed back in its cage and provided with chow and glucose measurements initiated. 
For studies involving calcium channel blockers, animals had two intra-nuclear injections fifteen 
minutes apart. Glucose measurements started after injection of the second substance. 
For studies involving NPY antagonists, animals were given the first treatment by intraperitoneal 
injection of 100µl. The second treatment delivered by intra-nuclear injection was given after thirty 
minutes to give enough time for the circulation of the first treatment. 
 
 
2.2.7 Collection of tissue samples  
In all studies, unless otherwise stated in the methods, rats were euthanised in the early light phase 
by carbon dioxide asphyxiation followed by cervical dislocation.  
Materials 
Isopentane (Sigma) 
Dry ice (BOC) 
1.25% India ink (VWR) 
4% paraformaldehyde diluted in 0.01M PBS (Appendix I) 
30% sucrose solution (Appendix I) 
Methods 
For in situ hybridisation and glucokinase activity assay brains were rapidly removed after cervical 
dislocation and snap-frozen by immersion in ice cold isopentane on dry ice. Tissues were stored at -
80°C. 
For cresyl violet staining 1µl intra-arcuate injection of india ink was injected after euthanisation. 
Brains were then rapidly removed and fixed by placing into 4% formaldehyde solution for 24 hours. 
The tissue was then dehydrated in 30% sucrose solution for 3 days and snap-frozen by immersion in 
ice cold isopentane on dry ice.   
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2.3 Methods used for ex vivo measurement of glucose sensing 
2.3.1 Glucokinase activity assay 
The glucokinase activity assay measures production of NADPH in a two-step reaction. First, 
glucokinase catalyses the phosphorylation of glucose to G-6-P in the presence of ATP.  Second, G-6-P 
dehydrogenase converts G-6-P to 6-phophate-D-gluconolactone and generates NADPH. The assay 
was modified from a previously reported G-6-P dehydrogenase assay to measure GK activity in small 
tissue samples (Goward, Hartwell et al. 1986). 
 
 
 
 
 
Figure 2.1 Schematic of the two step reaction in the GK activity assay. 
 
 
Absorbance of NADPH is measured to calculate the concentration of NADPH produced in the 
reaction and therefore GK activity. Inhibitors of hexokinases are added to the reaction to ensure that 
only GK can catalyse the reaction. The advantage of this assay over previously used GK activity 
assays is that small amounts of tissue can be used. Measurement of GK from Bacillus 
stearothermophilus indicates that the assay has a high sensitivity even at very small concentrations 
of enzyme. In this study, glucokinase from rat hypothalamic nuclei were individually quantified and 
samples did not require pooling to increase sensitivity. 
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Glucokinase 
NADP NADPH 
Glucose 
ATP ADP 
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phosphate 
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Materials 
GK extraction buffer (Appendix I) 
Micropunch needles (custom made 1mm diameter) 
Cryostat (Bright) 
Poly-D-lysine glass slides 
Glucokinase from Bacillus stearothermophilus (0.25µg/ml) 
Reaction Mix: (Appendix I) 
Glycine buffer (50mM) (VWR) 
5-Thio-D-glucose-6-phosphate (45µM) (Sigma) 
MgCl2 (7.5mM) (VWR) 
ATP (10mM) (VWR) 
NADP (0.75mM) (VWR) 
Glucose (100mM) (VWR) 
3-O-methyl-N-acetylglucosamine (0.5mM) (Enzo Life Science) 
G-6-PD (type IX, from Baker’s yeast) (1.25 units) (VWR) 
 
Methods 
Three hundred micrometre thick coronal sections of brain tissue was cut using a cryostat with a 
chamber temperature of -7°C and adhered using slight defrosting onto glass slides. Slides were kept 
on dry ice to keep frozen and the ARC, PVN and VMN were identified using a rat brain atlas (Paxinos 
& Watson, 1998) and removed using a micropunch needle and placed in separate microcentrifuge 
tubes. Nuclei were homogenised with a handheld homogeniser and 200µl extraction buffer added. 
The samples were centrifuged at 13,000 RPM at 4°C for 40 minutes. Fifty microlitres of each 
supernatant were added to 500µl reaction mix and incubated at 37°C for thirty minutes. Fifty 
microlitres of GK standard at a series of dilutions were simultaneously added to 500µl reaction mix 
to provide a standard curve. Samples were then placed into cuvettes. 
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Absorbance of each sample was read at 340nm using a spectrophotometer. Concentration of NADPH 
was calculated using the following equation: 
Absorbance at 340nm (A) = Molar absorptivity of NADPH (ɛ) x Concentration (c) x length (l) 
A = 6.2x103 Lmol-1cm-1 x c molL-1 x 1 cm 
GK concentration was calculated by extrapolating values with the standard curve. Samples were 
normalised to protein content using a Pierce bicinchoninic acid (BCA) assay. Twenty microlitres of 
each sample were incubated with 180µl extraction buffer and 500µl BioRad dye reagent for 5 
minutes. Absorbance at 595nm was compared with known protein concentrations on a standard 
curve constructed using BSA. Samples were thus measured in units of GK activity per mg protein. 
 
 
2.3.2 Production of radiolabelled RNA probes for in situ hybridisation 
Single stranded mRNA probes significantly improve the sensitivity of examination of gene expression 
by in situ hybridisation (Cox, DeLeon et al. 1984). The RNA is complimentary to the gene of interest 
therefore uniquely binds to any endogenous mRNA. There are multiple ways to label a probe, 
including using nucleotides bound to different radioactive isotopes, digoxigenin, biotin and 
fluorescent markers. 35S labelled radio-probes are considered the most sensitive method for brain 
sections (Wilcox 1993). 
Materials 
200ng/µl of linearised GK template (from section 2.1.9) 
100M DTT (VWR) 
RNase inhibitor RNase Out (40U/µl) (Invitrogen) 
10x nucleotide mix (10mM of each ATP, UTP, GTP) (New England Biolabs) 
T3 and T7 RNA polymerase (20U/µl) (Thermo Fisher Scientific) 
5x RNA polymerase buffer (Promega) 
[35S]-CTPαS (46.2TBq/mmol, 2.6GBq/ml) (Perkin Elmer) 
DNase 1 (2U/µl) (Thermo Fisher Scientific) 
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10x DNase buffer (Appendix I) 
7.5M Ammonium acetate (Appendix I) 
100% ethanol stored at -20°C (VWR) 
Methods 
RNA was radioactively labelled in a transcription reaction to act as a probe for ex vivo mRNA. Two 
hundred nanograms of template were added to an eppendorf containing 9.5µl GDW warmed to 
37°C. To this the following was added in order: 1µl DTT, 1µl RNase inhibitor, 1µl NTP mix, 4µl 5x 
buffer, 0.5µl CTPαS, 1µl RNA polymerase. T3 polymerase was used to transcribe GK and WPRE 
antisense whereas T7 was used for GK and WPRE sense. The reaction was incubated for at least 2 
hours at 37°C. Six microlitres of GDW, 1µl 10x DNase buffer and 3µl DNase 1 was then added 
followed by 15 minutes incubation. RNA was then precipitated by addition of ammonium acetate to 
a final concentration of 2.5M and 2.5 volumes of ice cold absolute ethanol. The mixture was left at    
-20°C for at least 1 hour. RNA was recovered by centrifugation at 8,000xg for 8 minutes and the 
pellet was dissolved in 200µl GDW. The level of the radioactively labelled probe was measured by 
sampling 1µl in triplicate in a microbeta liquid scintillation counter (Wallace). Probes were 
considered successfully transcribed when radioactive counts were above 200,000/µl. 
 
 
2.3.3 In situ hybridisation for glucokinase and WPRE mRNA 
In situ hybridisation is similar in technique to northern blot except that the tissues are not 
homogenised and the cellular structure of the tissue is preserved.  
Materials 
4% (v/v) formaldehyde in 0.01M phosphate buffered solution (Appendix I) 
0.25% (v/v) acetic anhydride in 0.1M TEA pH8.0 (Appendix I) 
20x SSC (Appendix I) 
50, 70, 95 and 100% ethanol in GDW (VWR) 
Chloroform (VWR) 
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De-ionised formamide (VWR) 
5M sodium chloride (VWR) 
1M Tris-HCl, pH 8.0 (VWR) 
0.5M EDTA (VWR) 
1M DTT (VWR) 
10mg/ml Baker’s yeast tRNA (VWR) 
100x Denhart’s solution (Appendix I) 
50% (w/v) dextran sulphate (mw >500,000) in GDW at 60°C (Sigma) 
1x RNase A (10g/ml) (Appendix I) 
Biomax film (Kodak) 
Developing solution (Jet X-Ray) 
Fixing solution (Jet X-Ray) 
Methods 
Twelve micrometre brain sections were cut on a cryostat at -21°C (Bright Instrument Company), 
mounted onto poly-D-lysine coated slides and stored at -80°C until hybridisation. For in situ 
hybridisation, slides were allowed to thaw and fixed in 4% formaldehyde for 20 minutes on ice. 
Slides were washed twice in 0.01M PBS for 5 minutes and briefly in autoclaved GDW. Slides were 
acetylated in 0.25% acetic anhydride in 0.1M TEA for 10 minutes and washed twice in 0.01M PBS for 
2 minutes. Slides were dehydrated in ascending concentrations of ethanol (50, 70, 95 and 100%) for 
2 minutes each and delipidated in chloroform for 5 minutes. Finally, slides were slightly rehydrated 
in descending concentrations of ethanol (100 and 95%) for 2 minutes and allowed to air dry. 
Hybridisation buffer was made by adding 1ml of 50% dextran sulphate to a 3ml solution containing 
final concentrations of 375mM NaCl, 31% (v/v) formamide, 0.5mg/ml tRNA, 1.25X Denhart’s 
solution, 12.5mM Tris, 10mM DTT and 1.25mM EDTA. Individual probes for sense and antisense 
were added to make 1 million counts per 70µl. Seventy microlitres of hybridisation buffer were 
pipetted onto coverslips in a linear streak and were stuck onto the slides. At least one Sense slide 
was made to measure non-specific binding of the probe. Slides were incubated overnight at 60°C in 
slightly humid conditions in a water bath. 
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Coverslips were removed in 4 X SSC and slides washed a further 4 times in 4 X SSC for 5 minutes 
each. Slides were incubated in RNase solution containing 20mg/ml RNase A, 0.5M NaCl, 10mM Tris 
and 1mM EDTA for 30 minutes at 37°C. Stringency washes followed to remove incompletely bound 
probe. Slides were washed twice in 2 X SSC for 5 minutes, 1 X SSC for 10 minutes, 0.5 X SSC for 10 
minutes and 0.1 X SSC for 30 minutes at 60°C. Slides were cooled in 0.1 X SSC, dehydrated in 
ascending concentrations of ethanol and allowed to completely dry. Slides were then placed into a 
photoplate cassette and exposed to chromatography paper for between 2-10 days. To develop, the 
paper was washed in developing solution until the slides appeared, rinsed briefly in water and fixed 
using fixing solution for at least 3 minutes. Slides could then be visualised on a light box or high 
resolution scanner. 
 
 
2.3.5 Hypothalamic explant static incubation system 
The static incubation system used was a modification of the method previously described to 
measure neurotransmitter release from hypothalamic explants in response to glucose or 
pharmacological agents (Dhillo, Small et al. 2002). It is a useful tool to investigate the response of 
basal hypothalamic neurones ex vivo. This method has the advantage that the neuropeptide 
response from explants can be compared to basal levels so act as their own controls. The limitations 
of this technique are that the saturation of 95% oxygen during the experiment is not sufficient to 
prevent cell death. Therefore the tissue under investigation is partially necrotic, particularly in the 
centre. As the ARC is situated on the outside of the tissue the damage may be limited. However to 
confirm that the explants still remained viable throughout the experiment, widespread 
neurotransmitter release was stimulated by potassium enriched aCSF. Only hypothalami that 
showed a 100% secretion over baseline in response to 56 mM KCl were used in the analysis. 
 
Materials 
Artificial CSF (appendix I) 
Potassium enriched aCSF (Appendix I) 
5% CO2/ 95% O2 (BOC) 
30µM Glucokinase activator, CpdA (Merck) 
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100 µM Glibenclamide (Sigma) 
200 µM Diazoxide (Sigma) 
Methods 
Male Wistar rats were killed by decapitation and the brain was immediately dissected. The brain was 
mounted with ventral surface uppermost and placed in a vibrating microtome (Microfield Scientific 
Ltd). The blade was adjusted until it abutted the median eminence and a 1.7mm slice was taken 
from the basal hypothalamus and cut lateral to the Circle of Willis to include the arcuate nucleus 
(Seal, Small et al. 2001). The hypothalamic slice was incubated in individual chambers containing 1 
ml aCSF, equilibrated with 95% O2 and 5% CO2. The tubes were placed on a platform in a water bath 
maintained at 37°C. After an initial 2 hours equilibration period, the hypothalami were incubated for 
45 min in 600µl aCSF (basal period) before being challenged with the test drug (test period) for 45 
min. The viability of the tissue was verified by a final 45 min of exposure to aCSF containing 56 mM 
KCl; isotonicity was maintained by substituting K+ for Na+. Hypothalamic explants that failed to show 
peptide release above that of basal in response to aCSF containing 56 mM KCl were excluded from 
the data analysis. This was less than 10% of explants. At the end of each period, the aCSF was 
collected and stored at -20°C until measurement of NPY and α-MSH by radioimmunoassay.  
 
 
2.3.6 Measurement of NPY and α-MSH in aCSF samples 
Release of neuropeptides was measured by radioimmunoassay (RIA). The measurement of peptides 
by RIA relies on competition between radioactivity-labelled and unlabelled peptide for a specific 
binding site of an antibody. The amounts of antibody and labelled peptide are fixed; the only 
variable is the unlabelled peptide. The higher the concentration of unlabelled peptide, the less 
radioactively labelled peptide will be bound to the antibody. The bound and free peptide is 
separated by addition of dextran-coated charcoal which binds free antigen in the charcoal pellet. 
The activity in the bound and free components is measured in a γ counter and the data used to 
construct a standard curve. 
Hypothalamic α-MSH –like immunoreactivity was calculated using a specific and sensitive in-house 
method and NPY –like immunoreactivity was calculated using a commercial kit from Bachem, San 
Carlos, USA. α-MSH was iodinated using the iodogen or Bolton and Hunter method by Professor 
Mohammed Ghatei and purified by HPLC (Wood, Wood et al. 1981). A label test was performed to 
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identify the best fraction. Standard curves for each assay were prepared using synthetic peptide. 
Dilution factors of samples were based on previous studies within this laboratory (Dhillo, Small et al. 
2002). 
 
 
2.3.6.1 α-MSH radioimmunoassay 
Materials 
0.06 M phosphate buffer (pH 7.2) containing 0.3% BSA (Appendix I) 
125I labelled α-MSH (Produced by Prof M. Ghatei) 
α-MSH standard peptide (Bachem) 
Undiluted aCSF sample from hypothalamic explant 
Rabbit anti- α-MSH antibody (1:120,000 dilution) (Chemicon International Inc.) 
Sheep anti-rabbit antibody (Pharmacia & Upjohn, Sweden) 
Methods 
Three millilitre RIA tubes were labelled in RIA racks holding 128 tubes. Each assay began with 
duplicated tubes of; NSB (non-specific binding; without antibody), ½ x label, 2 x label, zeros (no 
sample), standard curve dilutions, zeros. All unknown samples were assayed in singlet separated by 
duplicated zeros every 24 samples. An additional standard curve was inserted at the end of the assay 
and finally duplicated excess antibody tubes. Each tube was made up to a total volume of 400μl 
buffered with phosphate buffer. The assay was incubated for 3 days at 4°C before separation of the 
free from antibody-bound label by sheep anti-rabbit antibody. These free and bound fractions were 
counted for 180 seconds in a gamma scintillation counter and sample concentrations were 
calculated using a data reduction programme (NE1600, NE Technology, UK). All samples were 
measured in one assay to avoid inter-assay variation.  
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2.3.6.2 NPY radioimmunoassay 
Materials 
0.06 M phosphate buffer (pH 7.2) containing 0.3% BSA 
125I labelled NPY (Bachem, San Carlos, USA) 
NPY standard peptide (Bachem, UK) 
Undiluted aCSF sample from hypothalamic explant 
Rabbit anti- NPY antibody (Bachem, San Carlos, USA) 
Goat anti-rabbit antibody (Bachem, San Carlos, USA) 
Methods 
NPY-like immunoreactivity was measured using the same set-up described earlier. Each tube was 
made up to a total volume of 400μl buffered with phosphate buffer. The assay was incubated 
overnight at 4°C before separation of the free from antibody-bound label by goat anti-rabbit 
antibody. These free and bound fractions were counted for 180 seconds in a gamma scintillation 
counter and sample concentrations were calculated using a data reduction programme (NE1600, NE 
Technology, UK). All samples were measured in one assay to avoid inter-assay variation. 
 
 
2.3.7 Cresyl violet staining of ink injected rat brains 
Materials 
Acetic acid (VWR) 
Ethanol (VWR) 
1% Cresyl violet stain (Appendix I) 
Xylene (VWR) 
DPX (Thermo Fisher Scientific) 
Poly-D-lysine glass slides (VWR) 
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Methods 
Rat brains were fixed onto a cold block and sliced with a Shandon sled microtome (Thermo Fisher 
Scientific). Forty micrometre coronal sections were cut and placed into wells containing anti-freeze. 
These were stored at -20°C until required. Sections were mounted onto glass slides and allowed to 
dry for at least four hours. Slides were fixed in a solution of 5% acetic acid in 100% ethanol, and then 
stained in cresyl violet for 15 minutes. Slides were washed twice in GDW, dehydrated in 70% ethanol 
and delipidated in xylene overnight. The following morning, slides were mounted with DPX and 
coverslips. Animals with ink more than 0.2mm outside the ARC when viewed under the microscope 
(Nikon, Eclipse 50i) were removed from subsequent analysis. 
 
 
2.4 Statistical analysis 
Results are displayed as mean and standard error of the mean (SEM) unless indicated. Generalised 
estimating equation (GEE) was used to compare cumulative data (namely body weight, chow, 
glucose and caloric intake) between control and treatment groups. GEE, based on generalised linear 
models, analyses longitudinal data and accounts for small variation in two groups that are time-
dependently different. Individual data points were further analysed by Mann-Whitney post-hoc test 
where appropriate. Data from multiple groups for glucokinase activity assays and hypothalamic 
explant studies were analysed using one-way statistical analysis of variance (ANOVA) followed by 
post-hoc Holm-Sidak test. Data from multiple groups for Calcium channel and NPY receptor 
experiments were analysed using one-way ANOVA followed by post-hoc Holm-Sidak test for specific 
columns. A paired Student’s t-test was used to compare absolute food and glucose intake data from 
cross-over studies. An unpaired Student’s t-test was used to compare all other data. Significance was 
set at P<0.05 unless indicated otherwise. Data analysis was performed using Graphpad Prism 6.05 
software (Graphpad Software, Inc.) except for GEE, which was performed using Stata 9 software 
(Stata). 
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Chapter 3: The effect of altered ARC 
glucokinase activity on glucose intake 
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3.1 Introduction 
Energy homeostasis is regulated by an array of neuronal circuits that control food intake and 
energy expenditure (Schwartz, Woods et al. 2000). Glucose sensing neurones play an 
integral role in allowing the brain to detect glucose levels (Anand, Chhina et al. 1964). These 
neurones are important for maintaining glucose homeostasis by regulation of downstream 
peripheral mechanisms and food intake (Dunn-Meynell, Sanders et al. 2009, Levin, Magnan 
et al. 2011). While the contribution of glucose sensing neurones in responding to 
hypoglycaemia is well known, their role in regulating food intake and body weight remains 
poorly understood.  
 
3.1.1 The glucostatic control of food intake 
Over 60 years ago, Mayer’s “glucostatic theory” suggested that changes in blood glucose are 
detected by the brain to alter hunger signals (Mayer 1953). It has since been demonstrated 
that alterations in CNS glucose concentration affects food intake. ICV injection of glucose 
decreases food intake in rats (Panksepp and Rossi 1981, Kurata, Fujimoto et al. 1986). ICV 
injection of 2-DG, an analogue of glucose that cannot undergo glycolysis, increases food 
intake (Tsujii and Bray 1990). The effects on food intake is specific to glucose, as ICV of 
glucose epimers such as D-mannose and D-galactose do not have any effect on food intake 
(Kurata, Fujimoto et al. 1986). Also, ICV fructose, which is not metabolised by GK, increases 
food intake (Miller, Martin et al. 2002). These studies implicate sensors of CSF glucose levels 
as mediators of appetite. 
 
3.1.2 Glucokinase and food intake 
Glucokinase is the primary enzyme that glucose sensing neurones use for translating glucose 
levels into neuronal signals. Neurones within the ARC exert a powerful effect on food intake 
as demonstrated by the potent effects of leptin and other metabolic signals (Cone, Cowley 
et al. 2001). GK activity in the ARC is also regulated by altered ambient glucose levels 
(Hussain, Richardson et al. 2014). Fasting increases GK activity in the ARC, but not in the 
VMN (Hussain, Richardson et al. 2014). However, GK mRNA expression in the VMN is 
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increased when challenged with insulin-induced hypoglycaemia (Kang, Sanders et al. 2008). 
It is likely that specific populations of neurones in the CNS are responsible for controlling 
particular aspects of glucose sensing and any physiological response. This is in contrast to 
other areas of glucose sensing; pancreatic GK levels remain unperturbed by altered glucose 
levels (Iynedjian, Pilot et al. 1989).  
Differences in nutrient availability between neurones in the VMN and ARC have already 
been described (Wang, Liu et al. 2004, Mullier, Bouret et al. 2010, Langlet, Levin et al. 2013). 
In addition, a robust network of neurones controlling the CRR to hypoglycaemia has been 
demonstrated across the VMN, brainstem and medial amygdala nucleus (Kang, Routh et al. 
2004, Dunn-Meynell, Sanders et al. 2009, Zhou, Podolsky et al. 2010). However, the role of 
CNS glucose sensing in influencing daily food intake remains to be investigated. 
 
3.1.3 Techniques used to alter glucokinase in vivo 
In order to investigate the role of ARC glucose sensing on food intake, approaches to alter 
the intracellular mechanisms of glucose sensing neurones can be used. Mice with 
homozygous or heterozygous deletion for the GK gene are diabetic, due to the combined 
effects of decreased GK in the liver, pancreas and CNS (Grupe, Hultgren et al. 1995, Baker, 
Atkinson et al. 2014). As gene expression is affected throughout the prenatal and growth 
stages of the animal in these models, it is possible that compensatory mechanisms can 
affect their phenotype. Therefore, the phenotypes may not represent the physiological role 
of GK in these models. An alternative approach is to develop transgenic mice with a ‘floxed’ 
GK gene to restrict genetic modification to a particular tissue or region, for example in the 
ARC. Stereotactic injection of rAAV containing Cre recombinase into the ARC ensures 
knockdown of GK is restricted to the area surrounding the injection site. This technique is 
more appropriate for investigating the specific role of ARC GK on the regulation of food 
intake. However, due to the difficulty in targeting the small mouse ARC, and in order to 
compare with previous studies of GK overexpression in rats, a model of glucokinase 
knockdown in rats is used in the present study. Transgenic alterations in rats are not widely 
used so a GK ‘floxed’ rat is currently unavailable.  
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As discussed in chapter 1, AAV2 is an effective vector for gene delivery to neurones 
(Howard, Powers et al. 2008). Maximal viral infection occurs at approximately 21 days in 
rodents and can last for at least 50 days (Hussain, Richardson et al. 2014). Recombinant AAV 
containing GK has previously been used to demonstrate selective overexpression of GK in 
the ARC of rats (Hussain, Richardson et al. 2014). In order to selectively decrease ARC GK 
expression in rats, rAAV containing antisense RNA can be injected to create long term 
expression of a molecule with sequence complimentary to that of the endogenous mRNA. 
Antisense RNA interferes with gene expression by hybridising to the mRNA sequence and 
disabling its translation (Kumar and Carmichael 1997). In the present chapter I utilise 
antisense technology to inhibit endogenous GK expression in vivo. Recombinant AAV 
containing GK antisense (rAAV-GKAS) was produced using the two-plasmid system as 
described previously (Grimm, Kern et al. 1999, Gardiner, Kong et al. 2005).  
In summary, ARC GK is hypothesised to regulate food intake. However, the exact role of GK 
in controlling glucose homeostasis has not been elucidated in the ARC and requires further 
investigation. Previous work within this laboratory has shown that chronic overexpression of 
ARC GK results in increased food intake and body weight gain (Hussain, Richardson et al. 
2014). The work in this chapter will build on this previous finding by investigating the effects 
of altered ARC GK activity using two different approaches. The first will be to acutely 
increase ARC GK activity using a pharmacological activator, and the second will be to 
chronically knock down ARC GK using rAAV encoding for GK antisense. 
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3.2 Hypothesis and Aims 
3.2.1 Hypothesis 
Acute activation of ARC GK will result in an increase in glucose-specific appetite, similar to 
previous findings, which chronically overexpressed ARC GK. In contrast, chronic reduction of 
ARC GK will result in a decrease in glucose-specific appetite, when measured in both an 
acute and cumulative setting. 
 
3.2.2 Aims 
To investigate my hypothesis I will: 
1. Identify endogenous GK expression in the ARC of rats using in situ hybridisation. 
2. Inject the pharmacological activator compound A into the ARC of rats via 
stereotactically inserted cannula, to investigate the effect of increased GK activity on 
short term food intake. 
3. Investigate altered preference for glucose in rats with increased ARC GK activity, by 
providing them with standard chow and glucose solution. 
4. Stereotactically inject rAAV-GK antisense into the ARC of rats, and confirm 
knockdown in the ARC. 
5. Investigate the acute effects of ARC GK knockdown, by measuring 24 hour glucose 
intake. 
6. Investigate the long-term effects of ARC GK knockdown, by measuring food intake, 
body weight and long-term glucose intake. 
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3.3 Results 
3.3.1 Localisation of GK expression in the hypothalamus 
In situ hybridisation was performed on coronal sections from wild-type rats provided with 
ad libitum standard chow. Expression of GK mRNA was observed in the VMN, ARC and MAN 
(figure 3.1a).  Expression was not due to non-specific binding of the radio-labelled probe 
(figure 3.1b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Endogenous GK mRNA expression in the rat hypothalamus. In situ hybridisation 
with: (A) GK antisense-labelled probe, (B) GK sense-labelled probe in 12µm coronal sections 
at -3.3 mm from bregma at 4x magnification. Abbreviations: 3v, third ventricle; ARC, arcuate 
nucleus; VMN, ventromedial nucleus; DMN, dorsal medial nucleus; MAN, medial amygdala 
nucleus. Black bars indicate 1mm length.  
A 
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3.3.2 Effect of pharmacologically increasing ARC GK activity on chow and glucose intake  
ARC GK activity was increased acutely using the glucokinase activator CpdA (Kamata, 
Mitsuya et al. 2004). Following injection, rats were allowed access to either; chow alone, a 
2% (w/v) glucose solution alone, or both chow and glucose. Acute activation of ARC GK 
caused a significant increase in chow intake when chow was presented alone during the first 
hour, compared with vehicle injected controls (control, 0.38±0.13g; CpdA, 1.07±0.27g; n=10 
per group, p <0.05) (figure 3.2a). This increase in chow intake was observed over 8 hours 
from injection but was not statistically significant beyond the first hour (after 8 hours: 
control, 3.17±0.64g; CpdA, 4.47±0.90g, n=8 per group, p =0.25) (figure 3.2b). Acute 
activation of ARC GK also caused a significant increase in glucose intake when glucose was 
presented alone, during the first hour compared with vehicle injected controls (control, 
4.56±1.00g; CpdA, 8.36±1.24g, n=8 per group, p <0.05) (figure 3.3a). Glucose intake was 
significantly increased over 8 hours (control, 5.83±1.16g; CpdA, 11.2±1.64g, n=8 per group, p 
<0.05) (figure 3.3b). When both chow and glucose were available, only glucose intake was 
significantly increased during the first hour (control, 3.06±1.12g; CpdA, 7.70±1.55g; n=7 per 
group, p <0.05) (figure 3.4a). There was no change in chow intake during the first hour 
(control, 1.68±0.43g; 1.43±0.70g, n=7 per group) (3.4b). The increase in glucose intake was 
maintained over eight hours but was not statistically significant (control, 6.10±2.39g; CpdA, 
10.6±2.64g, n=7 per group, p =0.23) (figure 3.4c). There was no change in chow intake over 
8 hours (control, 6.50±1.30g; CpdA, 5.81±0.89g, n=7 per group) (figure 3.4d). 
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Figure 3.2 Effect of increasing ARC GK activity on food intake. (A) Food intake one hour 
after ARC GK activation using stereotactic injection of 0.5 nmol CpdA as compared to the 
vehicle injected controls during a crossover study. (B) Eight hour food intake after ARC GK 
activation using stereotactic injection of 0.5 nmol CpdA as compared to the vehicle injected 
controls during a crossover study. Data are presented as mean±SEM, n=10 per group. 
Statistical significance was analysed by paired Student’s t-test: *= p <0.05. 
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Figure 3.3 Effect of increasing ARC GK activity on 2% glucose intake. (A) Glucose intake one 
hour after ARC GK activation using stereotactic injection of 0.5 nmol CpdA as compared to 
the vehicle injected controls during a crossover study. (B) Eight hour glucose intake after 
ARC GK activation using stereotactic injection of 0.5 nmol CpdA as compared to the vehicle 
injected controls during a crossover study. Data are presented as mean±SEM, n=8 per 
group. Statistical significance was analysed by Student’s t-test: *= p <0.05. 
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Figure 3.4 Effect of increasing ARC GK activity on chow and 2% glucose intake. (A) Glucose 
and (B) chow intake one hour after ARC GK activation using stereotactic injection of 0.5 
nmol CpdA as compared to the vehicle injected controls during a crossover study. (C) Eight 
hour glucose and (D) chow intake after ARC GK activation using stereotactic injection of 0.5 
nmol CpdA as compared to the vehicle injected controls during a crossover study. Data are 
presented as mean±SEM, n=7 per group. Statistical significance was analysed by Student’s t-
test: *= p <0.05. 
 
  
A B 
D C 
C o n t r o l C p d A
0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
2 . 5
F
o
o
d
 
in
t
a
k
e
 
(
g
)
79 
 
3.3.3 Visualisation of accurate ARC injection  
Permanent cannulas were stereotactically implanted 1mm above the ARC of rats (figure 
3.5). Pharmacological agents could be injected directly into the ARC via a 1mm projection 
beyond the implanted cannula. Only animals that had correct cannula placements were 
included in the analysis.  
 
 
Figure 3.5 Confirmation of cannula placement in rats cannulated into the ARC. Cresyl-
violet stained 30µm sections at 100x magnification showing edge of guide cannula (arrow) 
in a representative animal. Administered solutions are delivered into the ARC via an injector 
projecting 1mm from the end of the cannula. 3v, third ventricle. Bar = 100µm. 
 
  
3v 
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3.3.4 Measurement of total viral titre by dot blot analysis 
The total virus titres for rAAV encoding GK antisense (rAAV-GKAS) and rAAV encoding 
enhanced green fluorescent protein (rAAV-GFP) were 1.85x1013 and 8.57x1013 genome 
particles/ml respectively.  
 
3.3.5 Quantification of GK knockdown in vitro 
Transfection of HEPG2 cells with GKAS-containing plasmid resulted in decreased GK activity 
in lysates compared to pTR-CGW transfected controls (control, 0.31 ± 0.024 units/mg 
protein; GKAS, 0.19 ± 0.011 units/mg protein, n=4 per group, p <0.05) (figure 3.6).  
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Figure 3.6 Effect of in vitro GKAS-pTR-CGW plasmid transfection on GK activity: GK activity 
in HEPG2 cells 48hr after transfection with either GKAS-pTR-CGW plasmid (blue bar) or pTR-
CGW plasmid (green bar). Data presented as mean±SEM, n=4 per group. Statistical 
significance was analysed by Student’s t-test: * p <0.05 versus corresponding control values. 
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3.3.6 Quantification of knockdown of ARC GK in vivo 
Recombinant AAV encoding for GKAS was stereotactically injected into the ARC of rats. To 
ensure that the reduction in GK activity was exclusive to the ARC and that the VMN was not 
affected, GK activity was quantified. Animals were killed 11 weeks after stereotactic 
injection of either rAAV-GKAS or rAAV-GFP and GK activity was measured in the ARC, VMN 
and PVN of animals. There was a significant decrease in GK activity in the ARC in rAAV-GKAS 
injected animals compared with controls (iARC-GFP, 9.82±0.42U/mg; iARC-GKAS, 
4.08±0.74U/mg; n=9-11 per group, p <0.001) (figure 3.7). There was no difference in GK 
activity in either the VMN (iARC-GFP, 7.13±0.19U/mg; iARC-GKAS, 6.628±0.82U/mg; n=9-11 
per group) or PVN (iARC-GFP, 6.14±0.44U/mg; iARC-GKAS, 5.89±0.46U/mg; n=9-11 per 
group) between the two groups (figure 3.7). 
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Figure 3.7 Confirmation of GK knockdown by activity assay. Glucokinase activity in the 
arcuate nucleus (ARC), ventromedial nucleus (VMN) and paraventricular nucleus (PVN) of 
male Wistar rats following intra-ARC injection of either rAAV-GFP (iARC-GFP) or rAAV-GK 
antisense (iARC-GKAS). Data presented as mean±SEM, n=9-11 per group. Statistical 
significance was analysed by ANOVA with post-hoc Holm-Sidak test *** p <0.001 versus 
corresponding control values.  
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3.3.7 Effect of ARC GK knockdown on body weight 
Rats were maintained on a diet of standard chow for 33 days after recovery from rAAV 
injections. Knockdown of ARC GK slightly, but not significantly reduced body weight gain 
compared to controls (iARC-GFP, 153.9±6.06g; iARC-GKAS, 143.2±6.95g; p =0.37, n=9-11 per 
group) (figure 3.8).  
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Figure 3.8 Effect of decreasing ARC GK on body weight. Cumulative body weight following 
intra-ARC injection of either rAAV-GFP (iARC-GFP) or rAAV-GK antisense (iARC-GKAS) 
(n=9-11 per group). Data presented as mean±SEM. Statistical significance was analysed by 
GEE. 
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3.3.8 Effect of ARC GK knockdown on food intake 
Thirty three days after recovery from surgery there was a slight but non-significant decrease 
in chow intake compared with control rats (iARC-GFP, 1039.3±17.9; iARC-GKAS, 
994.2±14.1g; n=9-11 per group, p =0.0747) (figure 3.9).  
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Figure 3.9 Effect of decreasing ARC GK on food intake. Cumulative chow intake when 
provided ad libitum following intra-ARC injection of either rAAV-GFP (iARC-GFP) or rAAV-GK 
antisense (iARC-GKAS) (n=9-11 per group) Data presented as mean±SEM. Statistical 
significance was analysed by GEE. 
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3.3.9 Effect of ARC GK knockdown on acute glucose intake 
Forty days after surgery, ad libitum glucose and chow intake were measured for 24 hours 
from the start of the dark period. Knockdown of ARC GK resulted in a significant decrease in 
cumulative glucose intake from 2 to 24 hours, compared to control rats (at 24 hours: iARC-
GFP, 72.4±6.79g; iARC-GKAS, 46.8±4.01g; n=8-9 per group, p <0.05) (figure 3.10a).  However 
there was no significant difference in chow intake (at 24 hours: iARC-GFP, 30.6±0.78g; iARC-
GKAS, 32.4±1.14g; n=8-9 per group) (figure 3.10b). There was no significant difference in 
total energy intake between GK antisense or control injected rats (at 24 hours: iARC-GFP, 
477.0±19.4kJ; iARC-GKAS, 494.1±17.2kJ, n=8-9 per group) (figure 3.10c). 
 
 
 
 
 
 
Figure 3.10 Effect of decreasing ARC GK on acute glucose and chow intake. Cumulative (A) 
2% glucose intake, (B) chow intake and (C) caloric intake when provided ad libitum for 24 
hours, 40 days after intra-ARC injection of either rAAV-GFP (iARC-GFP) or rAAV-GK antisense 
(iARC-GKAS) (n=8-9). Data presented as mean±SEM. Statistical significance was analysed by 
GEE with Mann-Whitney post-hoc test * p <0.05 versus corresponding control values. 
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3.3.10 Effect of ARC GK knockdown on cumulative glucose intake 
Standard chow and 10% (w/v) glucose intake were measured for 33 days, 44 days after 
stereotactic injection of either rAAV-GKAS or rAAV-GFP. ARC GK knockdown resulted in a 
significant decrease in cumulative glucose consumption compared to controls (after 33 
days: iARC-GFP, 3675±174ml; iARC-GKAS, 3090±264ml; n=9-11 per group, p <0.05) (figure 
3.11). There was no significant difference in chow intake (after 33 days: iARC-GFP, 
684.8±21.2g; iARC-GKAS, 711.5±22.2g; n=9-11 per group) (figure 3.12). There was no 
significant difference in total energy intake (after 33 days: iARC-GFP, 16.82±0.37MJ; iARC-
GKAS, 16.36±0.49MJ; n=9-11 per group) (figure 3.13). There was also no significant 
difference in body weight gain when the animals were challenged with a high glucose diet 
(after 33 days: iARC-GFP, 66.6±3.3g; iARC-GKAS, 71.4±6.1g; n=9-11 per group) (figure 3.14).  
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Figure 3.11 Effect of decreasing ARC GK on glucose intake. Cumulative 10% glucose intake 
when provided ad libitum with chow 44 days after intra-ARC injection of either rAAV-GFP 
(iARC-GFP) or rAAV-GK antisense (iARC-GKAS) (n=9-11). Data presented as mean±SEM. 
Statistical significance was analysed by GEE * p <0.05 versus corresponding control values. 
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Figure 3.12 Effect of decreasing ARC GK on food intake. Cumulative chow intake when 
provided ad libitum with 10% glucose 44 days after intra-ARC injection of either rAAV-GFP 
(iARC-GFP) or rAAV-GK antisense (iARC-GKAS) (n=9-11 per group). Data presented as 
mean±SEM. 
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Figure 3.13 Effect of decreasing ARC GK on energy intake.  Cumulative total energy intake 
when provided with 10% glucose and chow ad libitum 44 days after intra-ARC injection of 
either rAAV-GFP (iARC-GFP) or rAAV-GK antisense (iARC-GKAS) (n=9-11 per group). Data 
presented as mean±SEM. 
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Figure 3.14 Effect of decreasing ARC GK on body weight. Body weight gain when provided 
with ad libitum chow and 10% glucose 44 days after intra-ARC injection of either rAAV-GFP 
(iARC-GFP) or rAAV-GK antisense (iARC-GKAS) (n=9-11 per group). Data presented as 
mean±SEM. 
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3.4 Discussion 
3.4.1 Endogenous expression of GK in the rat hypothalamus 
In situ hybridisation revealed that GK is expressed in the ARC, VMN and the MAN. This was 
not due to non-specific binding of the radio-labelled probe as there was no expression 
observed when “GK-sense” probe was applied [see review (Wilcox 1993)]. These 
observations agree with previous reports detailing GK expression in the hypothalamus 
(Jetton, Liang et al. 1994, Lynch, Tompkins et al. 2000). It is difficult to quantify expression 
using in situ hybridisation therefore the GK activity assay was performed to measure GK 
activity.  
 
3.4.2 Increasing arcuate glucokinase activity increases glucose intake 
Alteration of glucokinase activity affects the cell’s ability to sense glucose, thus altering the 
regulation of glucose homeostasis and appetite. Pharmacological activation of ARC GK by 
stereotactic injection of CpdA results in an increase in glucose intake from 1 hour. Doses of 
CpdA were based on previous experiments (Kamata, Mitsuya et al. 2004, Levin, Becker et al. 
2008). Previously, injection of CpdA into the VMH has been shown to induce peripheral 
hormone release from 30 minutes after injection (Levin, Becker et al. 2008). In contrast, the 
present study demonstrates that injection of CpdA into the ARC increases glucose intake 
from 30 minutes after injection. An increase in glucose intake is in agreement with my 
hypothesis and suggests that ARC GK promotes glucose intake.  
Activation of ARC GK also increased intake of standard chow. However when both glucose 
and chow were provided together, activation of ARC GK only increased glucose 
consumption. I propose that this is because pure glucose alters blood and CSF glucose levels 
more quickly than chow, which is sensed by ARC glucose sensors to affect appetite. 
Consistent with this hypothesis, glucose is also preferred over fructose and other 
sweeteners in animals with increased GK expression (Hussain, Richardson et al. 2014).  
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3.4.3 Accurate injection of substances into the ARC 
Histological techniques were used to confirm effective ARC injection. In cannulated animals, 
post-mortem localisation of the cannula placement was determined by staining with cresyl 
violet. Correct cannula placement was confirmed in over 90% of animals; those that did not 
seem to project into the left ARC were not included in the final analysis. I found that the 
majority of injections appeared to project into the lateral portion of the ARC, as insertion of 
the cannula into the medial ARC risked disturbing the 3rd ventricle. The majority of GE 
neurones have been identified in the lateral ARC, in accord with this finding (Wang, Liu et al. 
2004). It is possible that the injections could diffuse into other regions as direct localisation 
of the injection was not confirmed. Therefore VMN neurones could be affected and may 
contribute to the response. 
 
3.4.4 Methods and measurements of altered glucokinase activity  
Recombinant AAV was used to decrease ARC GK expression. AAV was preferred over 
adenoviral and retroviral vectors because it is non-immunogenic and the effects on gene 
expression are highly persistent in vivo (Ponnazhagan, Mukherjee et al. 1997). The plasmid 
used to make rAAV particles consists of an original backbone (pTR-CGW) that was 
engineered to include the complimentary (antisense) sequence for neuroendocrine 
glucokinase so that base pairing and suppression of translation would occur (Kumar and 
Carmichael 1998, O’Keefe 2013). The efficacy of the plasmid to alter glucokinase was first 
tested in vitro using HEPG2 cells, a liver cell line that express GK. HEPG2 cells were 
transfected with GKAS plasmid and cell lysates were assayed for GK activity after 48 hours. 
Transfection with GKAS plasmid resulted in a 38% reduction of GK activity compared with 
control plasmid. The level of knockdown achieved was slightly lower than previous studies 
using antisense AAV. RIN56 NPY-containing cells showed a 56% knockdown of NPY 
expression when transfected with antisense AAV (Gardiner et al, 2005). 
To test the efficacy of the plasmid to alter GK in vivo, I determined glucokinase activity in 
dissected hypothalamic nuclei of iARC-GKAS rats. Glucokinase activity was calculated using a 
modified NADPH assay as described previously (Goward, Hartwell et al. 1986, Hussain, 
Richardson et al. 2014). GK activity was reduced by more than 50% in the ARC and not 
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altered in the VMN or PVN, compared with iARC-GFP. This demonstrates that rAAV-GKAS 
can significantly alter GK activity in vivo. 
GK activity was measured using a modified NADP+-coupled activity assay rather than using 
previously used techniques. Previous assays for measuring GK activity were not specific to 
GK as hexokinases have a higher affinity and lower Km for glucose than GK (Printz, 
Magnuson et al. 1993). Other methods measure NADP+ in two separate experiments at high 
(20mM) and low (0.5mM) concentrations of glucose where GK activity should be lower than 
hexokinase activity in the second experiment. A comparison between the two experiments 
is necessary to eliminate the effects of other hexokinases, but total elimination cannot be 
confirmed (Osundiji, Lam et al. 2012). To circumvent the effects of hexokinases, I added 
hexokinase inhibitors to increase the accuracy of the assay. The glucose analogue 5-thio-D-
glucose is an antagonist for hexokinases except for GK (Wilson and Chung 1989). Similarly, 
3-O-methyl-N-acetylglucosamine inhibits glucose phosphorylation by N-acetylglucosamine 
kinase but not GK (Miwa, Mita et al. 1994). Accurate GK activity measurement was 
previously demonstrated in vitro and an improved sensitivity to GK was shown (Richardson 
2011).  
 
3.4.5 Decreasing arcuate glucokinase activity decreases glucose intake 
To investigate the physiological role of GK in the ARC, I injected rAAV encoding for antisense 
GK into rats. Selectively decreasing ARC GK in rats results in a decrease in glucose intake in 
both an acute and long-term study. This data backs up my hypothesis and correlates with 
my previous investigation of the role of ARC GK using pharmacological activators. 
Furthermore, knocking down ARC GK is in agreement with previous studies conducted in 
this laboratory. Overexpression of ARC GK (iARC-GKS), using rAAV encoding for GK sense, 
resulted in increased food intake and body weight gain (Hussain, Richardson et al. 2014). 
When iARC-GKS animals were provided with standard chow and glucose solution in a long-
term study, they consumed significantly more glucose than control rats whereas chow 
intake remained the same. In the present study, knockdown of ARC GK using a comparable 
approach decreased glucose intake. This provides evidence for the hypothesis that ARC GK 
regulates glucose-specific appetite over other foods.  
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3.4.6 ARC glucokinase and the control of overall calorie intake 
Decreasing ARC GK activity decreases glucose intake but not total energy intake. This is due 
to a slight but non-significant increase in normal chow intake as compensation. Body weight 
gain between the two groups was not significantly different. A decrease of glucose 
consumption is consistent with previous findings that increased ARC GK expression 
increases glucose intake (Hussain, Richardson et al. 2014). However, iARC-GKS also caused a 
significant increase in body weight gain by around 6% (Hussain, Richardson et al. 2014). 
Further analysis of this increase revealed that it was due to a rise in percentage bodyweight 
of fat. While there was not a statistically significant decrease in body weight gain in iARC-
GKAS animals, there was a reduction by around 7% after 33 days, similar to the 6% increase 
observed in iARC-GKS animals (Hussain, Richardson et al. 2014). Therefore it is likely that GK 
does alter overall body weight gain, particularly fat, but in the present study there was an 
increased variation between animals.  
 
3.4.7 Two separate physiological roles for hypothalamic glucokinase 
The findings in this chapter describe a novel role for ARC GK independent of the role 
previously described. Classically, hypothalamic GK has been shown to be involved in the CRR 
to hypoglycaemia. Infusion of insulin in rats to induce hypoglycaemia triggers adrenalin, 
noradrenalin and glucagon release to promote glucose availability and maintain 
homeostasis (Levin, Becker et al. 2008). Injection of CpdA into the VMH reduced adrenalin, 
noradrenalin and glucagon secretion in rats under conditions of insulin-induced 
hypoglycaemia, suggesting that increased GK inhibits the production of glucose (Levin, 
Becker et al. 2008). Glucose consumption was not reported in these experiments, and there 
were no reported changes in acute chow intake. This is contrary to the findings using CpdA 
in the present chapter, where glucose and chow intake were increased. However, CpdA 
injection sites were different between the two studies, and the model of insulin-induced 
hypoglycaemia was not used in this chapter. The reason why there were no reported 
changes in appetite may be because insulin directly inhibits food intake therefore the 
effects of CpdA would be masked (Woods, Lotter et al. 1979, Levin, Becker et al. 2008). Also, 
hypoglycaemia can indirectly affect appetite; as observed in humans by increasing anxiety, 
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dizziness and perspiration (Mitrakou, Ryan et al. 1991). Furthermore, Levin, Becker et al. 
(2008) used animals that were subjected to extra surgical procedures, such as jugular vein 
catheterisation, which could affect baseline measurements by inducing stress.  
The effects of reduced ARC GK in this chapter are not consistent with previous investigations 
in the hypothalamus. Injection of adenovirus containing short-hairpin RNA (shRNA) for GK 
reduced VMN GK expression by 70% over 10 days in rats but did not alter feeding (Dunn-
Meynell, Sanders et al. 2009). However, this experiment was not consistent with other 
studies by the same group who have shown robust changes in the CRR to hypoglycaemia 
with altered VMN GK activity (Kang, Routh et al. 2004, Levin, Magnan et al. 2011). VMN GK 
reduction by shRNA did not alter blood glucose or glucagon release when induced with 
hypoglycaemia (Dunn-Meynell, Sanders et al. 2009). This could be due to an immediate 
immunogenic response from adenoviral infection or as a result of decreased hexokinase 1 
expression (Levin, Becker et al. 2008, Dunn-Meynell, Sanders et al. 2009). In accord with the 
findings in previous models of GK knockdown, it is possible that the decrease in food intake 
with knockdown of ARC GK could be due to alterations in glucagon, adrenalin or insulin 
release (Levin, Becker et al. 2008). 
Alternative methods to decrease GK activity have similar limitations. Injection of the toxic 
glucose analogue alloxan into the VMN did not alter glucose tolerance or appetite (Dunn-
Meynell, Sanders et al. 2009). However this drug produces significant toxicity in glucose 
sensing cells and ICV injection of comparable doses has been shown to alter gene 
expression and behaviour (Šalković-Petrišić and Lacković 2003). Other studies investigating 
the effects of decreased GK have used the hexokinase inhibitor glucosamine but as it affects 
other hexokinases as well as GK, intracellular glucose metabolism is likely to be 
compromised (Zhou, Yueh et al. 2011). Therefore previous studies have not completely 
identified the effects of decreased GK activity so the reduction in glucose intake observed in 
the present study provides novel evidence of an alternate role for GK in the hypothalamus. 
The difference in effects between the techniques used in the present study and those by 
Levin et al. could also be due to variances in injection coordinates. While the VMN and ARC 
are located adjacent to each other in the hypothalamus, there are some notable differences 
between them. These have been described in chapter 1, but could primarily be due to the 
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different populations of neurones in the ARC and the increased tanycyte projections from 
the median eminence. Previous studies that investigated the effects of hypoglycaemia 
targeted the divide between the VMN and ARC (-8.5 to -9.5mm from the dura) (Levin, 
Becker et al. 2008, Dunn-Meynell, Sanders et al. 2009), whereas I target the ARC exclusively 
(-10.5mm from the dura). The powerful influence of ARC neurones on appetite and energy 
homeostasis demonstrates that these neurones are part of an important pathway to control 
feeding.  Therefore the differences observed between GK expressing neurones in the ARC 
and VMN may be due to differences in neuronal circuitry that are investigated.  
It was not confirmed that direct injection of substances only affected ARC neurones. With 
regard to genetic knockdown of ARC GK, a GK activity assay was performed to show that 
VMN GK activity was not altered. While it was assumed that each cannula projected into the 
ARC, diffusion of substances outside of the ARC could occur. Immunoreactivity of a neuronal 
activation marker, such as c-fos, could achieve confirmation of exclusive ARC activation.  
There is a possibility that pharmacologically increasing GK activity using CpdA results in 
intracellular hypoglycaemia by artificially driving metabolism of available glucose. 
Theoretically this could increase food intake as central hypoglycaemia has been shown to 
affect feeding. However there are several reasons why this is not likely to be due to 
hypoglycaemia. First, pharmacological and genetic activation of ARC GK does not increase 
fructose consumption, indicating that the effect of CpdA is specific for glucose (Hussain, 
Richardson et al. 2014). Second, GLUT control the transport of glucose into cells and have a 
high affinity for glucose. This means that under normal physiological conditions any 
available extracellular glucose will be taken up into the cell. Third, G6P; not glucose, controls 
metabolism therefore the rate of phosphorylation of glucose by other hexokinases 
determines cellular function. If there was a large increase in G6P with an increase of GK 
activity then food intake would decrease, according to previous reports (Dunn-Meynell, 
Sanders et al. 2009).  It therefore seems unlikely that CpdA drive feeding by indirectly 
triggering hypoglycaemia. 
In summary, the different approaches between the two studies may influence the behaviour 
observed with CpdA injection. Both approaches may still be beneficial for describing the 
physiological role of GK.  
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3.4.8 The physiological relevance of ARC GK in the regulation of food intake 
The finding that ARC GK regulates glucose appetite is not supported by evidence regarding 
glucose homeostasis in the VMN. The question arises as to the physiological relevance for a 
positive feedback where rising glucose levels further increase glucose consumption. 
However all energy homeostasis pathways comprise of orexigenic and anorexigenic signals 
working in parallel. A relevant example is the hedonic value of food, which plays a major 
part in the regulation of food intake (Berthoud and Morrison 2007). The principle of reward 
processing is that feeding promotes positive feelings and emotion therefore positive 
feedback mechanisms are powerful mediators of food intake. ARC GK represents an 
orexigenic pathway that promotes the consumption of the substrate that is a vital energy 
source for the brain. This might be a conserved behaviour to make use of any glucose when 
it becomes available. It is likely that this behaviour involves hedonic centres to communicate 
the reward value of glucose. This hypothesis is supported by findings that fasting results in 
an increase in ARC GK expression in rats (Hussain, Richardson et al. 2014). This is in accord 
with previous data showing an increase in hypothalamic GK expression (Zhou, Roane et al. 
2003, Sanz, Roncero et al. 2007, Kang, Sanders et al. 2008), even though pancreatic GK 
expression does not change (Iynedjian, Pilot et al. 1989). In addition, rat LH and VMH slices 
exhibit an increase in GK activity when glucose concentration decreases (Sanz, Roncero et 
al. 2007). Therefore it is likely that ARC GK plays a physiological role in food intake. If GK was 
present to only maintain homeostasis then fasting should have decreased GK activity to 
promote feeding (Levin, Magnan et al. 2011). In the next chapter I investigate the neuronal 
mechanisms of GK activation to better understand this pathway.  
 
3.4.9 Conclusion 
Activation of ARC GK activity in rats increases appetite specifically for glucose. Conversely, 
chronic knockdown of ARC GK in rats decreases food intake in both an acute and cumulative 
setting. Appetite for pure glucose is decreased but appetite for other foods is not. In 
addition, total energy intake is not affected by a decrease in glucose intake as overall food 
intake is slightly increased. These findings compliment previous investigations where 
chronic overexpression of ARC GK increases glucose appetite.   
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Chapter 4: Pharmacological manipulation 
of arcuate nucleus glucose sensing 
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4.1 Introduction 
The data presented in chapter 3 suggests that ARC GK regulates glucose appetite. 
Pharmacological activation of ARC GK increases glucose intake at 1 hour. While it is likely 
that this response is mediated by direct activation of GK, the intracellular mechanisms and 
neuronal circuitry that are involved in driving glucose intake are not known. Investigating 
the mechanisms of ARC glucose sensing is necessary in order to understand why regulation 
of glucose appetite only occurs in the ARC and not elsewhere in the hypothalamus. To 
identify the types of neurones involved and how GK may alter depolarisation, I will 
investigate the intracellular mechanisms that are involved in mediating the effects of ARC 
GK on appetite. To explore the neuronal pathways involved in glucose sensing neurones, I 
will investigate the neurotransmitters released as a result of ARC GK activation.  
 
4.1.1 The role of ATP-sensitive potassium channels 
KATP channels play a key role in glucose-stimulated insulin release from β-cells (Ashcroft and 
Rorsman 2013). The KATP channels involved in this glucose sensing pathway likely consist of 4 
Kir6.2 and 4 SUR1 subunits arranged to form an ion channel. The ratio of ATP to ADP dictates 
KATP channel opening probability. ATP binds to Kir6.2 to keep the channel closed and prevent 
K+ ions exiting the cell while ADP binds to SUR1 with an opposite effect on channel opening 
(Gribble, Tucker et al. 1997, Tucker, Gribble et al. 1998). ATP concentrations rise with an 
increase in GK activity in β-cells to stimulate further KATP channel closure and trigger insulin 
release. A similar mechanism has also been identified in GE neurones to trigger 
depolarisation. KATP channels are highly expressed in many cells including NPY and POMC 
neurones (Ibrahim, Bosch et al. 2003, van den Top, Lyons et al. 2007). Selective knockout of 
Kir6.2 in POMC neurones results in an impaired glucose tolerance and glucose-stimulated 
hypothalamic α-MSH release (Parton, Ye et al. 2007). However the role of KATP channels in 
regulating glucose intake is not known. 
The role of ion channels can be investigated by altering channel opening using 
pharmacological activators and inhibitors. Diazoxide stimulates channel opening by 
increasing the actions of ADP and Mg2+ (Kozlowski, Hales et al. 1989, Gribble, Tucker et al. 
1997). Sulfonylureas such as glibenclamide inhibit channel opening to cause depolarisation. 
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Many sulfonylureas have had some success as therapeutic treatments for type II diabetes to 
stimulate insulin release (U. K. Prospective Diabetes Study Group 1998, Turner, Cull et al. 
1999). The SUR1 subunit has at least two ligand binding sites for drugs that induce KATP 
closure: a benzamide-binding site and a tolbutamide-binding site (figure 1.3). Many 
sulfonylureas including tolbutamide and gliclazide bind to the tolbutamide-binding site but 
glibenclamide is thought to bind to both sites (Nagashima, Takahashi et al. 2004).  
The role of KATP channels in the CRR to hypoglycaemia has been investigated by direct 
administration of pharmacological agents into the brain. Injection of glibenclamide in the 
VMN impairs the compensatory increase in glucagon in response to hypoglycaemia (Evans, 
McCrimmon et al. 2004). In contrast, injection of diazoxide in the VMN amplifies the CRR to 
hypoglycaemia response by increasing adrenaline and glucagon (McCrimmon, Evans et al. 
2005). I aim to investigate the role of KATP channels in ARC GK-regulated glucose intake using 
these pharmacological agents. The previous studies investigating the role of KATP channels in 
the CRR to hypoglycaemia injected primarily into the VMN so the physiological role of KATP 
channels in the ARC has not yet been studied.  
 
4.1.2 The role of voltage-gated calcium channels in ARC GK-regulated glucose intake 
Voltage-gated calcium channels (VGCC) are important regulators of electrochemical 
gradients in neurones. The tight regulation of calcium influx requires the combination of 
many different types of VGCC with different physiological and pharmacological profiles. 
These are mainly dependant on the type of α1 subunit expressed, which forms the channel 
pore, voltage sensor and gate (Catterall, Perez-Reyes et al. 2005). High voltage-activated 
channels, including L, N and P/Q type channels, have ancillary subunits to further control the 
voltage required to trigger activation and inactivation of the channel. Neurones express 
many different types of channels to control many different physiological functions. For 
example; L, N, P/Q and R type channels all contribute to the calcium-induced increase in 
membrane currents in rat cerebellar granule neurones (Randall and Tsien 1995). The family 
of L type VGCC comprise of at least 4 different sub-types with different subunit composition 
(CaV1.1-1.4). Of note, CaV1.2 and 1.3 are expressed in neurones and endocrine cells and 
have been shown to regulate hormone secretion, action potential propagation and gene 
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expression (Catterall 2000). Most CaV1.2 and 1.3 channels are located on the post-synaptic 
terminal of neurones and are not associated with release of cortical neurones vesicles at the 
presynaptic terminal as they do not possess a motif for interactions with SNARE proteins. 
CaV1.3 are activated at a relatively hyperpolarised potential and have been shown to 
modulate post-synaptic activity in neurones (Xu and Lipscombe 2001). Dihydropyridines 
such as nifedipine are potent blockers of L type channels and have been used to identify the 
role of hippocampal VGCC in memory (Quevedo, Vianna et al. 1998). L type channels have 
been shown to regulate the orexin-A-induced activation of a minor population of ARC 
neurones (Wu, Wu et al. 2013); and to some extent, β-cells (Smith, Rorsman et al. 1989). 
Though the role of ARC GK on appetite does not likely involve AMPK (Hussain, Richardson et 
al. 2014) , L type channels may still play a role.  
P/Q type VGCC, also known as CaV2.1, are associated with vesicle release and are located 
very close to SNARE proteins at pre-synaptic terminals (Catterall, Perez-Reyes et al. 2005, 
Weiss and Zamponi 2012). P and Q type channels have slight variations in inactivation 
kinetics but are not easily distinguished. Both are blocked by ω-agatoxin IVA but at a slightly 
higher potency at P type channels (Llinas, Sugimori et al. 1989, Randall and Tsien 1995). 
N type VGCC (CaV2.2) are also associated with vesicle release at pre-synaptic terminals 
(Catterall, Perez-Reyes et al. 2005). They have a high single-channel conductance in order to 
quickly induce a transient increase in Ca2+ so are ideal for vesicle release (Weber, Wong et 
al. 2010). The voltage dependence of N type channels varies considerably, presumably due 
to different vesicle release requirements, therefore the most accurate identifier of N type 
channels is via their sensitivity to cone snail neurotoxin ω-conotoxin GVIA (Casali, Gomez et 
al. 1997). Both P/Q and N are also expressed in dendrites and play a role in dendritic Ca2+ 
transients (Catterall 2000). 
R type channels, also known as CaV2.3, are expressed in cell bodies, dendrites and nerve 
terminals to trigger Ca2+-dependent action potentials and neurotransmitter release. While 
expressed in the cortex and hippocampus, their expression is not as high as other CaV2 
channels (Dunlap, Luebke et al. 1995).  
It is worth noting that as well as the actions of VGCC in vesicle release, P/Q, N and NaV1.2 of 
L type channels are also likely to be involved in action potential repolarisation rates due to 
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their association with potassium channels (Simms and Zamponi 2014). I aim to investigate 
the involvement of VGCC in mediating ARC GK-regulated glucose intake. 
 
4.1.3 The neurotransmitters involved in ARC GK-regulated increase in glucose intake 
Both POMC and NPY neurones express GK in the ARC (Muroya, Yada et al. 1999, Ibrahim, 
Bosch et al. 2003, Parton, Ye et al. 2007) therefore the neuronal mechanism of ARC GK 
action could be via these pathways. NPY is a widely distributed neurotransmitter in the CNS 
(Li, Xi et al. 2003) and is a potent orexigenic peptide (Mercer, Chee et al. 2011). The majority 
of NPY in the hypothalamus is produced by ARC neurones, which co-express AgRP 
(Broberger, Johansen et al. 1998). ARC NPY neurones innervate and inhibit nearby POMC 
neurones. NPY is contained in large dense core vesicles, which are exocytosed into the 
synapse by calcium-mediated vesicular release (Pelletier, Guy et al. 1984). The vesicles 
containing NPY can also be released at sites along the axon, indicating that it also acts as a 
neuromodulator on neighbouring neurones (Morris and Pow 1991). NPY binds to Y1 and Y2 
receptors on the post-synaptic terminal to hyperpolarise POMC neurones (Broberger, 
Landry et al. 1997, Roseberry, Liu et al. 2004). Regulation of feeding also requires the Y5 
receptor and stimulation of this receptor in the ARC inhibits α-MSH release (Galas, Tonon et 
al. 2002). NPY neurones also project to glutamatergic neurones in the VMN, GABAergic 
neurones in the PVN and MCH and orexinergic neurones in the LH (Tiesjema, Adan et al. 
2007, Mercer, Chee et al. 2011). Interestingly, the majority of glucose sensitive VMN 
neurones are also sensitive to NPY (Chee, Myers et al. 2010). In addition, NPY injection in 
the PVN stimulates food intake (Stanley, Chin et al. 1985). 
Alpha-MSH is cleaved from the POMC precursor and acts as an anorexigenic peptide (Rossi, 
Kim et al. 1998, Cone, Cowley et al. 2001). Alpha-MSH release from hypothalamic explants 
increases with increasing glucose concentrations (Parton, Ye et al. 2007). Alpha-MSH binds 
to melanocortin 4 receptors to inhibit food intake (Kim, Rossi et al. 2000). Pathways for 
melanocortin action have been demonstrated throughout the CNS, notably forming positive 
feedback within VMH neurones and inhibiting appetite in the PVN (Balthasar, Dalgaard et al. 
2005, Parker and Bloom 2012). Alpha MSH signalling in the central amygdala is also linked 
with alterations in preferences for dietary fats (Boghossian, Park et al. 2010). 
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In summary, the mechanisms of ARC GK control of glucose appetite require further 
investigation. KATP channels play a key role in glucose sensing in the ARC. The types of 
neurones involved in ARC glucose sensing remain to be determined but likely involves 
POMC or NPY neurones, the predominant ARC populations involved in regulation of food 
intake.  
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4.2 Hypothesis and Aims 
4.2.1 Hypothesis 
Pharmacologically closing KATP channels will affect food intake and glucose intake in a similar 
way to increasing GK activity. Similarly, opening KATP channels will have the opposite effect. 
The mechanism of ARC GK mediated glucose intake is likely to be mediated by neuronal 
pathways. Therefore alterations in ARC GK will alter neuronal firing, probably via orexigenic 
NPY neurones. The release of vesicular NPY at pre-synaptic terminals is likely controlled by 
multiple types of voltage-gated calcium channels (VGCC). Furthermore NPY likely acts at Y1 
and Y5 receptors on the post-synaptic terminals of second order neurones.  
 
4.2.2 Aims 
To investigate my hypothesis I will: 
1. Inhibit and stimulate ARC KATP channels by delivering pharmacological agents into the 
ARC via a stereotactically inserted cannula and measure food and glucose intake. 
2. Pharmacologically stimulate GK and KATP channels ex vivo in hypothalamic explants and 
measure neuropeptide release.  
3. Investigate the effect of pharmacologically blocking ARC VGCC on the previously 
described model of ARC GK-regulated increase in glucose intake. 
4. Investigate the effect of pharmacologically blocking central NPY receptors on ARC GK-
regulated increase in glucose intake. 
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4.3 Results 
4.3.1 Effect of pharmacologically inhibiting ARC KATP channels on chow and glucose intake 
Permanent cannulas were stereotactically implanted 1mm above the ARC nucleus of rats. 
ARC KATP channels were inhibited by 2 nmol injection of the sulfonylurea glibenclamide. 
Following injection rats were allowed access to either chow, a glucose solution or both chow 
and glucose. Acute inhibition of ARC KATP channels caused a significant increase in chow 
intake over the first 4 hours (control, 3.29±0.54g; glib, 4.43±0.70g; n=12 per group, p <0.05) 
(figure 4.1a). Acute inhibition of ARC KATP channels caused a slight, but not significant, 
increase in chow intake over 8 hours (control, 6.18±1.79g; glib, 7.39±0.93g; n=12 per group, 
p =0.08) (figure 4.1b). Acute inhibition of ARC KATP channels caused a significant increase in 
glucose intake over 4 hours (control, 5.22±1.81g; glib, 8.39±2.06g; n=11 per group, p <0.05) 
(figure 4.2a). This increase in glucose intake was sustained over 8 hours (control, 
6.12±1.99g; glib, 9.68±2.36g; n=11 per group, p <0.05) (figure 4.2b). Acute inhibition of ARC 
KATP channels caused a significant increase in glucose intake when both chow and glucose 
were available after 4 hours (control, 7.30±1.90g; glib, 10.22±2.46g, n=10 per group, p 
<0.05) (figure 4.3a). This increase was maintained but was not statistically significant after 8 
hours (control, 9.31±2.42g; glib, 10.45±2.47g; n=10 per group) (figure 4.3c). However, there 
was no significant difference in chow intake over 4 hours (control, 3.37 ±0.52g; glib, 3.35 
±0.81g; n=10 per group) (figure 4.3b) or 8 hours (control, 6.49±0.68g; glib, 6.15±1.40g; n=10 
per group) (figure 4.3d). 
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Figure 4.1 Effect of inhibiting KATP channels on food intake. Food intake; (A) four hours, (B) 
eight hours, after ARC KATP channel inhibition using stereotactic injection of 2 nmol glib as 
compared to the vehicle injected controls during a crossover study. Data are presented as 
mean±SEM, n=12 per group. Statistical significance was analysed by paired Student’s t-test: 
*= p <0.05. 
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Figure 4.2 Effect of inhibiting KATP channels on glucose intake. 2% glucose intake; (A) four 
hours, (B) eight hours, after ARC KATP channel inhibition using stereotactic injection of 2 
nmol glib as compared to the vehicle injected controls during a crossover study. Data are 
presented as mean±SEM, n=11 per group. Statistical significance was analysed by Student’s 
t-test: *= p <0.05. 
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Figure 4.3 Effect of inhibiting KATP channels on chow and glucose intake. Food intake; (A) 
four hours, (C) eight hours, and 2% (w/v) glucose intake; (B) one hour, (D) eight hours, after 
ARC KATP channel inhibition using stereotactic injection of 2 nmol glib as compared to the 
vehicle injected controls during a crossover study. Data are presented as mean±SEM, n=10 
per group. Statistical significance was analysed by Student’s t-test: *= p <0.05.  
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4.3.2 Effect of pharmacologically activating ARC KATP channels on chow and glucose intake 
Permanent cannulas were stereotactically implanted 1mm above the ARC nucleus of rats. 
Rats were fasted overnight and ARC KATP channels were stimulated by injection of 1 nmol of 
the activator diazoxide. Following injection rats were allowed access to either chow, a 2% 
(w/v) glucose solution or both chow and glucose. Acute activation of ARC KATP channels 
caused a significant decrease in chow intake over the first 30 minutes compared with 
controls (control, 4.81±0.42g; Dia, 3.72±0.30g; n=9 per group, p <0.01) (figure 4.4a). 
However chow intake was not reduced beyond 30 minutes (after 8 hours, control, 
15.8±1.15g; Dia, 14.8±0.90g; n=9 per group) (figure 4.4b). Acute activation of ARC KATP 
channels caused a significant decrease in glucose intake over four hours (control, 
25.8±4.95g; Dia, 19.3±3.97g; n=9 per group, p <0.05) (figure 4.5a). However this was not 
sustained over 8 hours (control, 44.1±9.59g; Dia, 44.5±13.9g; n=9 per group) (figure 4.5b). 
Acute activation of ARC KATP channels caused a significant decrease in glucose intake over 4 
hours (control, 18.6±3.57g; Dia, 12.7±1.44g; n=9 per group, p <0.05) (figure 4.6a). There was 
a slight, but not significant, decrease in glucose intake after 8 hours (control, 22.5±3.58g; 
Dia, 19.9±1.82g; n=9 per group, p =0.12) Figure 4.6c). However there was no difference in 
chow intake during the first thirty minutes (control, 3.63±0.79g; Dia, 3.69±0.51g; n=11 per 
group) (figure 4.6b) or over 8 hours (control, 14.6±1.55g; Dia, 16.5±0.90g; n=11 per group) 
(figure 4.6d). 
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Figure 4.4 Effect of KATP channel activation on food intake. Food intake; (A) 30 minutes, (B) 
eight hours, after ARC KATP channel activation using stereotactic injection of 1 nmol 
diazoxide (dia) as compared to the vehicle injected controls during a crossover study. Data 
are presented as mean±SEM, n=9 per group. Statistical significance was analysed by 
Student’s t-test: **= p <0.01, *= p <0.05. 
  
A 
B 
110 
 
C o n t r o l D i a
0
1 0
2 0
3 0
4 0
*
G
lu
c
o
s
e
 i
n
ta
k
e
 (
m
l)
 
0 2 4 6 8
0
2 0
4 0
6 0
8 0
*
*
T i m e  ( h )
G
lu
c
o
s
e
 
in
t
a
k
e
 (
m
l)
 
Figure 4.5 Effect of KATP channel activation on glucose intake. 2% glucose intake; (A) four 
hour, (B) eight hours, after ARC KATP channel activation using stereotactic injection of 1 nmol 
diazoxide (Dia) as compared to the vehicle injected controls during a crossover study. Data 
are presented as mean±SEM, n=9 per group. Statistical significance was analysed by 
Student’s t-test: *= p <0.05. 
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Figure 4.6 Effect of KATP channel activation on chow and glucose intake. 2% glucose intake; 
(A) four hours, (C) eight hours, and chow intake; (B) 0.5 hours, (D) eight hours, after ARC KATP 
channel activation using stereotactic injection of 1 nmol diazoxide (dia) as compared to the 
vehicle injected controls during a crossover study. Data are presented as mean±SEM, n=9 
per group. Statistical significance was analysed by Student’s t-test: *= p <0.05. 
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4.3.3 Effect of pharmacologically activating ARC GK and KATP channels on NPY and α-MSH 
release from hypothalamic neurones 
Neurotransmitter release was measured ex vivo using rat mediobasal hypothalamus 
explants as described previously (Seal, Small et al. 2001). Explants were acclimatised to 
aCSF; basal samples were taken, and treated with one of the following: 30µM GK activator 
CpdA, 100µM KATP channel inhibitor glibenclamide or 200µM KATP channel activator 
diazoxide. These concentrations were chosen from previous similar experiments (Lam, Pocai 
et al. 2005, Kang, Dunn-Meynell et al. 2006, Chan, Lawson et al. 2007). Neurotransmitter 
release in the aCSF was measured by RIA and compared with the basal sample.  
Activation of hypothalamic GK caused a significant increase in NPY release compared to 
basal levels (control, 8.9±1.5 fmol/explant; CpdA, 11.4±1.7 fmol/explant; n=10-12 per group, 
p <0.05) (figure 4.7a). Similarly, inhibition of hypothalamic KATP channels caused a significant 
increase in NPY release compared to basal levels (control, 9.1±1.3 fmol/explant; Glib; 
12.0±1.5 fmol/explant; n=10-12 per group, p <0.05). In contrast, activation of hypothalamic 
KATP channels caused a significant decrease in NPY release compared to basal levels (control, 
11.3±1.5 fmol/explant; Dia; 8.7±1.3 fmol/explant; n=10-12 per group, p <0.05).  
Activation of hypothalamic GK did not alter α-MSH release compared to basal levels 
(control, 14.2±4.2 fmol/explant; CpdA, 16.2±5.6 fmol/explant; n=6-9) (figure 4.7b). Similarly, 
inhibition of hypothalamic KATP channels did not alter α-MSH release compared to basal 
levels (control, 12.1±2.2 fmol/explant; Glib, 15.7±4.1 fmol/explant; n=6-9). In addition, 
activation of hypothalamic KATP channels did not alter α-MSH release compared to basal 
levels (control, 13.7±3.2 fmol/explant; Dia, 13.2±1.7 fmol/explant; n=6-9). 
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Figure 4.7 Effect of pharmacological agents on neuropeptide release from hypothalamic 
neurones. (A) NPY and (B) αMSH release from hypothalamic explant slices in response to 
pharmacological agents labelled. Addition sign (+) denotes drug wash; subtraction sign (-) 
denotes basal levels without drug. Data are presented as mean±SEM, NPY, n=10-12 per 
group, α-MSH, n=6-9. Statistical significance was analysed by ANOVA followed by post-hoc 
Holms-Sidak test: *= p <0.05.  
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4.3.4 Effect of pharmacologically activating KATP channels on the ARC GK-regulated 
increase in glucose intake  
As demonstrated previously, pharmacological activation of ARC GK with CpdA significantly 
increases 2% (w/v) glucose consumption over 1 hour (figure 3.2). In contrast, 
pharmacological activation of ARC KATP channels with diazoxide significantly decreases 
glucose consumption (figure 4.5). To investigate the combined involvement of GK and KATP 
channels ARC glucose sensing I activated KATP channels and measured the effects of CpdA 
stimulated activation of ARC GK. 
Permanent cannulas were stereotactically implanted into the ARC nucleus of rats. Rats were 
fasted overnight before 2 nmol diazoxide was administered by intra-ARC injection to open 
KATP channels. After 15 minutes ARC GK activity was increased by 0.5 nmol CpdA by intra-
ARC injection and glucose intake was measured. Consistent with the previous studies, CpdA 
with pre-treatment of a control substance significantly increased glucose intake over the 
first hour (control, 5.22±0.22ml; CpdA, 10.86±0.69ml; n=10 per group, p <0.001) (figure 
4.8a). Glucose intake stimulated by CpdA was significantly attenuated by pre-treatment with 
a KATP channel activator (control, 5.53±0.42ml; CpdA, 6.26±0.67ml; n=10, p <0.001). This 
decrease in glucose intake was not due to the activator alone as there was no significant 
difference when diazoxide was injected without CpdA (vehicle; 5.22±0.22ml, diaz; 
5.53±0.42ml, n=10 per group). The effects of all treatments were sustained during 8 hours 
(figure 4.8b). These results indicate that KATP channels are involved in the ARC GK-regulated 
increase in glucose intake. 
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Figure 4.8 Effect of KATP channel activation on the ARC GK-regulated increase in glucose 
intake. 2% glucose intake one hour (A) and up to 8 hours (B) after ARC GK activation 
following pre-treatment with KATP channel activator over 4 sets of injections in a random 
order during a crossover study. Rats received intra-ARC injection of 2 nmol diazoxide or 
vehicle (5mM NaOH) 15 minutes before stereotactic injection of 0.5 nmol CpdA or control 
(0.1% DMSO). Data are presented as mean±SEM, n=10 per group. Statistical significance was 
analysed by one way ANOVA with Holm-Sidak’s multiple comparisons test: ***= p <0.001 
relative to intra-nuclear injected controls, †††= p <0.001 relative to vehicle treated and 
CpdA-injected group.   
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4.3.5 Effect of simultaneously activating ARC GK and KATP channels on hypothalamic NPY 
release  
Activation of GK with 30µM CpdA resulted in a significant increase in NPY release from 
hypothalamic neurones compared to basal levels (control, 9.00±0.94 fmol/explant; CpdA, 
14.3±1.40 fmol/explant; n=13 per group, p <0.01) (figure 4.9). Stimulation of KATP channels 
with 200µM diazoxide significantly decreased NPY release compared to basal levels (control, 
17.0±3.65 fmol/explant; Dia, 8.45±1.31 fmol/explant; n=12 per group, p <0.05). NPY release 
is similar to previous studies under the same conditions (figure 4.7a). Activation of both GK 
and KATP channels with 30µM CpdA and 200µM diazoxide did not significantly alter NPY 
release compared with basal levels (control, 6.75±0.36 fmol/explant; CpdA + Dia, 8.07±0.85 
fmol/explant; n=15). However, NPY release stimulated by CpdA was significantly attenuated 
by treatment with diazoxide (CpdA, 14.3±1.40 fmol/explant; CpdA + Dia, 8.07±0.85 
fmol/explant; n=13-15 per group, p <0.001).   
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Figure 4.9 Effect of increased ARC GK and KATP channel activities on hypothalamic NPY 
release. NPY release from hypothalamic explant slices in response to pharmacological 
agents labelled. Addition sign (+) denotes drug wash; subtraction sign (-) denotes basal 
wash. Data are presented as mean±SEM, n=12-15 per group. Statistical significance was 
analysed by ANOVA followed by post-hoc Holms-Sidak test: *= p <0.05, **= p <0.01; relative 
to respective control, †††= p <0.001 relative to CpdA.  
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4.3.6 Role of voltage-gated calcium channels in the ARC GK-regulated increase in glucose 
intake 
Pharmacological activation of ARC GK with CpdA increases glucose consumption. 
Stimulation of GK also releases neuropeptides from hypothalamic neurones in ex vivo 
hypothalamic explants indicating that the mechanism is mediated via a neuronal pathway. 
To further elucidate the mechanism of ARC GK action I blocked ARC VGCC and measured the 
effects of ARC GK-regulated increase in glucose intake.  
Permanent cannulas were stereotactically implanted into the ARC nucleus of rats. P/Q and L 
type VGCC were blocked with 1.0µg ω-agatoxin IVA (agatox) or 1.6µg nifedipine (nifed) 
respectively by intra-ARC injection. Selective inhibitions of these channels were chosen 
because they are highly expressed in neurones. After 15 minutes ARC GK activity was 
increased with 0.5 nmol CpdA by intra-ARC injection and glucose intake was measured. 
Consistent with the previous studies, CpdA with pre-treatment of a control substance 
(vehicle) significantly increased glucose intake over the first hour compared with control 
(control, 3.10±0.51ml; CpdA, 8.90±0.54ml; n=13 per group, p <0.001) (figure 4.10a). Glucose 
intake stimulated by CpdA was significantly attenuated by pre-treatment with P/Q channel 
blocker (agatox, 3.36±0.40ml; n=13 per group, p <0.001). Glucose intake stimulated by CpdA 
was not altered by pre-treatment with L channel blocker (nifed, 9.44±0.67ml; n=13 per 
group). P/Q or L type channel antagonism did not significantly alter glucose intake alone 
compared with control without CpdA (control, 3.10±0.51ml; agatox, 3.05±0.54ml; nifed, 
3.82±0.52ml; n=13 per group). The effects of all treatments were sustained during 8 hours 
(figure 4.10b). These results indicate that P/Q type, but not L type channels are involved in 
ARC GK-regulated increase in glucose intake. 
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Figure 4.10 Effect of VGCC inhibition on the ARC GK-regulated increase in glucose intake. 
2% glucose intake one hour (A) and 0.5-8 hours (B) after ARC GK activation following P/Q 
type and L type VGCC antagonism over 6 sets of injections in a random order during a 
crossover study. Rats received intra-ARC injection of 1.6µg nifedipine, 1µg agatoxin or 
vehicle (water) 15 minutes before intra-ARC injection of 0.5 nmol CpdA or control (0.1% 
DMSO). Data are presented as mean±SEM, n=13 per group. Statistical significance was 
analysed by one way ANOVA followed by post-hoc Holm-Sidak test: ***= p <0.001 relative 
to intra-nuclear injected controls, †††= p <0.001 relative to vehicle treated and CpdA-
injected group. 
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4.3.7 Effect of NPY receptor inhibition on the ARC GK-regulated increase in glucose intake 
Pharmacological activation of ARC GK with CpdA increases glucose consumption. 
Stimulation of GK also releases NPY from hypothalamic neurones in ex vivo hypothalamic 
explants. To further elucidate the mechanism of ARC GK action and to investigate which 
receptors NPY exerts its effects; I blocked NPY receptors and measured the effects of ARC 
GK-regulated increase in glucose intake.  
Permanent cannulas were stereotactically implanted into the ARC nucleus of rats. NPY 
receptors Y1 or Y5 were blocked with 10mg/kg BMS193885 (BMS) or 10mg/kg CGP71683 
(CGP) respectively by peripheral IP injection. After 30 minutes ARC GK activity was increased 
with 0.5 nmol CpdA by intra-ARC injection and glucose intake was measured. Consistent 
with the previous studies, CpdA with pre-treatment of a control substance (vehicle) 
significantly increased glucose intake over the first hour compared with control (control, 
4.93±1.02ml; CpdA, 10.21±0.86ml; n=12 per group, p = <0.001) (figure 4.10a). Glucose 
intake stimulated by CpdA was significantly attenuated by pre-treatment with Y1 antagonist 
(BMS; 4.11±0.66ml; n=12 per group, p = <0.001) and Y5 antagonist (CGP; 6.32±0.75ml; n=12 
per group, p = <0.001). Y1 or Y5 receptor antagonism did not significantly alter glucose 
intake alone compared with control without CpdA (control, 4.93±1.02ml; BMS; 3.25±0.30ml; 
CGP; 4.58±0.77ml; n=12 per group). The effects of all treatments were sustained during 8 
hours (figure 4.11b). These results indicate that both Y1 and Y5 receptors are involved in 
ARC GK-regulated increase in glucose intake. 
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Figure 4.11 Effects of NPY receptor inhibition on the ARC GK-mediated increase in glucose 
consumption. 2% glucose intake one hour (A) and 8 hours (B) after ARC GK activation 
following NPY Y1 and Y5 receptor antagonists over 6 sets of injections in a random order 
during a crossover study. Rats received 100µl IP injection of 10mg/kg BMS 10mg/kg CGP or 
vehicle (40%DMSO) thirty minutes before stereotactic injection of 0.5 nmol CpdA or control 
(0.1% DMSO). Data are presented as mean±SEM, n=12 per group. Statistical significance was 
analysed by one way ANOVA followed by post-hoc Holm-Sidak test: ***= p <0.001 relative 
to intra-nuclear injected controls, †††= p <0.001 relative to vehicle treated and CpdA-
injected group.  
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4.4 Discussion 
4.4.1 The link between GK and KATP channels in ARC glucose sensing neurones 
Understanding how ARC GK neurones are able to sense glucose is important for 
understanding the differences between ARC and other hypothalamic glucose sensing 
neurones. Data in chapter 3 showed that acute activation of ARC GK increases glucose 
intake. The present chapter demonstrates that inhibition of ARC KATP channels results 
increases glucose intake similar to when GK is activated. In contrast, pharmacological 
activation of ARC KATP channels reduces glucose intake. Regulation of appetite by KATP 
channel activators or inhibitors appears to be specific for glucose; when chow and glucose 
are provided together only glucose intake is affected.  
The experiments in this chapter consistently demonstrate that acute activation of ARC GK 
increases glucose intake. This model is used to investigate the intracellular mechanisms 
involved in ARC glucose sensing. Pre-treatment with a KATP channel activator attenuates the 
GK-regulated increase in glucose intake by reducing glucose intake to baseline levels over 1 
hour. This suggests that KATP channels are involved in the regulation of ARC glucose sensing. 
In support of this finding, previous studies have proposed that KATP channels may be 
involved in the CRR to hypoglycaemia in other glucose sensing neurones (Miki, Liss et al. 
2001, Evans, McCrimmon et al. 2004, Levin, Routh et al. 2004). Injection of diazoxide in the 
VMN amplifies adrenalin and glucagon release in response to insulin-induced hypoglycaemia 
similar to inhibition of GK activity (McCrimmon, Evans et al. 2005). This indicates that KATP 
channels are linked to hypothalamic GK activity albeit in the regulation of physiological 
responses other than appetite.  
 
4.4.2 ARC GK neurones release NPY  
The hypothalamic explant incubation system was used to investigate neuropeptide release 
in glucose sensing neurones. Incubation of hypothalamic slices in aCSF has previously been 
used to demonstrate altered neuropeptide release in response to an increasing glucose 
concentration (Parton, Ye et al. 2007, Hussain, Richardson et al. 2014). The procedure is 
optimised for mediobasal hypothalamic slices as each explant includes the VMN and ARC 
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and parts of the medial preoptic, PVN, DMH, and LHA (Seal, Small et al. 2001). Therefore 
this technique can be used to investigate neurotransmitter release but is not specific to the 
ARC.  
Both POMC and NPY neurones have been implicated in ARC glucose sensing (Mountjoy, 
Bailey et al. 2007, Parton, Ye et al. 2007). However, incubation of hypothalamic explants 
with either a GK activator or KATP channel inhibitor increases NPY release and does not 
significantly alter α-MSH release. NPY is a powerful orexigenic peptide and has been shown 
to increase appetite when injected directly into regions of the hypothalamus (Stanley, Chin 
et al. 1985). The ARC is a major source of NPY neurones (Wynne, Stanley et al. 2005) 
therefore it is conceivable that the GK-regulated increase in glucose intake is due to an 
increase in NPY release. The present study describes a novel role for ARC NPY neurones as 
they have previously only been shown to be inhibited by glucose, albeit via an AMPK-
mediated mechanism (Mountjoy, Bailey et al. 2007). 
The findings of NPY in the glucose sensing pathway are consistent with previous reports 
showing that NPY mediates a preference for carbohydrate intake. Overexpression of NPY in 
neurones of mice increases food intake and body weight gain when provided with a diet 
consisting of 50% sucrose powder, but not with normal chow, compared with controls 
(Kaga, Inui et al. 2001). NPY injections into rat hypothalami increase the preference for 
carbohydrates and fats over proteins (Stanley, Anderson et al. 1989). 
 
4.4.3 ARC GK-induced increase of glucose intake is mediated via P/Q-type VGCC 
To demonstrate that neurotransmitter release from ARC neurones is responsible for the GK-
regulated increase in glucose intake, I selectively blocked ARC VGCC. Blocking P/Q type 
channels, but not L type channels, within the ARC attenuated the GK-regulated increase in 
glucose intake. Therefore it is likely that P/Q type VGCC are involved in ARC NPY release in 
glucose sensing neurones. This is consistent with previous reports of P/Q channels in ARC 
NPY neurones. Decreasing glucose concentrations in ARC primary neurone cultures induces 
an influx of intracellular calcium ions as a potential marker of GI neuronal firing (Chen, Zhou 
et al. 2012). Blocking P/Q type VGCC and AMPK signalling, but not blocking L or N type 
channels, attenuates the calcium influx. However, GI neurones and AMPK are not thought to 
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be involved in the ARC GK-regulated increase in glucose intake therefore other populations 
of NPY neurones may be involved.  
Most L, N and P/Q type channels are expressed in the pre-synaptic terminals of neurones 
therefore are able to directly stimulate vesicle release (Catterall, Perez-Reyes et al. 2005). 
Limited expression of VGCC occurs within axons, which may modulate action potential 
frequency and rates of repolarisation. However, blocking the channels in the axons will not 
likely alter action potential frequency during the short time period between injections of 
VGCC blocker and CpdA. Also, due to the significant effect of the channel blockers, it is likely 
that the P/Q channels are located in the pre-synaptic terminal and directly regulate vesicle 
release. 
Other VGCC such as L type channels mediate the orexin-A effect on feeding behaviour in the 
ARC via an AMPK-mediated mechanism (Wu, Wu et al. 2013). As blocking L type channels 
did not affect the GK-regulated increase in glucose intake, it further shows that this AMPK-
mediated decrease in food intake is part of a separate pathway. Both L and N type VGCC 
have been identified with ARC NPY neurones and may be important in release of hormones 
or for modulating neuronal firing rather than initiating it (Sahu, Crowley et al. 1993). Due to 
the lack of effect on GK-regulated glucose intake observed with the L-type VGCC blocker 
nifedipine, it could be contrived that an appropriate concentration was not injected to exert 
an effect. A positive control measuring the effect of nifedipine on muscle contractions could 
have been conducted to demonstrate that the compound was active, as previously 
described (Longo, Jain et al. 2003). 
 
4.4.4 ARC GK-regulated increase in glucose intake is mediated by Y1 and Y5 receptors 
To investigate the role of NPY in ARC glucose sensing neurones, I determined the effects of 
selectively blocking NPY receptors on the GK-regulated increase in glucose intake. Y1 and Y5 
receptors are the major receptors involved in the regulation of feeding (Gerald, Walker et al. 
1996, Mashiko, Moriya et al. 2009). Pre-treatment with Y1 antagonist attenuated the GK-
regulated increase in glucose intake. Pre-treatment with Y5 antagonist had a similar effect, 
indicating that both of these receptors are likely to be involved in mediating the effects of 
NPY in ARC glucose sensing. This is in agreement with previous studies investigating 
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hypothalamic NPY. ARC NPY neurones project widely within the hypothalamus, acting on 
neurones involved in food intake in the LH, PVN, DMH and locally within the ARC (Edwards, 
Abusnana et al. 1999, Mercer, Chee et al. 2011, Lee, Verma et al. 2013). In particular, ARC 
NPY neurones provide negative feedback to POMC neurones to reduce anorexigenic signals 
(Broberger, Landry et al. 1997, Cowley, Smart et al. 2001). Therefore a possible pathway for 
NPY-regulated glucose sensing is by inhibition of POMC neurones to increase appetite. In 
accord with this hypothesis, the VMN has a high density of Y1 receptors on post-synaptic 
terminals (Bouali, Fournier et al. 1995). However, VMN Y1 receptors may be predominantly 
expressed in GI neurones, where activation causes hyperpolarisation and a decrease in 
glutamatergic activity (Chee, Myers et al. 2010). NPY receptor antagonists here could reduce 
appetite by promoting anorexigenic pathways via GI neurones. 
Other targets of ARC NPY neurones include the PVN (Stanley, Chin et al. 1985, Mercer, Chee 
et al. 2011). There are two pathways that could contribute to the GK-regulated increase in 
glucose intake within the PVN. First, NPY acts at Y1 receptors to hyperpolarise MC4R-
expressing PVN neurones and therefore inhibit anorexigenic tone (Ghamari-Langroudi, Srisai 
et al. 2011). Second, NPY acts at pre-synaptic Y1, Y2 and Y5 on GABAergic terminals 
(Pronchuk, Beck-Sickinger et al. 2002). Dense ARC projections to the PVN make these 
pathways a likely candidate for NPY mediated glucose sensing. 
Furthermore, NPY inhibits orexin and MCH neurones involved in arousal in the LH 
(Broberger, De Lecea et al. 1998, Fu, Acuna-Goycolea et al. 2004). These neurones can also 
negatively feedback to regulate ARC NPY expression (Della-Zuana, Presse et al. 2002). 
However, the role of LH pathways in the control feeding is unclear. In conclusion, it is 
uncertain where NPY is exerting an effect in the GK-regulated increase in glucose intake, 
therefore further investigation is required. 
ICV injection of BMS reduces NPY-stimulated food intake and slightly, but not significantly, 
increased food intake on its own (Antal-Zimanyi, Bruce et al. 2008). However, in the present 
study there was a slight decrease in glucose intake as a result of BMS injection without 
CpdA. The current evidence on BMS indicates that it is unlikely that a side effect of BMS is 
causing the decrease in glucose intake observed in the control treatment in the present 
study (Antal-Zimanyi, Bruce et al. 2008).  
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As Y1 and Y5 receptor antagonists were injected peripherally, the treatment is not targeted 
specifically to ARC neurones. Outside of the hypothalamus, Y1 receptors are widely 
expressed in the cortex, hippocampus, limbic system and NTS (Dumont, Jacques et al. 1998). 
Y5 receptors are highly expressed in the hippocampus, supraoptic nucleus and piriform 
nucleus (Morin and Gehlert 2006). Therefore, a non-specific effect of NPY receptor 
antagonism due to orexigenic actions of these neurones cannot be ruled out. In addition, it 
is not known why Y1 and Y5 antagonists produced a greater than 50% reduction in GK-
regulated glucose intake each if both receptors are involved in the mechanism. 
 
4.4.5 Other mechanisms of glucose sensing 
An AMPK-mediated pathway, previously observed in GI neurones, may also be involved in 
ARC glucose sensing (Claret, Smith et al. 2007). Insulin and low glucose levels increase the 
ratio of AMP to ATP, which alters AMPK and NO signalling to depolarise neurones via 
chloride channels (Fioramonti, Lorsignol et al. 2004, Canabal, Potian et al. 2007). Reduced 
AMPK has been associated with depolarisation of some glucose sensing neurones and could 
contribute to the change in food intake in the present studies (Mountjoy, Bailey et al. 2007). 
However, previous experiments performed in this laboratory observed no change in AMPK 
activity due to increased ARC GK (Hussain, Richardson et al. 2014). Therefore it is unlikely 
that alterations in AMPK contribute to the change in food intake. This hypothesis is justified 
by the significant contribution of KATP channels in the GK-regulated increase in glucose 
intake. As diazoxide almost completely abolished the increase in glucose intake observed 
with CpdA injection, it is likely that KATP channels are the primary mediators of GK action. 
However, intracellular ATP concentrations have not been investigated to fully confirm this 
hypothesis.  
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4.5 Conclusions 
A population of glucose sensing neurones in the ARC exert an orexigenic drive to increase 
consumption of foods rich in glucose when activated. These neurones sense ambient 
glucose concentrations via phosphorylation of glucose by glucokinase to increase 
intracellular ATP levels and close KATP channels. Neuronal depolarisation is partly triggered 
by increasing K+ ion concentrations due to closure of KATP channels, resulting in neuronal 
firing and vesicular release of NPY via opening of P/Q type VGCC. NPY likely activates Y1 and 
Y5 receptors to drive orexigenic output and promote glucose intake. This mechanism is 
separate to neurones used to maintain glucose homeostasis. 
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Chapter 5: General discussion 
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5.1 Introduction 
Understanding the mechanisms involved in the development of diabetes and obesity is vital 
for the development of appropriate treatments. However, we lack an in-depth knowledge of 
altered neuronal circuitry during these disease states. Many diet and environmental factors 
contribute to the diabetes and obesity pandemics. An increase in the intake of dietary sugar 
is undoubtedly one of the primary contributing factors, as delineated by the high sugar 
content in many Western-type diets. A strong effort is thus required to understand why we 
are designed to consume extra unnecessary sugar. 
The CNS plays an important role in the control of feeding. Nutrients are sensed by 
specialised neurones, activating specific networks to control many different peripheral 
processes. The CNS is thought to regulate intake of dietary glucose, but the mechanism of 
this is unclear. This thesis describes work investigating the role of arcuate nucleus glucose 
sensing neurones in controlling our appetite for glucose. 
 
5.2 Previous investigation of glucose sensing 
Glucose sensing neurones play a crucial role in maintaining glucose appetite and 
homeostasis (Levin, Routh et al. 2004, Kang, Dunn-Meynell et al. 2006). Many glucose 
sensing neurones are positioned in the ventromedial hypothalamus and other nuclei located 
near the 3rd and 4th ventricles and circumventricular organs. The glucose phosphorylating 
enzyme glucokinase (GK) is expressed in glucose sensing neurones and is specifically 
involved in glucose sensing (Lynch, Tompkins et al. 2000). GK has a higher Km for glucose 
than other hexokinases therefore is not saturated at glucose concentrations below 2.5mM 
and can phosphorylate glucose at a rate that is proportional to the ambient concentration 
(Printz, Magnuson et al. 1993). In pancreatic β-cells, GK plays an integral role in glucose 
sensing and the release of insulin (Schuit, Huypens et al. 2001). In the CNS, insulin-induced 
hypoglycaemia activates glucose sensing neurones and triggers neuronal pathways to alter 
peripheral hormone release (Levin, Routh et al. 2004, Kang, Dunn-Meynell et al. 2006). For 
these reasons, GK was selected as an appropriate target for investigating glucose sensing 
neurones with regard to appetite. Preliminary studies subsequently revealed that 24 or 48 
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hour fasting in rats increases GK activity in the ARC but not in the VMN or PVN (Hussain, 
Richardson et al. 2014). Mimicking high ARC GK activity via overexpression of ARC GK in rats 
increases food intake and body weight. This increase in appetite with increased GK 
expression challenges the previous hypothesis regarding the role of ARC GK, which was 
thought to be identical to that in VMN neurones (Kang, Sanders et al. 2008). This 
preliminary evidence suggests that ARC and VMN GK respond to altered glucose 
concentrations in a different way. 
 
5.3 Investigating the role of ARC GK in appetite 
I have demonstrated that acute activation of ARC GK increases food intake and glucose 
intake. In contrast, reduction of ARC GK activity reduces glucose intake both acutely and 
cumulatively. Previous findings have not identified any changes in food intake when VMH 
GK is altered (Levin, Becker et al. 2008). However, the CNS is thought to regulate glucose 
intake as it is a primary food source for the brain and has been shown to deliver a reward 
response via hypothalamic and limbic circuits (Sclafani 2004, Levin, Becker et al. 2008, 
Domingos, Sordillo et al. 2013). It is postulated that there is a mechanism to promote the 
consumption of glucose-rich foods, if one is available, to ensure that there is enough to 
supply the brain.  
My findings identify an alternative role for ARC GK than previously hypothesised. In the 
current model of GK action, an increase in GK activity promotes a decrease in blood glucose 
concentrations via a counterregulatory hormone response. Insulin-induced hypoglycaemia 
increases VMH GK mRNA and contributes to an increased responsiveness to glucose (Kang, 
Sanders et al. 2008). However, I have found that ARC GK neurones act to promote further 
glucose intake: which likely increase blood glucose concentrations. This is not likely 
intended for providing homeostatic feedback for plasma glucose regulation; it is probably 
part of a homeostatic pathway to alter preference for glucose. Fasting induces an increase 
in ARC GK activity (Hussain, Richardson et al. 2014). It is possible that the palatability of 
foods is altered during fasting states, in order to specifically increase consumption of 
glucose for metabolism in the brain. In agreement with this hypothesis, chronically diet-
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restricted rats show an increased preference for an artificial sweetener (Chen, Yan et al. 
2010).  
It is possible that ARC GK neurones involved in the regulation of glucose appetite are the 
same as those neurones involved in the regulation of glucose homeostasis. Injection of GK 
activators into the divide between the ARC and VMN produces a counterregulatory 
response, similar to an injection of GK activators into the VMN alone (Kang, Dunn-Meynell 
et al. 2006, Levin, Becker et al. 2008, Dunn-Meynell, Sanders et al. 2009, Levin, Magnan et 
al. 2011). In addition, preliminary unpublished investigations indicate that increasing ARC GK 
expression improves glucose tolerance in parallel to its effects on appetite (Richardson 
2011). However, I have found that ARC GK primarily acts to regulate glucose appetite. These 
findings are novel and challenge the previous hypothesis that CNS GK only acts to balance 
glucose homeostasis (Levin, Routh et al. 2004).  
 
5.4 Investigating the mechanisms of ARC glucose sensing 
KATP channels control depolarisation of glucose sensing cells in the CNS and pancreas (Schuit, 
Huypens et al. 2001, McCrimmon, Evans et al. 2005). I demonstrate that KATP channels play a 
similar role in ARC glucose sensing neurones as inhibition of KATP channels increases glucose 
intake and activation of KATP channels inhibits the effects of a GK activator on glucose intake. 
Furthermore, I demonstrate that hypothalamic GK activation or KATP channel inhibition leads 
to NPY release. Blocking P/Q type VGCC or Y1 and Y5 receptors inhibits the GK regulated 
increase in glucose intake. Therefore it is likely that the primary mechanism for altering 
glucose intake by ARC GK neurones is via release of vesicular NPY.  
A role of NPY in mediating the effects of glucose sensing neurones is in accord with previous 
electrophysiological work. Seventy five percent of NPY-sensitive neurones in the VMN are 
also involved in glucose sensing, thus NPY pathways from the ARC could exert an effect on 
extra-ARC neurones (Chee, Myers et al. 2010). My results provide novel evidence of a direct 
link between glucose sensing neurones and NPY release in vivo. In contrast, altered 
hypothalamic GK or KATP channels do not affect α-MSH release from POMC neurones. 
Consistent with this observation, selective knockout of KATP channels in POMC neurones 
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does not affect body weight or food intake (Parton, Ye et al. 2007). Therefore it is likely that 
ARC glucose sensing neurones rely on orexigenic rather than anorexigenic pathways to exert 
their effects on food intake. Figure 5.1 summarises the mechanism by which ARC glucose 
sensing neurones drive altered glucose intake in rats. 
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Arcuate nucleus glucose sensing 
 
Figure 5.1 Proposed mechanism of ARC glucose sensing: ARC glucokinase activity increases 
with high ambient glucose concentrations to promote glucose intake if a glucose-rich food 
source is available. Increased glucose phosphorylation increases the ratio of ATP to ADP and 
inhibits KATP channels to trigger neuronal firing. Subsequent activation of P/Q type VGCC 
releases NPY, which acts at Y1 and Y5 receptors to increase appetite. If a glucose-rich food 
source is not available then normal food intake is increased, likely increasing body weight.   
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5.5 The significance of this work for obesity and diabetes research 
This work is of clinical significance as it identifies a novel pathway for the regulation of 
glucose consumption. Currently, GK activators are being investigated as treatments for 
diabetes by pharmaceutical companies with the goal that they can be used to stimulate 
insulin secretion from pancreatic β-cells (Matschinsky 2009). As the effects of GK activators 
outside of the liver and pancreas are relatively unknown, evidence supporting a role for CNS 
GK is important to assess the specificity of new drugs. However, the effects of weight gain 
and increased food intake highlighted in the present study do not increase the confidence of 
the hypothesis that pharmacological activation of GK will be totally beneficial for treating 
diabetes (U. K. Prospective Diabetes Study Group 1998). Furthermore, weight gain is a 
common side effect of current treatments of diabetes using sulfonylureas such as 
glibenclamide. My findings suggest that ARC glucose sensing may be a contributing factor in 
this side effect, yet a direct link remains unexplored.   
The influence of the consumption of dietary sugars to the obesity pandemic is unclear. 
While there is a strong trend in the increase in dietary sugars in Western-type diets causing 
obesity, the extent of which glucose causes obesity in relatively unknown. However, a way 
of inhibiting the postprandial hedonic effects of glucose and other dietary sugars would be 
of major interest. This work is the first study to show that a long-term alteration of 
hypothalamic GK activity alters body weight and food intake. Inhibition of ARC GK may be of 
therapeutic value to combat obesity.  
Previously, alterations in food intake and body weight have not been observed in models of 
altered hypothalamic GK (Levin, Becker et al. 2008, Dunn-Meynell, Sanders et al. 2009). In 
these studies however, potentially toxic pharmacological agents or immunogenic viral 
vectors were used to alter GK activity, likely masking any behavioural changes. The present 
study builds on the previous work by decreasing GK using a non-immunogenic viral vector 
specifically in the ARC. Exclusive reduction of ARC GK activity by rAAV-GKAS was 
demonstrated by glucokinase activity assay thus conclusively showing reliability of the 
technique. In addition, a reproducible response was obtained after stereotactic injection of 
non-toxic pharmacological agents into the ARC. An increase in glucose consumption was 
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repeatedly observed after 1 hour from GK activator injection allowing the use of this model 
for investigating the effects of other pharmacological agents in the same pathway. 
 
5.6 Limitations and unresolved questions 
Possible limitations of injections of pharmacological agents into cannulated animals are that 
all cells within the injection range are targeted, regardless of GK expression. In particular, 
KATP channels are expressed in multiple cell types in the ARC therefore injection of activators 
and inhibitors may lead to non-specific effects. However, the effects of ARC KATP channel 
inhibition are similar to that of ARC GK activation and therefore are in accord with the 
hypothesis that KATP channels are involved in mediating the effects of GK in the CNS. 
Inhibition of VGCC and Y receptors may equally cause non-specific effects. However, they 
had no effect on glucose intake when administered alone. They were only effective in the 
presence of the GK activator. More specific techniques to alter the machinery involved in 
ARC glucose sensing could be achieved using Cre-Lox recombination. Selective knockout of 
GK in the ARC can be attained by inserting LoxP sites around the endogenous GK gene. 
Stereotactic injection of rAAV Cre recombinase into the ARC would provide knockout of GK 
in only the affected cells. This would eliminate the requirements for antisense technology, 
but is only currently available in mice. 
Identification of NPY as a neurotransmitter in ARC glucose sensing neurones relied on the 
use of ex vivo hypothalamic explants and their response to pharmacological agents added to 
the incubating solution. The explants were not specific to the ARC; they included other parts 
of the mediobasal hypothalamus such as the VMN (Seal, Small et al. 2001). Although two of 
the major neuropeptides in the ARC were assessed, NPY and α-MSH, other 
neurotransmitters such as GABA and AgRP could be involved in the response. Further 
investigation is also required to confidently rule out a role for α-MSH. Therefore the 
mechanism presented here may be over simplistic as other factors are possibly involved in 
the response. In addition, basal and drug treatments were not randomly ordered due to the 
concern that elimination of the drug during washout may not fully occur. It is possible that 
the explants released increasing peptides over time, which may contribute to the observed 
effect. 
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A modified NADP+-coupled assay was used to measure GK activity in hypothalamic tissue 
(Goward, Hartwell et al. 1986). Previous techniques to measure GK activity used relatively 
large amounts of tissue therefore it was necessary to optimise a different technique for use 
in individual hypothalamic nuclei (Osundiji, Lam et al. 2012). Specific hexokinase and N-
acetylglucosamine kinase inhibitors were added to each experiment to inhibit 
phosphorylation of glucose by enzymes other than GK.  While the assay was tested against 
known concentrations of GK and compared with previous methods to measure GK activity, 
further assessment of accuracy is required. Also, hypothalamic tissue was dissected using a 
micropunch biopsy, whereas improved methods like micro-laser dissection could more 
accurately dissect the VMN from the ARC. Alternatively, analysis of GK expression by RT-PCR 
could provide information on GK expression, but this does not necessarily correlate with GK 
activity. 
Further work is required to understand how ARC GK activity is regulated. A 24 or 48 hour 
fast increases ARC GK activity in rats, however whether fasting directly influences GK activity 
is not known (Hussain, Richardson et al. 2014). In addition, GK mRNA expression is affected 
by circadian rhythms, being highly expressed in-phase with food intake (Frese, Bazwinsky et 
al. 2007). Real-time measurement of GK activity would be beneficial to fully investigate the 
regulation of GK activity. The GK activity assay is only able to measure GK activity during one 
time point whereas continuous real-time measurements could identify changes in activity 
when rats are provided with a Western-type diet. Similarly, further investigation into the 
effects of high glucose consumption on GK activity is required to understand whether 
hypothalamic GK affects adiposity in humans. However, a CSF marker or in vivo imaging 
technique for GK activity is not currently available. 
Chronic knockdown of ARC GK moderately reduces cumulative food intake and body weight, 
providing further evidence that ARC GK regulates appetite. However energy expenditure or 
locomotor activity were not measured in these animals therefore it has not been confirmed 
whether the reduction in body weight is due to reduced energy intake or expenditure. As 
acute activation of ARC GK increases food intake, any changes in body weight are likely due 
to energy intake. To rule out altered energy expenditure, measurement of oxygen 
consumption and locomotor activity in ARC GK knockdown rats could be performed using a 
Comprehensive Laboratory Animal Monitoring System.   
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5.7 Future directions 
Investigation of the role of ARC GK has revealed that central glucose sensing is complex and 
that it involves many different and intercommunicating networks, which may feedback onto 
many other feeding networks in the brain. I have characterised one orexigenic pathway 
involved in glucose sensing in the brain, however other pathways undoubtedly exist. For 
example the intracellular machinery involved in glucose inhibitory (GI) neurones is still 
debated (Mountjoy and Rutter 2007). While I demonstrate that orexigenic NPY neurones 
are integral to the role of ARC glucose sensing neurones in appetite, other 
neurotransmitters are likely involved. AgRP, ATP, GABA and GLP-1 may regulate 
neurotransmission or have a paracrine effect in ARC glucose sensing pathways. 
I was unable to provide evidence of a direct connection with other known feeding pathways. 
Rapid progress is currently being made to identify and understand individual feeding 
pathways in the brain. These studies have made use of Designer Receptors Exclusively 
Activated by Designer Drugs (DREADD) technology, which can simultaneously trace and 
inhibit second-order neurones (Aponte, Atasoy et al. 2011, Stachniak, Ghosh et al. 2014). An 
important advantage of this technology is that remote and non-invasive control of neuronal 
signalling can be performed. DREADDs can be used to further investigate ARC glucose 
sensing and would be able to identify which neurones are activated upon NPY activation in 
the ARC GK regulated increase in glucose intake. Similarly, mice with LoxP sites flanking the 
GK gene are commercially available therefore could be crossed with NPY-Cre or POMC-Cre 
mice to selectively knockdown GK in specific neuronal populations. 
The physiological roles of other CNS regions with high GK expression require further 
investigation. In particular, the medial amygdala nucleus and brainstem have high levels of 
GK therefore are possibly involved in the regulation of glucose appetite (Lynch, Tompkins et 
al. 2000, Maekawa, Toyoda et al. 2000). The medial NTS in the brainstem is an ideal target 
for investigation of glucose sensing as it is close to the AP and likely has access to glucose 
concentrations that are similar to those in the blood. Preliminary unpublished findings 
reveal that medial NTS GK activity increases due to 14 and 24 hour fasting, similar to ARC 
GK. Therefore medial NTS GK may regulate food and glucose intake. However, it is unclear 
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whether knockdown of medial NTS GK in rats alters food intake or body weight therefore 
further investigation is required.  
Finally, GKRP is postulated to regulate CNS GK activity (Alvarez, Roncero et al. 2002). GKRP 
inhibits GK during low glucose levels and dis-inhibits GK during high glucose levels or upon 
by treatment with GK activators (Zelent, Raimondo et al. 2014). It is therefore possible that 
GKRP regulates GK activity in ARC glucose sensing neurones. This hypothesis is in accord 
with my proposed mechanism of ARC glucose sensing as it suggests that high glucose levels 
can promote increased GK activity, therefore providing an increased orexigenic drive.   
 
 
5.8 Conclusion 
This thesis identifies a role for a subset of glucose sensing neurones in the arcuate nucleus 
(ARC) of the hypothalamus to promote glucose intake.  A population of GK neurones are 
able to activate orexigenic pathways in the CNS to drive glucose intake. In the absence of a 
pure glucose source, general food intake is increased. This pathway demonstrates a 
mechanism that may contribute to the obesity pandemic and therefore highlights a possible 
target for therapeutic treatment.  
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7. Appendix 
 
7.1 Appendix I – Solutions 
ABC Buffer  
Combine solutions A, B and C in the following proportions: 100:250:150 and store at -20°C.  
Solution A  
Add 1ml of 125mM MgCl2 and 1.25M Tris-HCl (pH 8.0) to 18μl 
mercaptoethanol, 5μl 100mM dATP, 5μl 100mM dTTP and 5μl dGTP.  
Solution B  
2M Hepes (pH6.6) titrated with 4M NaOH.  
Solution C  
Random oligonucleotides (112μg/ml).  
 
ω-agatoxin IVA was dissolved to a working concentration of 1µg/µl in 1% ethanol in GDW, 
aliquoted and stored at -80°C until required. 
Amasino wash  
Mix 250ml 1M Na phosphate buffer (pH 7.2), 2ml 500mM EDTA and 100ml 20% SDS with 
650ml GDW.  
 
5M Ammonium acetate  
Dissolve 385g CH3COONH4 in 600ml autoclaved GDW then make up to 1L.  
 
Ampicillin (100mg/ml)  
Dissolve 1g ampicillin in 10ml GDW, sterilise by passage through a 0.2μm filter and 
distribute in 1ml aliquots.  
 
aCSF: 
Make aCSF immediately before use. To make 500ml aCSF mix 100ml 0.1M NaHCO3, 100ml 
0.63M NaCl, 5ml 0.09M Na2HPO4.2H2O, 5ml 0.59M KCl, 5ml 0.09M MgSO4.7H2O, 450mg 
glucose, 88mg ascorbic acid, 5ml aprotinin (BDH) and 270ml GDW. Saturate with 95% O2 and 
5% CO2 for at least 10 minutes, then add 10ml 0.07M CaCl2.2H2O. 
 
56mM KCl aCSF: 
Make aCSF immediately before use. To make 100ml 56mM KCl aCSF, mix 20ml 0.1M NaHCO3, 
11.6ml 0.63M NaCl, 1ml 0.09M Na2HPO4.2H2O, 10ml 0.59M KCl, 1ml 0.09M MgSO4.7H2O, 90mg 
154 
 
glucose, 17.6mg ascorbic acid, 1ml aprotinin (BDH) and 53.4ml GDW. Saturate with 95% O2 and 
5% CO2 for at least 10 minutes, then add 10ml 0.07M CaCl2.2H2O. 
 
aCSF stock solutions: 
0.09M disodium hydrogen orthophosphate dehydrate: 
Dissolve 1.56g Na2HPO4.2H2O in 100ml GDW 
0.07M calcium chloride dehydrate: 
Dissolve 1.04g CaCl2.2 H2O in 100ml GDW 
0.09M magnesium sulphate heptahydrate: 
Dissolve 2.2g MgSO4.7H2O in 100ml GDW 
0.59M potassium chloride: 
Dissolve 4.42g KCl in 100ml GDW 
0.1M sodium bicarbonate: 
Dissolve 4.62g NaHCO3 in 500ml GDW 
0.63M sodium chloride: 
Dissolve 18.43g NaCl in 500ml GDW 
 
 
2.5mM Aurintricarboxylic acid (ATA)  
Dissolve 0.1183g ATA in 100ml GDW.  
 
Baker’s yeast tRNA (10mg/ml)  
Make up with GDW, aliquot and store at -20°C.  
 
BMS 193885 was dissolved in 100% DMSO, aliquoted and stored at -80°C. Immediately 
before use, aliquots were dissolved to a working concentration of 10mg/kg in 40%DMSO. 
 
Caesium chloride-saturated propan-2-ol: 
Mix 100g CsCl2, 100ml GDW and 100ml propan-2-ol and leave to settle. 
 
CGP 71683 was dissolved in 100% DMSO, aliquoted and stored at -80°C. Immediately before 
use, aliquots were dissolved to a working concentration of 10mg/kg in 40%DMSO. 
 
Compound A (CpdA) was dissolved in 100% DMSO, aliquoted and stored at -80°C. 
Immediately before use, aliquots were dissolved to a working concentration of 0.5 nmol in 
1% DMSO (cannulation studies) or 30 µM in 0.1%DMSO in aCSF (explant studies). 
 
1% Cresyl violet solution  
Add 1ml cresyl Violet to 99ml GDW, then pass through a Whatman GF/C filter.  
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Diazoxide was aliquoted and dissolved to a working concentration of 0.05M NaOH and 1% 
DMSO in GDW (cannulation studies) or 200 µM in 5mM NaOH and 0.1%DMSO in aCSF 
(explant studies). 
 
100x Denhart’s solution  
Dissolve 10g ficoll, 10g polyvinylpyrrolidone (PVP) and 10g BSA (Pentax fraction V) and make 
up to 500ml with GDW.  
 
Denaturing solution (DNA)  
Dissolve 43.5g NaCl in 430 ml GDW. Add 25ml 10M NaOH and make up to 500ml with GDW.  
 
1M Dithiothreitol (DTT)  
Dissolve 154g C4H10O2S2 in 1L GDW. Aliquot and store at -20°C. 
 
0.5M Ethylenediaminetetra-acetic acid (EDTA) (pH 8.0)  
Dissolve 181.6g C10H14H2O8Na.2H2O in 800ml GDW under pH 8.0 with NaOH. Make up to 1L 
with GDW.  
 
4% Formaldehyde in 0.01M PBS  
Add 8ml 40% formaldehyde solution to 400ml 0.01M PBS.  
 
Formamide (de-ionised)  
Add 2.7g duolite MB to 100ml formamide and stir until the duolite turns brown (~1 hour). 
Remove the duolite by passing through Whatman GF/C filters, aliquot and store at -20°C.  
 
Glucose Tris EDTA 
Final concentrations of 50mM glucose, 25mM Tris and 10mM EDTA. 
 
Glibenclamide was aliquoted and dissolved to a working concentration of 0.05M NaOH and 
1% DMSO in GDW (cannulation studies) or 100 µM in 5mM NaOH and 0.1%DMSO in aCSF 
(explant studies). 
 
1x Hepes buffered saline (HeBS) (pH 7.05) 
Dissolve 0.8g NaCl, 37.5mg KCl, 10.5mg, Na2HPO4, 0.11g dextrose and 0.5g Hepes in a total 
volume of 90mls GDW. Adjust to pH 7.05 with 0.5M NaOH and add GDW to a final volume 
of 100ml. Sterilise by passing through a 0.2μm filter and store in 5 ml aliquots at -20°C. 
 
Hybridisation buffer for northern blot analysis and for dot-blot analysis  
Add 0.5g dried milk powder and 0.5ml 500mM EDTA to 48ml GDW and leave at 37°C to 
dissolve. Allow to cool then add 25ml 1M Na phosphate buffer, 25ml 20% SDS and 1ml 2.5M 
ATA. 
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Hybridisation buffer for in situ hybridisation: 
Prepare dextran sulphate solution by the addition of 1.5ml GDW to 1g dextran sulphate and 
incubate in a water bath at 60°C for two hours. Ensure minimum bubbles present. In a total 
volume of 4ml add together 1.25ml formamide, 300μl 5M NaCl, 200μl tRNA (10mg/ml), 50μl 
100x Denhart’s, 50μl 1M Tris (pH 8.0), 40μl 1M dithiothreitol (DTT), 10μl 0.5M EDTA (pH 
8.0), 1.1ml GDW and 1ml (50%) dextran sulphate.  
 
LB culture medium (pH 7.5)  
Dissolve 10g NaCl, 10g tryptone and 5g yeast extract in 800ml GDW. Adjust to pH 7.5 with 
10M NaOH. Sterilise by autoclaving and make up to 1L.  
 
LB(amp) agar plates  
Add 7g agar to 500ml LB and melt by autoclaving. Add 1000μL 100mg/mL ampicillin once 
gently re-melted and set in plates at 4°C. 
 
Loading Buffer for DNA/RNA  
Mix 3.125ml 80% glycerol, 50μl 0.5M C10H14H2O8Na2.H2O and 6.075ml autoclaved GDW, 
then add 10mg orange G.  
2M Magnesium chloride (MgCl2)  
Dissolve 406.6g MgCl2.6H=O in 1L GDW.  
 
Neutralising solution (pH 7.5)  
Dissolve 43.5g NaCl and 60.2g NH2C(CH2OH)3 in 430 ml GDW and adjust to pH 7.5 with 
~35ml HCl.  
 
Nifedipine was aliquoted under low light conditions and dissolved to a working 
concentration of 5µg/µl in 1% ethanol in GDW. 
 
Phosphate buffered saline (PBS): 
0.1M PBS (10x)  
Dissolve 80g NaCl, 2g KCl, 14.4g Na2HPO4 (18.05g Na2HPO4.2H2O or 27.18g Na2HPO4.7H2O) 
and 2.4g KH2PO4 in 800ml GDW.  
0.01M PBS (1x)  
Add 100ml 0.1M PBS to 900ml GDW.  
 
Phosphate buffer (RIA buffer) 
Dissolve 48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g C10H14H2O8Na2.2H2O, 2.5g NaN3 in 5L 
boiled and cooled GDW. Adjust pH to 7.4 ± 0.1. 
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5M Potassium acetate (KAc)  
Dissolve 294.4g CH3COOK in 500ml GDW. Add 115ml glacial acetic acid and make up to 1L 
with GDW.  
 
3M Potassium hydroxide  
Dissolve 198g KOH in 1L GDW.  
 
Proteinase K (20mg/ml)  
Dissolve 20mg in 1ml GDW, distribute into 100μl aliquots and store at -20°C.  
 
RNase A (10mg/ml)  
Dissolve 100mg RNase A in 10ml GDW. (Previously used 10mM Tris-HCl (pH 7.5) and 15mM 
NaCl but not needed) and boil for up to fifteen minutes to denature DNAses. Allow to cool, 
distribute into 800µl aliquots and store at -20°C. (Usually comes in 250mg vials) 
 
20x Saline sodium citrate (SSC) buffer (pH 7.0)  
Dissolve 1.735g NaCl and 882g Na3C6H5O7.2H2O in 8L GDW. Adjust to pH 7.0 and make up to 
10L.  
 
Sephadex G50  
Add 8g fine grade Sephadex G50 beads (diameter: 20-80μm), 2ml 100x TE and 0.1ml 20% 
SDS to 200ml GDW and autoclave to expand the beads.  
 
2M Sodium acetate (pH 5.2)  
Dissolve 164.1g CH3COONa in 800ml GDW, adjust to pH 5.2 with glacial acetic acid and make 
up to 1L with GDW.  
 
3M Sodium chloride  
Dissolve 175.3g NaCl in 1L GDW.  
 
5M Sodium chloride  
Dissolve 292.2g NaCl in 1L GDW.  
 
20% (w/v) Sodium dodecyl sulphate (SDS)  
Add 200g SDS to 800ml GDW and heat to 60°C while stirring. Allow to cool and make up to 
1L with GDW.  
 
0.2M Sodium hydroxide/1%SDS  
Add 3ml 10M NaOH to 140ml GDW, mix and add 7.5ml 20% SDS.  
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10M Sodium hydroxide  
Dissolve 400g NaOH in 500ml GDW. Make up to 1Lwith GDW.  
 
1M Sodium phosphate buffer (pH 6.8)  
Dissolve 26g NaH2PO4 and 44.6g Na2HPO4 in 1L GDW.  
 
20x Sodium chloride, sodium hydrogen phosphate, EDTA (SSPE) buffer (pH 7.7)  
Dissolve 1.753g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 700ml GDW, adjust to 
pH 7.7 with 10M NaOH and make up to 1L with GDW.  
 
0.1M Triethanolamine (TEA) buffer (pH 8.0)  
Dissolve 18.6g C6H15NO3.HCl in 800ml GDW. Add NaOH to pH 8.0 and make up to 1L with 
GDW.  
 
50x Tris-acetate-EDTA (TAE) buffer  
Dissolve 242g NH2C(CH2OH)3 in 843ml GDW then add 57ml glacial acetic acid and 100ml 
0.5M C10H14H2O8Na2.2H2O.  
 
100x Tris-EDTA (TE) buffer (pH 7.5)  
Dissolve 121.1g NH2C(CH2OH)3 and 3.7g C10H14H2O8Na2.2H2O in 800ml GDW. Adjust to pH 
7.5 with hydrochloric acid and make up to 1L with GDW.  
 
Tris-EDTA-Sodium chloride (TES) buffer  
Mix 25ml 1M Tris-HCl (pH 8.0), 5ml 5M NaCl and 5ml C10 H14H2O8Na2.2H2O. Make up to 
500ml with GDW.  
Versene 
Dissolve 16g NaCl, 0.4g KCl, 2.88g Na2HPO4.2H2O, 1.2g C10H14H2O8Na2.2H2O and 0.4g KH2PO4 
in 1L GDW, add 3ml phenol red and make up to 2L with GDW. Sterilise by autoclaving.  
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7.2 Coronal section of the rat brain 
 
Figure 7.1 Schematic of a coronal section of the rat brain: Schematic showing 3.36mm 
posterior to bregma, which approximately corresponds to the co-ordinates used to target 
the ARC in this work   (-3.4 from bregma). The ARC is highlighted in red. Reproduced from 
“The Rat Brain in Stereotaxic Co-ordinates” (Paxinos and Watson 2007).   
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7.3 Appendix II – Nutritional Information for RM1 standard chow diet 
 
Figure 7.2 Nutritional information for RM1 standard chow diet.  
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7.4 Appendix III – DNA sequencing of plasmid for in situ hybrisidation 
BLAST analysis of the GK-pTR-CGW sequence revealed that the plasmid contained a 
69bp sequence with 100% homology to the rat pancreatic GK sequence (GenBank: 
M25807.1) as shown in figure 4.5. 
ACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCGGTACTCGAGCTACCGGTATTCAGA 
TCTGGTACCTGGGCTGGTGGCTGCGCAGATGCTGGATGACAGAGCCAGGATGGAGGCCAC 
CAAGAAGGAAAAGGTCGAGCAGATCCTGGCAGAGTTCCAGCTGCAGGAATTCGATATCAA 
GCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTTTAGT 
GAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTT 
ATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTG 
CCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGG 
GAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGC 
GTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGC 
GGCGAGCGG 
Figure 7.3 Sequence of GK-pTR-CGW-plasmid: containing GK insert (underlined) and 
cloning sites for BamH1 (highlighted green) and PstI (highlighted blue).  
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7.5 Appendix IV – List of suppliers 
Abbott Laboratories Ltd, Maidenhead, UK 
Advanced Biotechnology Centre, Imperial College, London, UK 
Animalcare Limited, Dunnington, York, UK 
Applied Biosystems, Warrington, UK 
ATCC, Middlesex, UK 
Bachem, San Carlos, USA 
Bachem, UK 
Bayer UK Ltd, Bury St Edmunds, UK 
Beckman Coulter, Buckinghamshire, UK 
Bilaney, Sevenoaks, UK 
Braun Medical Ltd., Sheffield, UK 
Bright Instrument Company, Huntingdon, Cambridgeshire, UK 
Boehringer Ingelheim, Berkshire, UK 
Charles River, Bicester, UK 
Chemicon International Inc., USA 
Clintech, Dublin, Ireland 
CP Pharmaceuticals, Wrexham, UK 
David Kofp Instruments, Tujunga, CA, USA 
Du Pont, Bristol, UK 
Eli Lilly & Co.Ltd, Basingstoke, UK 
Enzo Life Science, Exeter, UK 
Eppendorf, Hamburg, Germany 
Ethicon, Gargrave, Yorkshire, UK 
Fine Science Tools, Linton, UK 
Fisher Scientific UK, Loughborough, Leicestershire, UK 
163 
 
GE Healthcare, Buckinghamshire, UK 
Genomics Core Laboratory, Imperial College London, UK 
Graphpad Prism, Graphpad Sorfware, San Diego, CA, USA 
Helena biosciences, Sunderland, UK 
Invitrogen Life Technologies, Paisley, UK 
Jet X-Ray, London, UK 
Kemdent, Swindon, UK 
Kodak, Hemel Hempstead, Hertfordshire, UK 
Kopf Instruments, Tujunga, California, USA 
LEO Pharma, Buckinghamshire, UK 
L.E West, Barking, UK 
Life Sciences Technology, Eggenstein, Germany 
Linco Research, Missouri, USA 
Merck Pharmaceuticals, Whitehouse Station, NJ, USA 
Microfield Scientific Ltd, Dartmouth, UK 
Microvette, Sarstedt, Numbrecht, Germany 
Millipore, Watford, Hertfordshire, UK 
Millpledge Veterinary, Nottinghamshire, UK 
Montrose fasteners, Bucks, UK 
Nikon, Kingston Upon Thames, Surrey, UK 
NE Technology, UK 
New England Biolabs (UK) Ltd, Hitchin, Hertfordshire, UK 
Novagen, Nottingham, UK 
Oswell DNA Services, Southampton, UK 
Parke-Davis, Pontypool, UK 
Pharmacia & Upjohn, Sweden 
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Pierce, Rockford, IL, USA 
Plastics-One, Roanoke, Virginia, USA (via Bilaney) 
Promega, Madison, WI, USA 
Randox Laboratories Ltd, County Antrim, UK 
Research Diets Inc, New Brunswick, NJ, USA 
Seton Scholl Healthcare Ltd., Gloucester, UK 
Shandon Southern Products Ltd, Runcorn, UK 
Schering-Plough Ltd., Hertfordshire, UK 
Sigma Ltd, Poole, Dorset, UK 
Special Diet Services, Witham, Essex, UK 
Stata, Stata Corp LP, USA 
ThermoFisher Scientific Leicestershire, UK 
Tyco Healthcare, Hampshire, UK 
Ultracrimp, Du Pont, Wilmington, DE, USA 
Vet Tech Solutions Ltd, Cheshire, UK 
VWR International Ltd, Poole, UK 
Wallace, Waltham, MA, USA 
WPA, Cambridgeshire, UK 
 
 
